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From Verified Models to Verified Code for Safe Medical Devices
Abstract
Medical devices play an essential role in the care of patients around the world, and can have a life-saving effect.
An emerging category of autonomous medical devices like implantable pacemakers and implantable
cardioverter defibrillators (ICD) diagnose conditions of the patient and autonomously deliver therapies.
Without trained professionals in the loop, the software component of autonomous medical devices is
responsible for making critical therapeutic decisions, which pose a new set of challenges to guarantee patient
safety. As regulation effort to guarantee patient safety, device manufacturers are required to submit evidence
for the safety and efficacy of the medical devices before they can be released to the market. Due to the closed-
loop interaction between the device and the patient, the safety and efficacy of autonomous medical devices
must ultimately be evaluated within their physiological context. Currently the primary closed-loop validation
of medical devices is in form of clinical trials, in which the devices are evaluated on real patients. Clinical trials
are expensive and expose the patients to risks associated with untested devices. Clinical trials are also
conducted after device development, therefore issues found during clinical trials are expensive to fix.
There is urgent need for closed-loop validation of autonomous medical devices before the devices are used in
clinical trials. In this thesis, I used implantable cardiac devices to demonstrate the applications of model-based
approaches during and after device development to provide confidence towards the safety and efficacy of the
devices. A heart model structure is developed to mimic the electrical behaviors of the heart in various heart
conditions. The heart models created with the model structure are capable of interacting with implantable
cardiac devices in closed-loop and can provide physiological interpretations for a large variety of heart
conditions. With the heart models, I demonstrated that closed-loop model checking is capable of identifying
known and unknown safety violations within the pacemaker design. More importantly, I developed a
framework to choose the most appropriate heart models to cover physiological conditions that the pacemaker
may encounter, and provide physiological context to counter-examples returned by the model checker. A
model translation tool UPP2SF is then developed to translate the pacemaker design in UPPAAL to Stateflow,
and automatically generated to C code. The automated and rigorous translation ensures that the properties
verified during model checking still hold in the implementation, which justifies the model checking effort.
Finally, the devices are evaluated with a virtual patient cohort consists of a large number of heart models
before evaluated in clinical trials. These in-silico pre-clinical trials provide useful insights which can be used to
increase the success rate of a clinical trial. The work in this dissertation demonstrated the importance and
challenges to represent physiological behaviors during closed-loop validation of autonomous medical devices,
and demonstrated the capability of model-based approaches to provide safety and efficacy evidence during
and after device development.
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ABSTRACT
FROM VERIFIED MODELS TO VERIFIED CODE FOR SAFE MEDICAL
DEVICES
Zhihao Jiang
Rahul Mangharam
Medical devices play an essential role in the care of patients around the world, and
can have a life-saving effect. An emerging category of autonomous medical devices
like implantable pacemakers and implantable cardioverter defibrillators (ICD) diag-
nose conditions of the patient and autonomously deliver therapies. Without trained
professionals in the loop, the software component of autonomous medical devices is
responsible for making critical therapeutic decisions, which pose a new set of chal-
lenges to guarantee patient safety. As regulation effort to guarantee patient safety,
device manufacturers are required to submit evidence for the safety and efficacy of
the medical devices before they can be released to the market. Due to the closed-loop
interaction between the device and the patient, the safety and efficacy of autonomous
medical devices must ultimately be evaluated within their physiological context. Cur-
rently the primary closed-loop validation of medical devices is in form of clinical trials,
in which the devices are evaluated on real patients. Clinical trials are expensive and
expose the patients to risks associated with untested devices. Clinical trials are also
conducted after device development, therefore issues found during clinical trials are
expensive to fix. There is urgent need for closed-loop validation of autonomous med-
ical devices before the devices are used in clinical trials.
In this thesis, I used implantable cardiac devices to demonstrate the applications
of model-based approaches during and after device development to provide confidence
towards the safety and efficacy of the devices.
A heart model structure is developed to mimic the electrical behaviors of the heart
in various heart conditions. The heart models created with the model structure are
capable of interacting with implantable cardiac devices in closed-loop and provide
physiological interpretation for a large variety of heart conditions
With the heart models, I demonstrated that closed-loop model checking is capable
of identifying known and unknown safety violations within the pacemaker design.
More importantly, I developed a framework to choose the most appropriate heart
models to cover physiological conditions that the pacemaker may encounter, and
provide physiological context to counter-examples returned by the model checker.
A model translation tool UPP2SF is then developed to translate the pacemaker
design in UPPAAL to Stateflow, and automatically generated to C code. The au-
tomated and rigorous translation ensures that the properties verified during model
checking still hold in the implementation, which justifies the model checking effort.
Finally, the devices are evaluated with a virtual patient cohort consists of a large
number of heart models before evaluated in clinical trials. These in-silico pre-clinical
v
trials provide useful insights which can be used to increase the success rate of a clinical
trial.
The work in this dissertation demonstrated the importance and challenges to
represent physiological behaviors during closed-loop validation of autonomous medical
devices, and demonstrated the capability of model-based approaches to provide safety
and efficacy evidence during and after device development.
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Chapter 1
Medical Devices: Current State
and Challenges
The medical device market is worth $289 billion, of which $110 billion is from the US
alone, with this number projected to reach $133 billion in 2016 (Research and Markets
[2015]). Examples include everything from adhesive bandages, stents, artificial joints,
drug infusion pumps to surgical robots, implantable cardiac pacemakers, and devices
still undergoing basic research like the artificial pancreas. To take one example of
the societal impact of medical devices, an estimated 3 million people worldwide have
implanted cardiac pacemakers (a heart rate management device), with 600,000 added
annually. Clinical trials have presented evidence that patients implanted with cardiac
defibrillators (another heart rate management device) have a mortality rate reduced
by up to 31% (Moss et al. [2012]).
The US Food and Drug Administration (FDA) defines a medical device as an
instrument, apparatus, implement, machine, or implant which is:
• intended for use in the diagnosis of disease or other conditions, or in the cure,
mitigation, treatment, or prevention of disease, in humans or other animals, or
• intended to affect the structure or any function of the human body or other ani-
mals, and which does not achieve any of its primary intended purposes through
chemical action and which is not dependent upon being metabolized for the
achievement of any of its primary intended purposes.”
In general, medical devices are categorized according to their risk factors - Class
I, Class II and Class III, corresponding to low-risk, medium-risk and high-risk devices
(U.S.FDA [2014]). Fig. 1.1 gives an intuitive description of medical devices examples
across a range of diagnostic and therapeutic risk.
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Figure 1.1: Current medical devices across a range of diagnostic and therapeutic risk. Im-
plantable software-controlled devices such as the pacemaker and defibrillator which operate
in a closed-loop of sensing, control and actuation are amongst the highest risk
1.1 Closing the Device-Patient Loop
Medical devices operate across a range of invasiveness and intervention with the pa-
tient in the loop. For diagnostic-only devices, like an X-ray machine, the medical
professional operates the device to obtain patient data. Upon interpretation of the
data, the medical professional performs diagnosis followed by delivery of proper ther-
apy to the patient (Fig. 1.2.(a)). For therapy-only devices, e.g. a drug infusion pump,
the medical professional configures the device infrequently based on prior diagnosis of
the patient so the device only executes the therapy on the patient (Fig. 1.2.(b)). We
denote these devices as Open-loop Medical Devices as there is no direct feedback
between the patient and the device. For open-loop devices, the device operates under
the supervision of professionally-trained physicians. The device’s safety is mostly de-
termined by how accurately it provides information to the physicians or how faithfully
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Figure 1.2: Diagnostic-only and therapy-only devices do not interact with the patient in
direct closed-loop. The physician is responsible for the diagnostic and/or therapeutic de-
cisions. However in closed-loop medical devices, the devices interact with the patient in
closed-loop and have to make therapeutic decisions based on their own diagnosis.
it operates as instructed by the physicians.
There is a class of devices with both diagnostic and therapeutic functions, i.e. im-
plantable cardiac devices to treat cardiac arrhythmia, deep brain stimulation devices
(Coffey [2009]) to treat Parkinson’s disease and artificial pancreas to treat Type-1
diabetes. These devices capture and diagnose the patient’s physiological conditions
from patient signals, and deliver therapy in response (Fig. 1.2.(c)). These devices
usually operate autonomously with very little human intervention. We denote them
as Autonomous Medical Devices. The benefits of autonomous medical devices
are timely therapy and more independent life-style. However, autonomy of these
medical devices also brings about safety and efficacy concerns. With open-loop med-
ical devices, the diagnosis and therapy decisions are made by medical professionals,
who have expert knowledge of human physiology. Therefore they are able to identify
adverse health conditions and adjust the therapy accordingly. On the other hand,
closed-loop medical devices have to make both the diagnosis and therapy decisions
on their own. The domain expertise required to make those decisions has to be pro-
grammed into the device. It is not feasible to encode all the knowledge of human
physiology into the device. For unanticipated physiological conditions, when the ap-
propriate response has not been programmed into the device, the device may deliver
inappropriate therapy which can have an adverse effect on patient’s health. There-
fore, these devices are usually classified into the highest risk category and undergo
the most stringent regulation.
1.1.1 Challenges for Developing Autonomous medical De-
vices
There are multiple challenges to develop safe and effective autonomous medical de-
vices:
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Physiological Complexity
Human physiology is complex and not completely understood. For instance, the
functionality of the heart can be interpreted from multiple perspectives : from its
electrical activity, mechanical contractions of the heart muscles, and dynamics of
blood flow. The physiology of the heart can also be analyzed with multiple scales :
from the molecular level to cellular level all the way to the organ and system level. It is
impossible to encode all these contexts into the device, hence inappropriate diagnosis
and therapy are observed due to the lack of physiological contexts ( Sandler et al.
[2010], Hauser and Maron [2005]).
Physiological Variability
Physiological conditions and parameters demonstrate different levels of variability
both within the individual at different times, levels of exertion and under the in-
fluence of medication and also across individuals. For instance, a segment of the
population may have additional electrical conduction pathways within their heart,
which makes them vulnerable to certain heart diseases. Consequently, autonomous
medical devices should be able to safely operate under a large variety of physiological
conditions. This is difficult to guarantee, as the device designer must consider all
possible physiological conditions, and their interaction with the device, during the
development of the device.
Limited Observability
Autonomous medical devices normally rely on minimally invasive measurement of the
physiological parameters in order to allow the patients to live their normal life. For
example, implantable pacemakers and defibrillators commonly have only two leads
and therefore two points of observation for the whole heart. The limited observability
inevitably leads to ambiguities as different physiological conditions can map to the
same input sequence to the device, resulting in inaccurate diagnosis and therapy.
Software-related Medical Device Recalls
The diagnostic and therapeutic functions of the autonomous medical devices are
mostly controlled by their software components due to their complexity. For instance,
implanted cardiac pacemakers and defibrillators have approximately 80,000-100,000
lines of software code which essentially makes all sensing, control and actuation de-
cisions autonomously within the human body, over the 5-7 year device lifetime 1.
Software embedded in a medical device, unlike electrical and mechanical components,
does not fail due to corrosion, fatigue or have statistical failures of sub-components.
Software failures are uniquely sourced in the design and development of the system.
1Paul L. Jones. Senior Systems/Software Engineer, Office of Science and Engineering Laborato-
ries, U. S. FDA. Personal communication, 2010.
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Figure 1.3: Medical device recalls due to software issues have risen from 10% in the 1990s
to 1˜5% in the past decade (U.S.FDA [2012])
According to the US Food and Drug Administration, in 1996, 10% of all medi-
cal device recalls were caused by software-related issues (Maisel et al. [2001]). This
percentage rose to an average of 15% of recalls from 2008 to 2012 (Fig. 1.3). Mal-
functions of closed-loop medical devices usually have severe consequences, which will
be categorized as Class I, meaning there is a “reasonable probability that use of these
products will cause serious adverse health consequences or death.” (U.S.FDA [2006],
Zhang et al. [2015], Sandler et al. [2010]).
1.2 Medical Device Regulation Efforts and Chal-
lenges
In the United States, the FDA is the primary regulatory authority responsible for
assuring the safety, efficacy and security of patients using medical devices. Based
on the rationale that 1) manufacturers know their devices better than the regulator,
and 2) the variety of medical devices requires a variety of approaches, it is the device
manufacturers’ responsibility to demonstrate the safety and efficacy of the medical
devices. Manufacturers are required to complete a pre-market submission before the
devices can be released to the market. The level of requirements for the submission
is determined by the safety classification of the devices.
1.2.1 Guidelines During Device Development
A set of general guidelines are recommended by the FDA (U.S.FDA [1997, 2002,
2005]) which list the activities that need to be performed during the development of
the devices. In safety-critical industries such as automotive electronics, avionics and
nuclear systems, international standards are enforced for software system develop-
ment, evaluation, manufacturing and post-market changes (Fu¨rst et al. [2009], Feiler
et al. [2010]). This awareness is only beginning to enter the medical device industry as
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Figure 1.4: International standards for medical device safety. These standards define the
required activities during the development process.
compliance with international standards are ”recommended” in the aforementioned
guidelines (Jetley et al. [2006]).
Fig. 1.4 describes the primary standards to enforce medical device safety and
their relationships. The basic rationale behind these standards is that: if all the
risks/hazards of the device are identified and reasonably mitigated, and the device
is developed with rigorous process, the device is reasonably safe. The IEC 60601
Medical Electrical Equipment - General requirements for basic safety and essential
performance is a product safety standard that all electronic medical devices must
comply to. IEC 60324 specifies the processes and activities needed to perform during
the software development life cycle to ensure software safety.
Risk management is a core activity throughout the software development life cy-
cle. ISO 14971 is specified for the application of risk management to medical devices.
In addition, for each risk management activity of ISO 14971, ISO 80002-1 provides
additional guidelines for the software component, which highlights and explains ap-
proaches to assuring that software safety is adequately addressed.
1.2.2 Pre-Market Evaluation with Clinical Trials
Devices that have high risk factors are required to submit clinical evidence for their
safety and efficacy, often in form of clinical trials. In clinical trials, the devices are
used on a preselected population of patients following carefully-designed protocols.
The goal of a medical trial, in part, is to obtain unambiguous results for the primary
question of the trial which can support the safety and/or efficacy of the devices.
However, conducting clinical trials is very time consuming and expensive, and risks
found during clinical trials are very expensive to fix (U.S.FDA [2013]).
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1.2.3 Lack of Closed-loop Validation During and After De-
vice Development
While formal methods are used for medical device software validation (Boston Sci-
entific Corporation [2007a], Gomes and Oliveira [2009b], Jee et al. [2010a]), testing
continues to be the primary method for safety and efficacy evaluation during device
development. Testing for medical device software currently is ad hoc, error prone,
and very expensive. Traditional methods of testing do not suffice as the test genera-
tion cannot be done independently of the current state of the patient and organ. The
primary approach for system-level testing of medical devices is unit testing using a
playback of pre-recorded electrogram and electrocardiogram signals (Cortner [2003],
Vip [2006]). This tests if the input signal triggers a particular response by the de-
vice, but is unable to check how the device affects the physiological conditions of the
patient.
The only closed-loop validation activity is clinical trials, which is very expensive
and expose the patients to uncertified devices. Issues found during clinical trials
are also expensive to fix. There is urgent need for closed-loop validation approaches
during and after device development to provide safety and efficacy confidence to the
device design.
1.3 Model-based Design and Pre-certification of
Medical Devices
In industries like automotive and avionics, mathematical models of the physical en-
vironment that the system operates in are developed for analyzing the safety and
efficacy of the control systems (or their models) (Fu¨rst et al. [2009], Feiler et al.
[2010]). Similar approaches can potentially help during the development process
of autonomous medical devices and provide extra confidence to the devices before
conducting clinical trials. However, unlike man-made systems like automobiles and
aircrafts, physiological systems are less understood with larger variations for the type
and degree of patient conditions. The lack of faithful models of physiological envi-
ronment for the autonomous medical devices is one of the reason that model-based
approaches are not well-adopted in the medical device industry.
As computational models of human physiology are developed, they can be used
to interact with closed-loop medical devices or their models. The FDA is starting to
recognize in-silico modeling and simulation as regulatory-grade evidence for device
safety and efficacy. For example, Ghorbani and Bogdan [2013] developed glucose-
insulin models that can be used to evaluate control algorithms for artificial pancreas
devices which can sense blood glucose and deliver insulin. Simulation results with
the models have been recognized by FDA to replace animal trials, in part, which
significantly reduced cost (B. P. Kovatchev and M. Breton and C. Dalla Man and
C. Cobelli [2009]). With the increasing interest and recognition from the regulators,
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Figure 1.5: Percentage of computer simulation is expected to increase as safety and effec-
tiveness evidence of medical devices (http://mdic.org/)
computer models and simulations are expected to play bigger role as as “regulatory-
grade evidence” evidence in the development of future closed-loop medical devices
(Fig. 1.5).
1.4 Contributions
In this dissertation, implantable cardiac devices are used as working examples to
demonstrate how model-based approaches can help improve the safety and efficacy of
autonomous medical devices during and after their development. By demonstrating
the process of developing verified models to generate verified code of the devices,
the results of model-based closed-loop validation can provide confidence towards the
safety and efficacy of the devices.
The contribution of this dissertation is fourfold:
1. Clinical Electrophysiology heart model structure: A heart model struc-
ture was developed that can represent a large variety of heart conditions and
interact with implantable cardiac devices in closed-loop. The heart model struc-
ture is available in both software and hardware for different applications of
closed-loop validation.
2. Automated heart model abstraction and refinement: An abstraction
tree structure was developed to abstract the heart models to capture the large
variability of heart conditions during closed-loop model checking of implantable
pacemaker, and refine the heart models to provide physiological interpretability
to the counter-examples.
3. Automated model translation for code generation: An automated model
translation tool UPP2SF was developed to translate verified UPPAAL device
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Figure 1.6: Model-based design for implantable cardiac devices with closed-loop validation
model to Stateflow model, which allows rigorous translation from model to C
code.
4. in-silico Pre-clinical trials: A large virtual population of heart models was
generated to evaluate the VT/SVT discrimination algorithms of Implantable
Cardioverter Defibrillators before clinical trials.
Fig. 1.6 demonstrates the structure of the dissertation. The dissertation can be
broken down into 4 themes, which are illustrated in Fig. 1.6.
The remaining dissertation is arranged as follow: Chapter 2 discusses a dual
chamber pacemaker design (Boston Scientific Corporation [2007b]) as the motivat-
ing example to illustrate the safety hazards that the device may pose to the patients.
Chapter 3 discusses the physiological models that are necessary for closed-loop evalua-
tion of medical devices, and how to use those models to represent complex physiology
with large variability Jiang et al. [2012a]. Chapter 4 discusses the use of model-
checking techniques to evaluate the safety and efficacy of device design early in the
device design stage, with focus on the abstraction and refinement of the heart models
to cover large variety of physiological conditions (Jiang et al. [2014]). Chapter 5 dis-
cusses the rigorous translation from verified device model to device implementation
which maintains the verified properties (Pajic et al. [2012b]). Chapter 6 discusses the
in-silico pre-clinical trial, which the devices are evaluated on a virtual patient cohort
consists of physiological models to provide useful insights for planning a clinical trial.
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1.5 Useful terminologies for often misinterpreted
terms
Ensuring the safety and efficacy of complex medical devices has drawn interest not
only from stakeholders like regulators and industries, but also medical professionals
and academia. Different communities have different interpretations over certain ter-
minologies, often causing misunderstandings. In this dissertation, terminologies from
the regulation perspective are adopted. Most of the definitions are referred from
the FDA guideline document General Principles of Software Validation (U.S.FDA
[2002]). Below are several terminologies that are used throughout the dissertation
which worth clarifying.
1.5.1 Requirements vs. Specifications
By the definition of the FDA (U.S.FDA [2005]), the requirements of a system describe
what the system should achieve and the specifications of a system describe how the
system is designed to satisfy the requirements. For instance, a requirement for an
autonomous car is ”The car should not hit objects”. The corresponding specification
can be ”brake if the speed of the car is greater than x and the distance to the object
is less than y”. It is obvious that a car satisfying its specification may not satisfy the
requirement (e.g. when the car is driving too fast or the obstacle pops up right in
front of the car). In this dissertation, the word requirement in particular denotes the
intended uses of the medical devices to improve physiological conditions.
1.5.2 Validation vs. Verification vs. Testing
As defined in U.S.FDA [2002], software validation is the confirmation by examination
and provision of objective evidence that:
1. software specifications conform to user needs and intended uses, and
2. the particular requirements implemented through software can be consistently
fulfilled
The first aspect ensures the device is safe and effective. The second aspect maintains
the traceability of requirements throughout the development life cycle. Software
verification fulfills the second aspect of software validation by ”providing objective
evidence that the design outputs of a particular phase of the software development
life cycle meet all of the specified requirements for that phase. ”
Testing is the technique that can be used for validation and/or verification. Fig. 1.7
illustrates the relationship between validation, verification and testing, and different
activities during the software development life cycle to ensure the safety and effec-
tiveness of the software.
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1.5.3 Closed-loop vs. Open-loop Evaluation
In open-loop evaluation, i.e. open-loop testing, input sequences are send to the sys-
tem and system outputs are compared with expected outputs. In open-loop testing,
the system outputs do not affect the inputs afterward. In closed-loop evaluation, the
environment of the system is taken into account. System outputs affect the state of
the environment and thus affect the input sequences. For closed-loop medical de-
vices, clinical trials are currently the most common closed-loop evaluation method.
Enabling closed-loop evaluation during device design requires models of the environ-
ment, which is human physiology for closed-loop medical devices.
Closed-loop evaluation accomplishes two goals in model-based design: 1) It en-
forces environmental constraints so that the test space is smaller and the test cases
have physiological relevance, 2) Execution traces can be better interpreted as the
physiological models encode domain knowledge.
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Chapter 2
A Motivating Example: A Dual
Chamber Pacemaker Design
Intuitively, an autonomous medical device like pacemaker should satisfy the following
requirements: 1) improve unhealthy physiological conditions of a patient (efficacy),
and 2) not to deteriorate current physiological condition (safety). Evaluating both
requirements requires understanding of the physiological environment the device is
in. In the following sections, the physiological basis for the heart and the pacemaker
is introduced, followed by a dual chamber pacemaker specification (Boston Scientific
Corporation [2007b]). Potential safety hazards for a pacemaker were then analyzed
and two known safety hazards were discussed in detail. The dual chamber pacemaker
specification is then used throughout the thesis to demonstrate how different model-
based techniques can be used to validate the safety and efficacy of an autonomous
medical device.
2.1 Physiology Basis of the Heart and the Pace-
maker
First, we use this small section to introduce the physiology basis of the heart and the
application of implantable cardiac devices. Readers with knowledge of this subject
can skip to the following sections.
2.1.1 Blood Circulation System
The heart is the ”motor” for blood circulation within our body. The heart has
two ventricles which pump the blood out of the heart, and two atria which gather
blood from the body and pump them into the ventricles. (Fig. 2.1.(a)) There are two
circulations through the heart: the Pulmonary circulation and the Stemic circulation.
In the pulmonary circulation, the right atrium collects oxygen-depleted blood from
all over the body and pumps it into the right ventricle. The right ventricle then
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Figure 2.1: (a) The circulation system (http://revisionworld.com/). (b) Electrical Conduc-
tion system of the heart
pumps low-oxygen blood to the lungs. The blood gets oxygenated in the lungs and
gathers into the left ventricle. In the stemic circulation, the oxygenated blood in the
left atrium is pumped into the left ventricle. The left ventricle pumps the blood to
the rest of the body and the heart itself. After the body extracts the oxygen from
the blood and injects carbon dioxide, the oxygen-depleted blood then flows back to
the right atrium.
2.1.2 Electrical Conduction System of the Heart
The oxygen demand of the body changes during different activities. For example, the
demand is higher while running and lower while sleeping. To satisfy these demands,
the heart muscles in the atria and the ventricles have to contract with certain pat-
tern and frequency in accordance to optimize the Cardiac Output, which refers to the
volume of blood pumped by the heart per minute (mL blood/min). The coordinated
contractions of the heart muscles are governed by the electrical conduction system of
the heart (Fig. 2.1.(b)) A Normal Sinus Rhythm (NSR) is the healthy heart rhythm
which provides efficient blood flow. During a NSR, electrical signals are periodically
generated by the Sinoatrial (SA) node in the upper right atrium, which acts as the in-
trinsic pacemaker of the heart. The signals conduct throughout both atria and trigger
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Figure 2.2: (a) Lead placement for a dual chamber pacemaker. (b) Electrogram (EGM)
signals measured from pacemaker leads and corresponding internal pacemaker events
muscle contractions to push blood into the ventricles. After a long conduction delay
at the AV node so that both ventricles are fully filled, the signals conduct through
fast-conducting His-Purkinje system to trigger almost simultaneous contractions of
the ventricles and pump blood out of the ventricles.
Derangement from NSR can result in insufficient cardiac output and thus insuf-
ficient oxygen supply to the body and/or the heart itself, which are referred to as
Arrythmia. Arrhythmia impair the heart’s ability to efficiently pump blood and com-
promise the patient’s health. Arrhythmia are categorized into so-called Tachycardia
and Bradycardia. Tachycardia features undesirable fast heart rate which can cause
inefficient blood pumping. Bradycardia features slow heart rate which results in in-
sufficient blood supply. Bradycardia are due to failure of impulse generation with
anomalies in the SA node, or failure of impulse propagation where the conduction
from atria to the ventricles is delayed or blocked.
2.1.3 Electrophysiology and Implantable Cardiac Devices
The electrical activities of the heart closely couple with the mechanical contractions
thus the electrical activities of the heart can be monitored and used to diagnose
arrhythmia. The most well-known method is Electrocardiogram (ECG), which mea-
sures the integration of electrical activities of the heart measured along different axis
on the body surface. The electrical activities can also be directly measured by insert-
ing electrodes through the vein into the heart. The electrodes are placed against the
inside heart wall and localized electrical activities can be measured. Physicians can
also deliver pacing sequence through the electrodes to explore the heart conditions.
This procedure is referred to as Electrophysiological (EP) Testing (Josephson [2008])
and the signals are referred to as electrograms (EGMs) (Fig. 2.2.b). The timing and
morphology of the ECG and EGM signals together are used to diagnose arrhythmia.
The implantable cardiac pacemakers are rhythm management devices designed to
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treat bradycardia. A typical dual chamber pacemaker has two leads inserted into the
heart through the veins which can measure the local electrical activity of the right
atrium and right ventricle respectively (Fig. 2.2.a). According to the timing between
sensed impulses, the pacemaker may deliver electrical pacing to the corresponding
chamber to maintain proper heart rhythm.
2.2 A Dual Chamber Pacemaker Specification
The focus of this section is implantable pacemaker, which is one of the simpler im-
plantable cardiac devices. The specifications are based on the algorithm descriptions
from Boston Scientific manuals (Boston Scientific Corporation [2007b]) and the func-
tional description released as part of the Pacemaker Challenge (Boston Scientific
Corporation [2007a]).
The pacemaker is designed for patients with bradycardia (i.e. slow heart rate).
Two leads, one in the right atrium and one in the right ventricle, are inserted into
the heart and fixed onto the inner wall of the heart. These two leads monitors the
local activation of the atria and the ventricles, and generate corresponding sensed
events (AS, VS) to its software. The software determines the heart condition by
measuring time difference between events and delivers pacing events (AP, VP) to the
analog circuit when necessary. The analog circuit then delivers pacing signals to the
heart to maintain heart rate and A-V synchrony. In order to deal with different heart
condition, pacemakers are able to operate in different modes. The modes are labeled
using a three character system (e.g. xyz). The first position describes the pacing
locations, the second location describes the sensing locations, and the third position
describes how the pacemaker software responds to sensing. Here we introduce the
widely used DDD mode pacemaker which is a dual chamber mode with sensing and
pacing in both atrium and ventricle.
A DDD pacemaker has five basic timing cycles triggered by external and internal
events, as shown in Fig. 2.3.
Lower Rate Interval (LRI)
The Lower Rate Interval (LRI) defines the longest interval allowed between two ven-
tricular events, thus keeping the heart rate above a minimum value. In DDD mode,
the LRI interval is divided into a V-A interval (TLRI-TAVI) and a A-V interval
(TAVI). Since the last ventricular event (VS, VP), if no atrial event has been sensed
(AS), the pacemaker will deliver atrial pacing (AP) after TLRI-TAVI. (Marker 1 in
Fig. 2.3)
Atrio-Ventricular Interval (AVI) and Upper Rate Interval (URI)
The function of the AVI timer defines the longest interval between an atrial event
and a ventricular event. If there is no ventricular event (VS) within TAVI after an
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atrial event (AS, AP), and the time since the last ventricular event (VS, VP) is longer
than TURI, the pacemaker will deliver ventricular pacing (VP). (Marker 3 in Fig. 2.3)
The URI limits the ventricular pacing rate by enforcing a lower bound on the times
between consecutive ventricle events.
2.2.1 Post Ventricular Atrial Refractory Period (PVARP)
and Post Ventricular Atrial Blanking (PVAB)
Ventricular events, especially Ventricular Pace (VP) are sometimes so strong that the
atrial lead can sense the activation as well. This signal may be falsely recognized as an
atrial event and disrupt normal pacemaker function. This scenario is called crosstalk
and was discussed in our previous work (Jiang and Mangharam [2011]). In order to
prevent this undesired behavior, and filter potential noises, there is a blanking period
(PVAB) followed by a refractory period (PVARP) for the atrial events after each
ventricular event (VS, VP). Atrial events during PVAB are ignored and atrial events
during PVARP trigger AR! events which can be used in some advanced diagnostic
algorithms. (Marker 2 in Fig. 2.3)
2.2.2 Ventricular Refractory Period (VRP)
The VRP follows each ventricular event (VP, VS) to filter noise and early events in
the ventricular channel which could otherwise cause undesired pacemaker behavior.
1 2
3
Figure 2.3: Basic 5 timing cycles for a dual chamber pacemaker which include the Lower
Rate Interval (LRI), Atrio-Ventricular Interval (AVI), and Upper Rate Interval (URI). Also
included are the blanking intervals, Post Ventricular Atrial Refractory Period (PVARP)
and Ventricular Refractory Period (VRP), to inhabit action by the pacemaker.
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Figure 2.4: Fault Tree Analysis (FTA) for two failures of a pacemaker
2.3 Identify Hazards in the Dual Chamber Pace-
maker Design
Implantable pacemakers are designed to treat bradycardia by increasing the heart
rate with external pacing. Therefore the heart rate should not only be 1) increased
to the minimum physiological need, but also 2) should not be increased beyond phys-
iological need. Failing to satisfy the two requirements leads to failures that may be
harmful to the patient. Fault tree analysis (FTA) is a top down and deductive failure
analysis in which an undesired state of a system is analyzed using Boolean logic to
combine a series of lower-level events. Fig. 2.4 demonstrates two FTAs for two failures
corresponding to the two requirements. In this section we introduce two well-studied
safety hazards in a basic dual chamber pacemaker design.
2.3.1 Endless-Loop Tachycardia
As introduced in the last section, a dual-chamber pacemaker paces the ventricle if
no ventricular events are sensed after TAVI, which is equivalent to a virtual atria-to-
ventricles conduction pathway. This forms a timing loop with the intrinsic (physiologi-
cal) A-V conduction pathway (see Fig. 2.5(a)). A Premature Ventricular Contraction
(PVC), i.e. an early extra beat in the ventricles, may trigger another ventricular
event (VS) and initiate a V-A conduction through the intrinsic pathway (Marker 1 in
Fig. 2.5(b)). The pacemaker registers this signal as an Atrial Sense (AS) (Marker 2 in
Fig. 2.5(b)). A ventricular pace (VP) is delivered after TAVI, as if the signal conducts
through the “virtual” A-V pathway (Marker 3 in Fig. 2.5(b)). The VP will trigger
another V-A conduction and this VP-AS-VP-AS looping behavior will continue (see
Fig. 2.5(b)). The interval between atrial events is TAVI plus the V-A conduction
delay, which is normally shorter than the delay between intrinsic heart beats, thus
17
Intrinsic pathway
Fast “pathway”: pacemaker
A-V synchrony
(a) Virtual circuit formed by the pacemaker
and the heart
0 1000 2000 3000 
AS AS AS AS AS 
VS VP VP VP VP VP 
ms 
AS 
1 
2 
3 
(b) Pacemaker trace for ELT initialized by a
early ventricular signal
Figure 2.5: Endless Loop Tachycardia case study demonstrating the situation when the
pacemaker drives the heart into an unsafe state (Jiang et al. [2011])
driving the ventricular rate as high as the Upper Rate Limit. During ELT, the heart
rate is not only high, but also fixed without changing according to physiological need,
which is an unsafe scenario.
2.3.2 Atrial Tachycardia Response
Supraventricular Tachycardia (SVT) is an arrhythmia with an abnormally fast atrial
rate. Typically, in a heart without pacemaker, the AV node, which has a long re-
fractory period, can filter most of the fast atrial activations during SVT, thus the
ventricular rate remains relatively normal. Fig. 2.6(a) demonstrates a pacemaker
event trace during SVT, with a pacemaker in ODO mode, which just sensing in both
channels. As there is no pacing in ODO mode, the heart is in open-loop with the
pacemaker. In this particular case, every 3 atrial events (AS) correspond to 1 ventric-
ular event (VS) during SVT. As an arrhythmia, SVT is still considered a safe heart
condition since the ventricles operate under normal rate and still maintain adequate
cardiac output.
However, in the closed loop case with the DDD pacemaker, the AVI component of
a dual chamber pacemaker is equivalent to a virtual pathway in parallel to the intrin-
sic conduction pathway between the atria and the ventricles. The pacemaker tries to
maintain 1:1 A-V conduction and thus increases the ventricular rate inappropriately
to match the atrial rate. This is known as Pacemaker Mediated Tachycardia (PMT)
as the heart would have been safe without the pacemaker and its virtual pathway.
Fig. 2.6(b) shows the pacemaker trace of the same SVT case with DDD pacemaker.
Although half of the fast atrial events are filtered by the PVARP period ([AR]s),
the DDD pacemaker still drives the closed-loop system into 2:1 A-V conduction with
faster ventricular rate. Maintaining A-V delay is less important than maintaining
an appropriate ventricular rate. The DDD pacemaker violates a higher priority re-
quirement in order to satisfy a lower priority requirement, which is inappropriate.
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Figure 2.6: Benign open loop case: SVT without a pacemaker or with a pacemaker in
sense-only mode (ODO) (b) Dangerous closed-loop-case SVT with DDD pacemaker which
tries to match the fast atrial rate with a corresponding (and dangerous) fast ventricular
rate.
2.4 Discussion
Implantable cardiac devices such as implantable pacemakers are typical autonomous
medical devices. Despite their seemingly simple controllers, the pacemakers also
subject to the three challenges discussed in Chapter 1:
• The physiology of the heart and its interaction with the rest of the body are
complex.
• The pacemakers have to safely operate within a large variety of physiological
conditions.
• A dual chamber pacemaker can only observe electrical activities from two local
sites in the heart.
In the remaining dissertation, I will demonstrate the application of physiological
models in various model-based techniques to provide safety and efficacy confidence
to the pacemaker design.
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Chapter 3
Theme 1: Modeling the
Physiological Environment
The safety and efficacy of autonomous medical devices have to be evaluated within
their physiological environment. Models of human physiology can replace real patients
and enable closed-loop evaluation earlier during device development. In this chapter,
a heart model structure is developed for closed-loop validation of implantable cardiac
devices. This chapter aim to address the following questions:
• How much detail does the physiological model need?
• How to validate the physiological model?
• What applications can the physiological models be used?
3.1 Related Work
To study the mechanisms of heart diseases and their effects on cardiac output, differ-
ent physiological models of the heart have been developed. Fig. 3.1 illustrates several
aspects that these models capture. With the development of the imaging techniques
like MRI, detailed anatomical structures of the heart can be modeled and studied
(Schulte et al. [2001]). These models are fundamental in other modeling aspects as
well, as the anatomy of the heart dictates the electrical and mechanical behaviors of
the heart. Fig. 3.1.(a) shows models for heart muscle fiber orientations by E.W. Hsu
and C.S. Henriquez [2011]. With anatomy models the electrical and/or mechanical
properties of the heart can be studied. Fig. 3.1.(b) illustrate a model of blood flow
within the ventricles (Peskin and McQueen [1989]). Electrical properties of the heart
at cellular level has been modeled (Sachse et al. [2008]) and by combining these cel-
lular models with the structural models, the electrical activities of the whole heart
are studied, especially the mechanism of different arrhythmia (Trayanova and Boyle
[2014], Grosu et al. [2011], Murthy et al. [2013]). Intrinsic heart rate variability has
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Figure 3.1: Physiological models of the heart from different perspectives
been modeled to synthesize optimal control of pacemaker pacing. (Bogdan et al.
[2013]) Abstraction of the electrical cellular model has also been attempted by Islam
et al. [2014] to reduce model complexity without sacrificing accuracy. The electrical
properties and the mechanical properties of the heart are closely coupled. Models
combining both of these aspects are also developed to study the effects of different
arrhythmia on cardiac outputs (Trayanova and Boyle [2014], Rossi et al. [2011]).
3.2 EP Heart Model Structure for Closed-loop Val-
idation of Implant-able Cardiac Devices
Models should be designed in accordance with their respective applications. The
aforementioned models of the heart are designed for understanding the mechanisms
of different heart diseases. For closed-loop evaluation of autonomous medical devices,
physiological modeling should have the following considerations:
C1. Interfacing with the device: The model should be able to generate physio-
logical signals that the device sense from the real physiological entities. The model
should also be able to take device output as input and change its states accordingly.
Model complexity should also be adjusted according to the device interface to hide
unnecessary details.
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C2. Differentiate different physiological conditions: To evaluate the safety
and effectiveness of the device, the device has to be evaluated under certain phys-
iological conditions specified by the requirements. For example, the pacemaker is
supposed to maintain proper heart rate during Bradycardia. The model should be
expressive enough to be able to differentiate the physiological condition (Bradycardia
in the example) from other conditions. Failing to do so may result in false-positives
or false-negatives in the evaluation result.
C3. Physiological/logical interpretation of model states: In closed-loop
evaluation we are checking the device safety and effectiveness against the physiolog-
ical requirements. However, due to the limited interface (e.g. two leads for a dual
chamber pacemaker) it is always difficult to determine only from an execution trace
that the therapy is safe and effective. Therefore, being able to provide physiological
meanings to the states of the model also allows us to interpret the closed-loop execu-
tion more accurately, thus reducing the number of physiologically invalid executions
during the evaluation. To satisfy these requirements, the model structure of these
physiological models should base on physiological or clinical first principles so that
states and state transitions of the closed-loop executions can be explained with phys-
iological language.
C4. Available patient data: In closed-loop evaluation, physiological models are
developed to represent certain physiological condition across a population of patients
or even particular patients. The model parameters must be identified so that the be-
haviors of the models match the behaviors of the patients (groups). Due to the limited
sensing capability of closed-loop medical devices, the obtained data is sparse: i.e. we
can not put a sensor on every tissue region of the heart. Therefore the complexity of
the model should be in accordance with the available data to avoid over-fitting, which
occurs when a model has too many parameters relative to the number of observations,
and this can introduce errors during prediction.
The electrophysiological models mentioned in the last section (Trayanova and
Boyle [2014], Grosu et al. [2011]) satisfy C1-C3. However, the parameter space of
these models are too large (10+ parameters for each cellular model multiplied by
105 of elements) which not only increase simulation complexity, but also impossible
to identify due to lack of data. As introduced in Section 2.1.3, the pacemaker has
only two leads at fixed locations and only use timing between local activation events
for diagnosis. These models with high spatial fidelity possess details that can be
abstracted without sacrificing the model accuracy.
Electrophysiology testing (EP testing) has been an active clinical field to diag-
nose and treat arrhythmia with minimal-invasive procedures. During an EP testing
procedure, the physicians diagnose heart conditions by examining the patterns and
intervals of local electrical activations (temporal) measured from electrodes placed
into different locations of the heart (spatial). EP testing is the perfect level of ab-
straction for closed-loop evaluation of implantable cardiac devices because: 1) it is
the basis of implantable cardiac devices (C1), 2) physicians can use EP testing to
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Figure 3.2: (a) The generation of Action potential; (b) Action potential; (c1) The second
activation arrived during ERP; (c2) Arrived during RRP; (c3) Arrived after refractory.
diagnose most arrhythmia thus distinguish them (C2,C3), and 3) there are abundant
patient data available (C4).
In the remaining chapter we will introduce the heart model structure based on EP
testing, and model adaptation for two different applications of closed-loop evaluation
of implantable cardiac devices.
3.2.1 Timing Behaviors of Cellular Electrophysiology
The contraction of heart muscles is triggered by external voltage applied to the tissue.
After the activation, a transmembrane voltage change over time can be sensed due to
ion channel activities, which is referred to as an Action Potential (Fig. 3.2(a)). The
upstroke of the action potential is called depolarization, during which the muscle will
contract. The voltage change caused by the depolarization will depolarize the tissue
nearby, which causes an activation wave across the heart. After the depolarization
there is a refractory period during which the tissue recovers to the pre-excitation
state and the voltage drops down to the resting potential. The refractory period can
be divided into Effective Refractory Period (ERP) and Relative Refractory Period
(RRP) (Fig. 3.2(b)). During ERP, the tissue cannot be depolarized due to the lack
of charge. As a result, the activation wave will be ”blocked” at the tissue during
ERP (Fig. 3.2(c1)). During RRP, the tissue is partially recovered and the tissue can
be depolarized. However, the new action potential generated by the depolarization
will have different morphology (e.g. attenuated in magnitude and duration), thus
affecting the refractory periods of the tissue and conduction delay of the activation
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wave (Fig. 3.2(c2)). Fig. 3.2(c1)-(c3) show the action potential shape change and
corresponding timing change in refractory periods when the tissue is activated at
time stamp t1, t2, t3 after the initial activation t0.
3.2.2 Heart Model Components
We introduce the model components that can be used to configure heart models
corresponding to different heart conditions. As discussed earlier, the action potential
of a heart tissue has 3 timing periods during which the tissue responds to external
electrical stimuli differently. We use an extended timed-automata formulation (Alur
and Dill [1994]) to model the timing behaviors of a heart tissue during each cycle.
Node Automata: We refer to the tissue model as node automaton and Fig. 3.3.(a)
shows the structure of a node automaton i. 3 states correspond to the timing peri-
ods of the action potential. From Rest state, the node can either self-activate or get
activated by external stimuli (Act node) and go to ERP state. During ERP state the
node does not respond to external stimuli (blocked). During RRP state, the node can
still be activated and go to ERP state, however the ERP period and the conduction
delay of the tissue are affected by the ”earliness” of the activation arrived during
the RRP period, which is tracked by a shared variable C(i). The new ERP period
is determined by a function over clock value g(f(t)) which mimics the beat-to-beat
dynamics described in Josephson [2008]. The function g and f are given by:
f(t) = 1− t/Trrp (3.1)
and
g(x) =
{
Tmin + (1− (1− x)3) · (Tmax − Tmin), i = AV
Tmin + (1− x3) · (Tmax − Tmin), i 6= AV (3.2)
where Tmin and Tmax are the minimum and maximum value for Terp of the tissue.
Due to the limited number of observable points within the heart, modeling the
electrophysiological behavior of every tissue of the heart and its full anatomy is un-
necessary and unfeasible. In our heart models, only self-activating tissue and key
hubs of the electrical conduction system are modeled as node automata.
Path Automata: The electrical conduction through the tissue between nodes are
abstracted using path automata. The path automata can be used to represent struc-
tural or topological (functional) electrical connections between nodes. Fig. 3.3.(b)
shows a path automaton connecting node a and b.
The initial state of a path automaton is Idle, which corresponds to no conduc-
tion. The states corresponding to the two conduction directions are named after the
physiological terms: Antegrade (Ante) and Retrograde (Retro). These states can be
intuitively described as forward and backward conductions. If path actuation Act path
event is received from one of the nodes connected to it, there is a transition to Ante or
Retro state based on the activation source in the path automaton. At the same time,
the clock invariant of the state is modified according to the shared variable C(a/b).
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(a) (b)
(d)(c)
Figure 3.3: (a) Node automaton: The dotted transition is only valid for tissue (like SA
node) that can be activated by an external trigger; (b) Path automaton modeling the
electric conduction and propagation between two node automata; (c) Electrical conduction
system of the heart; (d) Model of the electrical conduction system of the heart using a
network of node & path automata ( Jiang et al. [2012a]).
This corresponds to the change of the conduction delay that is caused by the early
activation. Similar to node automaton, the changing trend is extracted from clinical
data and the function h is defined as:
h(c) =
{
path len/v · (1 + 3c), i = AV
path len/v · (1 + 3c2), i 6= AV (3.3)
where path len denotes the length of the path and v is the conduction velocity.
After Tante or Tretro time expires, the path automaton sends out Act node(b)
or Act node(a) respectively. A transition to Conflict state occurs followed by the
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transition to Idle state. The intermediate state Conflict is designed to prevent back-
flow, where the path is activated by the node b it has just activated. If during Ante
or Retro state another Act path event is received from the other node connected to
the path automaton, a transition to Double state will occur, corresponding to the
two-way conduction. In this case, the activation signals eventually cancel each other
and the transition to Idle state is taken.
3.2.3 Modeling the Heart’s Electrical Conduction System
The node and path automata are the basic building blocks for EP heart modeling.
Hearts with different conditions are modeled by using different conduction topologies
with appropriate timing parameters for each node and path automata. Fig. 3.3.(d)
shows one such topology of a network of node and path automata.
3.3 Interaction with the Heart Model
In this section, we first introduce a probe model we developed to generate synthetic
EGM signals from the EP heart model. We then use two case study to demonstrate
that the probe model enables the EP heart model to evaluate device malfunctions
due to sensing errors.
3.3.1 Probe Model for Synthetic EGM Generation
In EP testing and during pacemaker implantation, the local electrical activities, mea-
sured as electrogram (EGM) signals, are used to diagnose heart conditions. During
heart model construction, we can assign a node automaton at electrode locations
and the transitions to the ERP state can be used to represent the local activation
events. In a more general setup where electrodes are assigned anywhere within the
heart model, a probe model is designed to generate synthetic EGM signals using
spatio-temporal information from the proximity to the network of node and path
automata.
According to Stevenson and Soejima [2005], a potential difference is generated
when the activation wavefront passes by the electrode. The locations of the acti-
vation wavefronts are calculated from the locations of the path automata and their
current timer values. The amplitude of EGM decreases when the activation wavefront
moves away from the probe. We assume the decrease factor is a function related to
the distance between the activation wavefront and the probe. The potential differ-
ence caused by an activation wavefront to a probe is the signal strength of the path
multiplied by the decrease factor. The amplitude of EGM from a probe is the sum
of potential differences caused by all activation wavefronts. The bipolar EGM is the
difference between two unipolar EGMs. Fig. 3.4 shows that this probe model cap-
tures timing properties of EGM and the functional shape of the EGM impulses. The
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Figure 3.4: The influence of conduction velocity and probe configuration on the EGM
morphology. The left columns show the placement of probes in relation to the path; the
right columns show the functional EGM.
probes can be placed anywhere within the heart model and generate clinically-relevant
EGMs.
With the sensing model, the heart model structure can be used to identify safety
hazards caused by sensing errors.
3.3.2 Pacemaker Oversensing and Crosstalk
Oversensing is a general term for inappropriate sensing caused by noise or far-field
signals. It’s very common among pacemaker malfunctions and it may result in failure
to pace (Beaumont et al. [1995], Fuertes and Toquero [2003]), competitive pacing and
inappropriate therapy. Crosstalk is a special case for oversensing which occurs when
the pacemaker stimulus in one chamber is sensed in the other chamber. It happens
when two leads are close to each other or pacing signal in the other chamber is too
strong. It is common that the ventricular lead is placed in the right ventricle outflow
tract, which is close to the atrium (Saxonhouse et al. [2005]). Fig. 3.5(a) shows
simulated EGMs from a patient with bradycardia and complete heart block. During
atrial pacing (AP), the pacing signal is sensed by the ventricular lead 53 ms after the
AP. (Marker 1) It is treated as ventricular sense (VS) signal and thus inhibits the
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Figure 3.5: Crosstalk between pacemaker leads with high sensitivity in the ventricle, ad-
justed sensitivity and ventricular safety pacing
subsequent ventricular pacing (VP). This is indicated by no QRS-wave in the ECG
channel. (Marker 2) For a patient with complete heart block this will cause dangerous
ventricular asystole, meaning a long time without ventricular events.
Increasing the sensing threshold of the ventricular channel can prevent false sens-
ing. In Fig. 3.5(b), the small signals in ventricular EGM are ignored and ventricular
pacing are successfully delivered.
3.3.3 Lead Displacement
Lead displacement affects many patients and can result in inappropriate or ineffective
therapy. Fig. 3.6. (b) shows the simulation result for the pacemaker function when
the leads are in their designated location. From the figure we can observe: 1) Each
P-wave is initialized by an Atrial Pace signal. 2) Each QRS complex is initiated by
a ventricular pacing signal. 3) The interval between AP and VP is 150 ms, which
matches the programed AVI period.
One common case for lead dislodge is shown in Fig. 3.6.(a), where the atrial lead
has fallen into the right ventricle outflow tract. In this case the atrial lead senses from
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Figure 3.6: (a) Dotted line shows the location where the atrial lead should be (b) Pacemaker
function before lead dislodge. (c) Pacemaker function after lead dislodge
the ventricle rather than atrium and atrial pacing will initiate a ventricular event.
Fig. 3.6.(c) shows the simulated EGMs in this case. The figure reveals several facts:
1) No P wave is sensed or tracked (Marker 1). 2) Atrial Pace initiates an abnormal,
wide QRS which is then sensed by the ventricle lead (Marker 2). 3) Intermittent ap-
pearance of VP on QRS 110 ms after the AP. The ventricular lead can receive signal
from: 1) pacing signal sent from the atrial lead, 2) the intrinsic A-V conduction path.
The two paths are shown in Fig. 3.6.(a) and form a timing race condition. When the
signal from the atrial lead arrives the ventricular lead first, it will trigger VS. If the
intrinsic signal arrives the ventricular lead during the VSP sensing window (defined
in previous section), it will trigger VSP. Although the pacing is ’safe’ because the
pacing is early enough to avoid the vulnerable refractory period, the damage caused
by pacing on depolarized tissue is currently a matter of much investigation.
3.4 Heart-on-a-Chip Platform
The heart model structure is also available on hardware platform (Fig. 3.7) for closed-
loop testing of pacemaker implementations. Since each heart model is a network of
node and path automata running concurrently, we implemented the heart model on
an FPGA, so that increasing in the number of nodes and paths would not affect
real-time constraints. The second generation heart model implementation has been
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Figure 3.7: The heart model was developed in Matlab/Simulink and code was automatically
generated to operate on an FPGA platform for platform-level testing.
implemented on a lower cost fast micro-controller platform. The fast clock ensures
that executions of all nodes and paths can be finished within 1ms. The Heart-on-
a-Chip platform includes a heart model implementation which is able to represent
common heart conditions such as bradycardia, tachycardia, heart block, etc (for mode
details refer to Jiang et al. [2012a]). The parameters of the heart model can be
changed at run-time by either switching among pre-defined parameter sets, or sending
values directly to the model through a user interface in Matlab. A monitoring system
observes logical interactions between heart model and the pacemaker and checks them
against safety invariants at run-time.
As shown in (Fig. 3.8), with an analog interface the heart model can interact with
a commercial pacemaker in real time. Our analog interface uses an optical isolation
circuit to separate the pacemaker circuit and the heart implementation. Signals
generated from the heart are attenuated to the appropriate level to interact with a
Boston Scientific pacemaker and analog pacing signals are converted to pacing events
received by the heart model.
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Figure 3.8: Heart-on-a-Chip testbed for real-time closed-loop testing of the pacemaker or
model of the pacemaker with the heart model on the hardware platform
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3.5 EP Heart Model Validation
Since models are approximations of the actual environment, there are always discrep-
ancies between the model and the actual patient (group). The validity of closed-loop
validation results directly correlated to the validity of the physiological models.
In this section we validate the heart model structure by demonstrating its capa-
bility to represent physiological behaviors of 1) a particular patient for closed-loop
simulation, and 2) a group of patients for closed-loop model checking. The metrics
and process to validate the heart model are different for the two applications of heart
modeling: in closed-loop simulation, the accuracy of the model is more important,
while in closed-loop model checking, the model’s coverage on environmental behav-
iors is more important.
3.5.1 Validating Models for Closed-loop Simulation
A physiological model is considered valid for closed-loop simulation if (a) it is ca-
pable of generating the same output as the patient, for the same input; and (b) it
is general enough to represent other patients with similar conditions by adjusting
its parameters. The second point is to ensure that the model successfully captures
the underlying mechanism instead of over-fitting the data. In the following example
we validate the capability of our heart models to represent certain heart conditions
according to the mechanisms described in physiological literature, and output the
correct responses across a range of inputs.
Quantitative Heart Model Validation: During an EP testing procedure, the
physician places catheters inside the patient’s heart to observe local electrical activity
from different locations of the heart. The His bundle catheter (HBE) is particularly
important when evaluating the atria-to-ventricle conduction path (Fig. 3.9). For each
A to V conduction there are 3 impulses which correspond to atrial contraction (A), His
bundle activation (H) and ventricular activation (V). In this case study, two pacing
signals a1 and a2 are delivered to the heart from the high right atrial catheter (HRA).
By gradually decreasing the pacing interval in each test, certain tissue along the A-
V conduction path will be activated during its refractory period, thus affecting the
conduction delay further down the conduction path and change the intervals between
the impulses. Fig. 3.10(a) shows the relation between pacing interval (a1-a2) and
corresponding intervals between A, H and V impulses. On the left side it shows that
interval H1−H2 and V1−V2 decrease but remain equal as the pacing interval decreases,
indicating the tissue with the longest refractory period along the path is not between
the His Bundle and the ventricles. When the pacing interval decreases to 350ms both
intervals increases, indicating that the RRP of certain tissue has been reached and
the tissue is between the atria and the His bundle. On the right it shows that the
A2 −H2 interval increases as the pacing interval decreases, which further proves the
hypothesis that the AV node, which is between the atria and the His bundle, has the
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Figure 3.9: (a) Probe locations for a general EP testing procedure. (b) EGM signals
measured from the probes at the high right atrial (HRA), His bundle (HBE) and right
ventricular apex (RVA) standard catheter positions
longest refractory period along the A-V conduction path. We configured our heart
model such that the AV node has the longest refractory period and performed the
same study by decreasing the pacing interval. The heart model shows the same trend
as that of the real patient (Fig. 3.10(b)).
Validation by comparison to real patients: This heart condition can also show
Wenckebach type A-V nodal response. In this case, a sequence of pacing signals
with a short coupling interval (A1 − A2 <= AV.Terp + AV.Trrp) is delivered in the
atrium. This results in a gradual increase in the AV nodal conduction delay and then
a dropped beat occurs in the ventricle due to the increased ERP period of the AV
node. The EGMs for a real patient with Wenckebach type A-V nodal response are
shown in Fig. 3.11(a). With the VHM, we observe similar behavior, and the gradually
increasing ERP and conduction delay are visualized in Fig. 3.11(b).
3.5.2 Validating Models for Closed-loop Model Checking
In model checking, a lot of complex dynamics of the environment are abstracted so
that the environment model covers a larger number of environmental behaviors using
non-determinism. The validity of the model is obtained by a valid initial model and a
rigorous abstraction processes. In Jiang et al. [2014], we started with a valid detailed
deterministic model (as described above) and by applying different abstraction steps
we were able to generate a series of non-deterministic heart models. Between each
abstraction step, the heart models satisfy a timed simulation relationship (Yamane
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Figure 3.10: Key interval values when the coupling interval shortens for (a) a real patient
(Josephson [2008]) and (b) in heart model simulation (Jiang et al. [2010b]).
[2006]) which is described below. The timed simulation guarantees all behaviors are
covered in the more abstract model. More details regarding heart model abstraction
will be discussed in Chapter 3.
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(a) Real patient’s electrograms
(b) Heart model’s electrograms
Figure 3.11: (a) Electrograms of induced Wenckebach block in a patient. (b) Electrograms
of induced Wenckebach block in the heart model with a basic cycle length of 420 msec. The
heart model also displays lengthening in the A-H interval and block in A-V node (Marker
1). Rows 5 and 6 show the increase in the ERP and conduction delay of the A-V node.
3.6 EP Heart Model Identification
Physiological models are developed to represent certain clinical conditions common
across a population of patients, or the conditions of a specific patient. Consequently,
the structure of the model and corresponding parameters have to be identified. This
information can be obtained from electrogram data collected during medical proce-
dures and from physiological literature in which population data has been analyzed
and summarized. Due to limited interactions with the patient (e.g. during a device
implantation procedure or an ablation procedure), currently the quality and quan-
tity of patient-specific physiological data is sparse as there is generally not enough
information to identify all the parameters in the heart model. A model with the
spatio-temporal structure that is similar to the conduction patterns in the heart
helps simplify the process of identifying the model parameters. A rigorous procedure
for the model identification step is an important contributor to the model validation
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Figure 3.12: Simulation model of the heart showing the conduction pathways (left) with
electrogram signals from different probe locations (right) and an interactive pacing panel
(bottom left). In this case, the heart was paced four times at an interval of 500ms, followed
by a pacing at a shorter (250ms) interval. This EP Testing procedure is employed to trigger
conduction along alternative pathways and check for the existence of a reentry circuit.
step. In this section, we briefly discuss our model identification effort for heart models
used in two closed-loop validation applications, and their corresponding challenges.
Figure 3.13: (a) The illustration of the probe locations. (b) Multiple pacing sequences with
different timing outcomes. (c) The heart model with undecided parameters
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3.6.1 Heart Model Identification for Closed-loop Testing
In closed-loop simulation, a deterministic heart model should be identified to rep-
resent a specific patient under a certain heart condition. The constraints for model
parameters can be obtained from patient data with Electrophysiological (EP) Testing.
During EP testing, the physician delivers electrical pacing sequences from electrodes
placed inside the patient’s heart to instigate responses along fast and slow conduction
pathways (Fig. 3.12). The observed patterns and timing of electrical events are used
to extract conduction and propagation properties of different tissue regions across
the myocardium. Since the goal for any EP testing procedure is not to determine all
the timing parameters for a patient, the number of parameters that can be identified
from the patient data is limited.
Fig. 3.13 illustrates how timing parameters can be extracted during an EP testing
procedure. Fig. 3.13(a) shows a setup with two electrodes placed in the right atrium
and right ventricle of the heart respectively. EGM signals can be measured from these
two electrodes (Fig. 3.13(b)). The physician delivers a series of long interval pacing
sequences followed by one or more short interval pacing through the electrodes. This
may trigger different responses along primary and alternate conduction pathways
from the patient’s heart. Fig. 3.13(c) shows a heart model structure with unknown
parameter values. By analyzing the timing and pattern of the EGM signals we extract
constraints on the heart model parameters. In EGM sequence 1, the interval between
two intrinsic activations a1 and a2 in EGM A is 700ms, so we have:
ERP1 +RRP1 +Rest = 700ms
The interval between a1 and v1 is 150ms, so we have:
Td1 + Td2 = 150ms
In EGM sequence 2, the pacing interval from Electrode A is 300ms. By observing
that the interval between p1− v1 is less than the interval between p2− v2, we know
that p2 arrives during the RRP period of the AV node. So we have:
ERP1 +RRP1 ≤ 300ms
In EGM sequence 3, the pacing interval is further reduced to 250ms. There is no v2
corresponding to p2, indicating p2 arrives during the ERP period of the AV node. So
we have:
ERP1 ≤ 250ms
Each experiment provides additional time constraints for model parameters. By sys-
tematically conducting experiments certain model parameters can be uniquely iden-
tified within a relatively tight range. However, even with simplified model structure
like the one in the example, not all model parameters can be uniquely identified due
to limited number of electrodes and limited number of experiments during a real
procedure.
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Figure 3.14: Timing intervals measured during clinical studies (Josephson [2008])
Heart Model Identification in Closed-loop Model Checking
In model checking, the heart models have simpler structure and fewer parameters due
to non-deterministic abstraction. The placement and connectivity of nodes and paths
in the heart models are developed to be consistent with EP practice. This way, each
node and path automata and their timing parameters have physiological correspon-
dence to parameters found in literature (Fig. 3.14). The range for non-deterministic
parameters directly corresponds to the range for possible values of the respective
physiological parameters. Therefore, model identification for model checking is much
simpler and requires less EP testing data. It is important to note here that model
checking of abstract models of the closed-loop system and testing of the device in
the loop are complementary approaches for validating the safety and efficacy of the
overall system.
3.7 Discussion
The quality and validity of closed-loop validation results depend on the quality and
validity of the physiological models. It is essential for the physiological models to be
complex enough to accurately interpret the behaviors of physiological conditions, and
abstract enough to be identifiable from patient data. In order to evaluate the devices
in closed-loop, the models should also be simple enough so that they can be used for
model checking and interact with device implementations in real-time.
In this chapter, an EP heart model structure is developed for closed-loop evalu-
ation of implantable cardiac devices. The heart model structure is capable of repre-
senting a large variety of heart conditions and its parameters can be identified from
patient data.
However, the heart model structure can describe electrical activities of the heart,
thus heart conditions related to other perspectives (i.e. mechanical) cannot be inferred
from the model.
In the remaining dissertation, the heart model structure will be used in different
model-based techniques to provide safety and efficacy evidence for implantable cardiac
devices.
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Chapter 4
Theme 2: Closed-loop Model
Checking for Implantable
Pacemaker
Model checking is a technique in which the state space of the model under investiga-
tion is automatically and exhaustively explored to identify executions or states that
violate specified properties. Violations of the properties are returned by the model
checkers as counter-examples, which can be used by designers to revise the design. In
this chapter, model checking is used to evaluate an early design of a dual chamber
pacemaker. More specifically, model checking is used to identify known and unknown
physiological hazards induced by implantable pacemakers (e.g. when the pacemaker
provides inappropriate therapy which drives the heart to an unsafe state).
The chapter is organized as follow: first the basis for timed-automata formalism
is introduced. The dual chamber pacemaker specification introduced in Chapter 2
is implemented in model checker UPPAAL. The heart model structure in Chapter
3 is adjusted for closed-loop model checking of the pacemaker model. An abstrac-
tion tree of heart models is constructed to capture heart behaviors for different heart
conditions and provide physiological contexts to counter-examples. Finally the ab-
straction tree is used to check safety and efficacy properties of the pacemaker model,
as well as the effectiveness of additional algorithms developed to mitigate two known
safety hazards. We demonstrated that with appropriate models of the physiological
environment, closed-loop model checking is capable of finding safety and/or efficacy
violations within autonomous medical devices during device development.
4.1 Related Work
Jee et. al present a safety assured development approach of real-time software using
pacemaker as their case study in Jee et al. [2010b]. They formally model and verify
a single chamber VVI pacemaker using UPPAAL and then implement it and check
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the preservation of properties transferred from model to implementation code.
Chen et. al Chen et al. [2014] extended our verification work (Jiang et al. [2012b]).
They developed a hybrid heart model which is able to simulate action potential at
tissue level. The model is a more refined model than our Virtual Heart Model (Jiang
et al. [2012a]), with linear dynamics on each state of the heart tissue. They also
developed a probability model to simulate natural pacemaker function. They then
used the combined heart model for quantitative verification of the pacemaker. How-
ever, since the pacemaker only sense the timing of the heart tissue activation, their
hybrid extension for action potential does not bring much benefit but increased model
complexity dramatically. As a result, they have to use bounded model checking thus
sacrificed accuracy.
Tuan et. al propose an RTS formal model for pacemaker and its environment
and verified it against number of safety properties and timed constraints using the
PAT model checker (Tuan et al. [2010]). They have modeled the pacemaker for all 18
operating modes as described in Boston scientific, but their work lacks specification
and analysis of complex behaviors of the pacemaker, such as mode-switch.
Wiggelinkhuizen uses mCRL2 and UPPAAL to formally model the pacemaker
from the firmware design of Vitatron’s DA+ pacemaker (Wiggelinkhuizen [2007]).
Two main approaches have been used to investigate the feasibility of applying formal
model checking to the design of device firmware. The main approach consists of
verifying the firmware model in context of a formal heart model and a formal model
of a hardware module which fails for high heart rates because of the state explosion.
Another approach is to verify a part of firmware design which was feasible and was
able to detect a known deadlock rather soon.
Macedo et. al have developed a concurrent and distributed real-time model for
a cardiac pacemaker through a pragmatic incremental approach (D. et al. [2008]).
The models are expressed using the VDM and are validated primarily by scenario-
based test, where test scenarios are defined to model interesting situations such as
the absence of input pulses. The models cover 8 modes of pacemaker operation.
Gomes et. al present a formal specification of pacemaker system using the Z
notation in Gomes and Oliveira [2009a]. They have also tried to validate that the
formal specification satisfies the informal requirements of Boston Scientific by using a
theorem prover, ProofPower-Z. They have partially checked the consistency of their
specification through reasoning. No validation experiment regarding safety conditions
were performed yet.
Mery et. al in Mery and Singh [2009], formally model all operational modes of
a single electrode pacemaker system using event-B and prove them. They use an
incremental proof-based approach to refine the basic abstract model of the system
and add more functional and timing properties. They use the ProB tool to validate
their models in different situations such as absence of input pulses.
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4.2 Model of A Dual Chamber pacemaker
During development of a dual chamber pacemaker, the specification can be translated
into a model so that it can be analyzed by model checkers. The pacemaker specifica-
tion discussed in Chapter 2 utilizes the timing and patterns of electrical events in the
heart, which can be intuitively modeled by timed-automata (Alur and Dill [1994])
and evaluated using model checker UPPAAL Larsen et al. [1997].
4.2.1 Timed Automata
Timed automata (Alur and Dill [1994]) is an extension of a finite automaton with a
finite set of real-valued clocks. It has been used for modeling and verifying systems
which are triggered by events and have timing constraints between events. UPPAAL is
a standard tool for modeling and verification of real-time systems, based on networks
of timed automata. The graphical and text-based interface makes modeling more
intuitive. Safety and efficacy requirements can be specified using Computational
Tree Logic (CTL), as described in Clarke and Emerson [1982], and violations can be
visualized in the simulation environment.
Syntax of Timed Automata
A timed automaton G is a tuple 〈S, S0,Σ, X, inv, E〉, where
• S is a finite set of locations.
• S0 ∈ S is the set of initial locations.
• Σ is the set of events.
• X is the set of clocks.
• inv is the set of invariants for clock constraints at each location.
• E is the set of edges. Each edge is a tuple 〈s, σ,Ψ, λ, s′〉 which consists of a
source location s, an event σ ∈ Σ, clock constraints Ψ, λ as a set of clocks to
be reset and the target location s′.
For the clock variables X, the clock constraints Ψ ∈ ΨX can be inductively defined
by Ψ := x⊥c‖Ψ1 ∧Ψ2, where ⊥ ∈ {≤,=,≥}, and c ∈ N.
Semantics of Timed Automata
A state of a timed automaton is a pair 〈s, v〉 which contains the location s ∈ S and
the valuation v for all clocks. The set of all states is Ω. For all λ ∈ X, v[λ := 0]
denotes the valuation which sets all clocks x ∈ λ as zero and the rest of the clocks
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unchanged. For all t ∈ R, v + t denotes the valuation which increase all the clock
value by t. There are two kinds of transitions between states. The discrete transition
happens when the condition of an edge has been met. So we have:
〈s, σ,Ψ, λ, s′〉 ∈ E, v |= Ψ, v[λ := 0] |= inv(s′)
⇒ (s, v) σ−→ (s′, v[λ := 0])
The timed transition happens when the timed automaton can stay in the same location
for certain amount of time. We have:
δ ∈ R,∀δ′ ≤ δ, v + δ′ |= inv(s)
⇒ (s, v) δ−→ (s, v + δ)
4.2.2 UPPAAL Model of a Dual Chamber Pacemaker
The five timing cycles introduced in Chapter 2 can be modeled as timed automata
in UPPAAL (Fig. 4.1). Different components communicate with each other using
broadcast channels in UPPAAL. The pacemaker model takes Aget and V get events
as inputs from the heart model, and outputs AP and V P as pacing signals to the
heart.
4.3 Heart Models for Closed-loop Model Checking
During closed-loop model checking, the device model is verified against safety and
efficacy properties under physiological conditions covered by the human physiology.
It is challenging to develop physiological models for closed-loop model checking of
autonomous medical devices. The following aspects need to be taken into account:
• Model Interpretability: How much detail should the physiological models
have in order to unambiguously describe a physiological behavior? In particular,
if the model checker returns an execution trace as counter-example, how much
detail should the physiological model have so that the execution traces can be
interpreted by medical domain experts?
• Behavior Coverage: What approach must we use for physiological models to
cover the large variability of human physiology? How can these models cover
rare physiological cases and those that are unknown to us?
• Model Ambiguity: Multiple physiological conditions can map to the same
event trace due to the limited observability of the device. How can we eliminate
only the healthy execution from the model so that it would not cause a false-
positive?
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Figure 4.1: Five basic timing cycles for a dual chamber pacemaker, which include the Lower
Rate Interval (LRI), Atrio-Ventricular Interval (AVI), and Upper Rate Interval (URI). Also
included are the blanking intervals, Post Ventricular Atrial Refractory Period (PVARP)
and Ventricular Refractory Period (VRP), to inhabit action by the pacemaker.
The heart model structure proposed in Chapter 3 can be used to model various heart
conditions. The model structure provides interpretability for closed-loop interaction
between the heart and the pacemaker and is capable of solving ambiguities between
heart conditions that can map to the same pacemaker execution. However, physiolog-
ical conditions cannot be exhaustively enumerated and model checking on all possible
heart models is infeasible. In the remaining section, over-approximation is first pro-
posed to increase behavior coverage of heart models. However, over-approximation
inevitably introduces invalid behaviors into the model, which can cause false-positives.
Moreover, due to the loss of details during over-approximation, the interpretability of
the model decreases which prevents the model to distinguish between different heart
conditions. At the end of this section, an abstraction tree framework is proposed to
balance model abstraction and refinement for closed-loop model checking.
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4.3.1 Covering More Behaviors With Over-approximation
Over-approximation Clarke et al. [2003] has originally been proposed to reduce model
complexity during model checking. For timed-automata, timed-simulation is a form
of over-approximation.
For two timed automata T 1 = 〈S1, S10 ,Σ1, X1, inv1, E1〉
and T 2 = 〈S2, S20 ,Σ2, X2, inv2, E2〉, a timed simulation relation is a binary relation
sim ⊆ Ω1 × Ω2 where Ω1 and Ω2 are sets of states of T 1 and T 2. We say T 2 time
simulates T 1 (T 1 t T 2) if the following conditions holds:
• Initial states correspondence: (〈s10,0〉 , 〈s20,0〉) ∈ sim
• Timed transition: For every (〈s1, v1〉 , 〈s2, v2〉) ∈ sim, if 〈s1, v1〉 δ−→ 〈s1, v1 + δ〉,
there exists 〈s2, v2 + δ〉 such that 〈s2, v2〉 δ−→ 〈s2, v2 + δ〉 and
(〈s1, v1 + δ〉 , 〈s2, v2 + δ〉) ∈ sim.
• Discrete transition: For every (〈s1, v1〉 , 〈s2, v2〉) ∈ sim, if 〈s1, v1〉 σ−→ 〈s′1, v′1〉,
there exists 〈s′2, v′2〉 such that 〈s2, v2〉 σ−→ 〈s′2, v′2〉 and (〈s′1, v′1〉 , 〈s′2, v′2〉) ∈ sim.
Certain properties are preserved for timed simulation relation. For ϕ ∈ ATCTL,
if M t M ′, we have M ′ |= ϕ⇒M |= ϕ Yamane [2006]. However, M ′ 6|= ϕ⇒M 6|= ϕ
does not hold. Violations of ATCTL yield counter-examples and the validity of which
need to be checked.
In this work, the property of introducing additional behaviors is used as our
advantage to cover more behaviors into a more abstract heart model. By applying
physiological abstraction rules to heart models, we creates over-approximation of the
heart models that not only covers all behaviors of the original heart model, but also
covers additional behaviors that belong to other heart conditions.
It is known that timed simulation relation is also closed under composition Yamane
[2006]. So when we have two heart models H1 t H2 we will have H1‖P t H2‖P
where P is the timed-automata model of the pacemaker. For ϕ ∈ ATCTL, we have
H2‖P |= ϕ⇒ H1‖P |= ϕ.
4.3.2 Counter-Example-Guided Abstraction Refinement
The abstract heart models obtained by over-approximation can be used for closed-loop
model checking of the device model. If the closed-loop system satisfies a requirement,
the device under verification satisfies the requirement under environment conditions
covered by the abstract models. However, if the requirement is not satisfied, the
model checker returns a counter-example. In device modeling, the counter-example is
considered spurious if it can not be produced by the device (as shown in (Fig. 4.2(a)).
However in environment modeling, even if the counter-example can not be produced
by any of the initial environment models, it might still be a physiologically valid
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Figure 4.2: (a) Device modeling with CEGAR framework (b) Closed-loop model checking
with environment abstraction tree.
behavior. Thus the validity of a counter-example cannot be determined by refining
the environment model, but can ultimately only be determined by domain experts.
Counter-examples returned from abstract models can be difficult to interpret by
domain experts. One abstract counter-example could be produced by multiple phys-
iologically valid conditions, which causes ambiguity. Thus, a rigorous framework is
necessary to balance the need to cover a wide range of environmental conditions and
the need to provide counter-examples to the physicians within their physiological
context.
Another challenge for closed-loop model checking of medical devices is the amount
of domain expertise needed during: 1) physiological modeling, 2) model abstraction
and refinement, and 3) checking the validity of counter-examples. Thus the frame-
work must also allow non-domain experts to perform verification (item 2 above), and
establish ‘hand-off’ points where the results of verification can be handed back to the
experts for interpretation.
4.3.3 Abstraction Tree for Heart Model Abstraction Refine-
ment
The ideal heart model for closed-loop model checking of an implantable pacemaker
not only covers all possible inputs to the pacemaker, but also has physiological expla-
nations to all known heart conditions. However, no single heart model can satisfy
both requirements. Therefore, a set of heart models must be employed where the
different abstraction levels of the models strike a balance between coverage and ex-
pressiveness. More importantly, the heart models should have rigorous relationships
among each other to provide formal guarantees.
In this section we present the abstraction tree framework that maintains formal
Timed Simulation relationships between heart models and enables automated closed-
loop model checking of implantable pacemaker.
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Figure 4.3: Node and Path Automata which models the timing properties of the heart
tissue. A network of node and path automata models the generation and conduction of
electrical activities of a heart
Initial Set of Heart Models
The heart model structure discussed in Chapter 3 is implemented in UPPAAL as
shown in Fig. 4.3. Dynamic changes of the ERP periods and conduction delays are
abstracted as ranges using non-determinism in timed-automata. This enables the
heart model structure to capture behaviors of the heart models with timing vari-
ability. This heart model structure is based on clinical electrophysiology, with state
variables and parameters directly corresponding to physiological parameters. There-
fore, domain experts from clinical electrophysiology can construct models of different
heart conditions with their domain expertise and literature.
An example set of initial heart models is shown in Fig. 4.4. The different topologies
of node and path automata represent the mechanism of different heart diseases. These
heart models represent the current knowledge for heart condition variability, thus the
set is inherently incomplete, meaning there is no guarantee for 100% safety even if a
property is satisfied in all of these models. These models are mostly used for providing
physiological contexts for counter-examples returned by the model checker. Domain
experts can always expand the set with knowledge of new heart conditions.
Interaction With the Pacemaker
The interactions between the heart and the pacemaker are modeled by using binary
event channels. For the atrial lead, we have: NA.Act path! →Aget!, and for ventric-
ular lead we have NV .Act path!→Vget!.
The pacemaker accordingly generates atrial or ventricular pacing actions AP!→ NA.Act node!
and VP!→ NV .Act node!.
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Figure 4.4: Examples of the initial set of heart models. The models are different in node
and path topology and/or timing parameters.
Physiological Abstraction Rules
The initial set of heart models only represents a subset of all possible conditions.
There always exists conditions that are beyond our knowledge or that are combina-
tions of known conditions. By using over-approximation, heart models can be created
that cover the observable behaviors of the initial set and that introduce behaviors that
were not captured in the initial set. Inevitably, some of the introduced behaviors will
be physiologically invalid. This problem can be alleviated by carefully designing the
abstraction rules so that behaviors introduced are mostly physiologically valid. The
physiologically invalid behaviors can be eliminated during a validity check in the
abstraction tree.
Physiological abstraction rules are developed to cover observable behaviors of heart
models. Applying one abstraction rule to heart model(s) H1, Hi . . . Hn, n ≥ 1 yields
an abstract heart model H ′ such that all observable behaviors of Hi are covered by
H ′. For each heart model Hi, H ′ is a timed simulation of Hi. To illustrate, a subset
of abstraction rules is described intuitively. The complete set of abstraction rules
and the proofs of timed simulation relationship can be found in the tech report Jiang
et al. [2015].
Rule R1: Convert Reentry Circuits to Activation Nodes
Within the conduction network of the heart, there can be multiple pathways between
two locations, forming conduction loops. If the timing parameters of the tissue along
the loop satisfy certain properties, there can be scenarios in which a depolarization
wave circling along the circuit. The circuits are referred to as Reentry Circuits. Since
the time interval for an activation wave to circle a reentry circuit is usually less
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than the intrinsic heart cycle length, the heart rate will be ”‘hijacked”’ by the reentry
circuit once the cycling is triggered, causing tachycardia. Reentry is the most common
mechanism for tachycardia, which can be captured by our heart models that are used
in Jiang et al. [2010a].
The effect of reentry tachycardia is that activation signals coming out of the circuit
with a given cycle length equal the sum of conduction delays along the circuit. It
is therefore reasonable to model a reentry circuit as a self-activation node with the
self-activation range equal to the sum of conduction delays.
Applicable Condition: The rule only affects the topology of the model, and
therefore can be applied without preliminaries.
Output model: The ”essential structure” of a heart model is the shortest paths
(in terms of conduction delay) connecting self-activation nodes and/or sensing nodes.
First detect all circles in the input graph. For each circle with nodes Ni, i ∈ [1 . . . n]
and paths Pj, j ∈ [1 . . .m], remove all ”non-essential” nodes and paths, create a node
automaton Ns and connect to the nearest sensing node with a path automaton Ps.
Effect on parameters: For the new node automaton Ns, the minimum of the Trest
parameter is set to the minimum of the sum of the conduction delays within the
reentry circuit, and the maximum is set to infinity
Effect on behaviors: The new model captures the behavior of the original model
when the reentry circuit is active and inactive. Additionally, the new model captures
the behaviors of other heart conditions in which the rate of the reentry circuit is
lower.
Fig. 4.5 shows an example in which a circle is replaced by a self-activation node.
R1
Figure 4.5: Rule R1: Remove reentry circuits from the model
Rule R2: Remove Non-essential Structures
After the circles within the topology are removed, the topology of the heart model is
in the form of a tree. Since the ”non-essential” structures do not affect the activation
signals from and/or to the sensing nodes, all the ”non-essential” structures can be
removed.
Applicable Conditions: The rule can only be applied after Rule 1 has been applied.
Output model: Trimmed topology with only the essential structure remaining.
Effects on parameters: There are no effects on parameters of the node and path
automata.
Effects on behaviors: Applying this rule does not affect the observable behaviors
of the model.
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Fig. 4.6 shows an example in which non-essential structures are removed.
R2
Figure 4.6: Rule R2: Remove non-essential structures
Rule R3: Removing Unnecessary Non-self-activation Nodes
The effect of non-self-activation nodes is blocking electrical events with interval shorter
than its ERP period. If the self-activation nodes at both ends of a core path have
self-activation interval longer than the maximum ERP period of nodes along the core
path, the nodes can be removed.
For a core path from a self-activation node N1 to another core node N2, for any
structure P1 − Nn − P2 which Nn is a non-self-activation node, if Nn.ERPmax <
min(N1.Restmin, N2.Restmin), replace P1 −Nn − P2 with P3 so that:
P3.condmin = P1.condmin + P2.condmin
P3.condmax = P1.condmax + P2.condmax
SA.Trest=[a1,b1]
SA.Trest=[a2,b2]
SA.Trest=[a3,b3]
SA.Trest=[min(a1,a2,a3),max(b1,b2,b3)]
R4
Figure 4.7: Rule R4: Merging parameter ranges
Rule R4: Merge Parameter Ranges
Timing periods of heart tissue, such as Rest and ERP, are modeled as locations in
the node and path automata. The minimum and maximum time an automaton can
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Figure 4.8: Rule R6 application example: the blocking property of N31 is fulfilled by a
non-deterministic conduction path P 12
remain in a location is governed by the parameters in the guards and invariants. By
merging and expanding these periods, new behaviors are introduced where a heart
model may remain longer in Rest, activate or self-activate a node faster, andsoforth.
Applicable Conditions: This rule applies to heart models with the same node
and path topology but possibly with different parameters.
Output Model: The abstract model has the same topology as the original models.
Effects on parameters: The parameter ranges in the new model are a super-set of
the parameter ranges in the old models.
Effects on behaviors: The abstract model captures all behaviors of the original
models. In addition, heart conditions with parameters outside of the ranges of the
original models are covered.
Rule R5: Merge Self-activation Nodes with Interaction Nodes
The effect of self-activation nodes on the interaction of the pacemaker is triggering
sensing events within certain delay. In this rule we merge all the self-activation nodes
to their neariest interaction nodes. If there exists multiple self-activation nodes merg-
ing to the same interaction node, the parameters of the new model are determined
following Rule 3.
50
Rule R6: Replace Blocking With Non-deterministic Conduction
Consider the structure N11P
1
1N
3
1P
2
1N
2
1 with three nodes and two paths, where N
3
1 is
a passive node (i.e. not self-activating). If N31 blocks an activation signal from N
1
1
to N21 , this is equivalent to the paths P
1
1 or P
2
1 not conducting. In this rule, the
structure P 11N
3
1P
2
1 is replaced by a path P
1
2 whose automaton can take a self loop
when it receives an activation signal, thus effectively stopping the conduction. This
is shown in Fig. 4.8. Because the blocking effect of nodes is now incorporated into the
paths, the node automata of self-activating nodes can be modified to the one shown
in Fig. 4.8, which does not have the (now useless) ERP period.
Subgraph to which it applies. Line graphs with 3 vertices N11P
1
1N
3
1P
2
1N
2
1 , and
self-activating nodes.
Applicability conditions. N21 is a passive node.
Output subgraph. N12P
1
2N
2
2as shown in Fig. 4.8
Effect on parameters For the new path, P.condmin = P1.condmin +P2.condmin and
P.condmax = P1.condmax+P2.condmax For the new nodes, N
′.T restmin = N.Terpmin+
N.Trestmin and N
′.T restmax = N.Terpmax +N.Trestmax.
Rule R7: Replace Conduction With Self-activation
We describe Rule R7 as it illustrates both effects of an abstraction rule: structure
change and modifications to the automata. The effect of a conduction path is to
conduct electrical activity from a node. Since the pacemaker cannot distinguish
self-activation of the node and activation triggered by path conduction, we can use
self-activation to replace path conduction. If all self-activation nodes are allowed at
any time by setting their minimum Rest period to 0, all the conduction paths can
be removed, while preserving the original behaviors (where the Rest period was con-
strained to a finite interval).
Applicability conditions. This rule can only be applied after Rule 5 and Rule 6
have been applied.
Output graph. All edges are deleted. The node automata are replaced with the
one shown on the right in Fig. 4.9.
Effect on parameters For every node automaton N in G′, N.Trestmin = 0.
Now we use R7 as example to demonstrate the timed-simulation relationship be-
tween heart models before and after the application of R7. Consider Fig. 4.9 showing
an application of R7, H1 = N
2
1P
1
2N
1
2 is abstracted to H2 = N
1
3N
2
3 . Here we prove
that H1 t H2 with observable events Σo = {N1.Act path,N2.act path}. The state
of H1 is represented by (N
1
2 .loc, P
1
2 .loc,N
2
2 .loc,N
1
2 .t, P
1
2 .t, N
2
2 .t) and the state of H2
is represented by (N13 .loc,N
2
3 .loc,N
1
3 .t, N
2
3 .t). Due to space limit, only one transition
from each category is presented:
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Figure 4.9: Rule R7 application example: The conduction property of P 12 is replaced by self
activation of N13 and N
2
3
Initial state: First for the initial state we have:
〈(Rest, Idle, Rest, 0, 0, 0), (Rest, Rest, 0, 0)〉 ∈ simo
Timed transitions: Consider a timed transition in H1
(Rest, Idle, Rest, t1, t2, t3)
τ−→ (Rest, Idle, Rest, t1 + τ, t2 + τ, t3 + τ)
in which (τ ∈ R) ∧ (t1 + τ ≤ N12 .T rest max) ∧ (t3 + τ ≤ N22 .T rest max). For a
state in H2 such that 〈(Rest, Idle, Rest, t1, t2, t3), (Rest, Rest, t1, t3)〉 ∈ simo, there is
a timed transition:
(Rest, Rest, t1, t3)
τ−→ (Rest, Rest, t1 + τ, t3 + τ)
and 〈(Rest, Idle, Rest, t1 + τ, t2 + τ, t3 + τ), (Rest, Rest, t1 + τ, t3 + τ)〉 ∈ simo.
Discrete transitions: Consider a discrete transition in H1
(Rest, Ante, Rest, t1, t2, t3)
N22 .Act path!−−−−−−−−−−−−−−−−−−−−→
t2∈[P 12 .T cond min,P 12 .T cond max)
(Rest, Idle, Rest, t1, t2, 0)
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in which N22 .Act path! ∈ Σo.
For a state in H2 such that 〈(Rest, Idle, Rest, t1, t2, t3), (Rest, Rest, t1, t3)〉 ∈ simo,
there is a discrete transition:
(Rest, Rest, t1, t3)
N23 .Act path!−−−−−−−−−−−−→
t3∈[0,N23 .T rest max)
(Rest, Rest, t1, 0)
and 〈((Rest, Idle, Rest, t1, t2, 0)), (Rest, Rest, t1, 0)〉 ∈ simo. Basically activation due
to conduction is replaced by self-activation of the corresponding node automata.
Additional behaviors: The timed-simulation also allows additional behaviors into
H2. Consider a discrete transition in H2
(Rest, Rest, t1, t3)
N23 .Act path!−−−−−−−−−−−−→
t3∈[0,N23 .T rest min)
(Rest, Rest, t1, 0)
However, for a state in H1 such that 〈(Rest, Idle, Rest, t1, t2, t3), (Rest, Rest, t1, t3)〉 ∈
simo, when t3 ∈ [0, N22 .T rest min] there is no available discrete transitions. Physio-
logically, these implicitly included behaviors correspond to fast heart rate, premature
heart events and even noise.
Abstraction Tree
By applying the abstraction rules to the initial set of heart models, an abstraction
tree is created. Fig. 4.10 shows an example of an abstraction tree with the root
model capturing all possible input sequences to the pacemaker. Self-activating nodes
are marked as red and the Trest parameters are specified next to them. Note that
this abstraction tree is not unique. With a different initial set of heart models and/or
different rule application orders the abstraction tree can be very different. The ab-
straction tree can also be extended at any time if new heart conditions are specified.
The following section demonstrates the use of this abstraction tree during the closed-
loop model checking of the pacemaker design.
4.4 Efficacy Validation for Implantable Pacemaker
The most essential function for the pacemaker is to treat bradycardia by maintaining
the ventricular rate above a certain threshold. We define the region where the ven-
tricular rate is slow, as unsafe. The monitor PLRI test is designed to measure intervals
between ventricular events and is shown in Fig. 4.11(a). For property
ϕLRI =A[] (PLRI test.secV imply PLRI test.t≤TLRI)
we have a closed-loop system with heart model H0 :
H0‖P‖PLRI test |= ϕLRI
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Figure 4.10: One example of abstraction tree of heart models
The pacemaker is not designed to treat tachycardia so it can only pace the heart to
increase its rate and cannot slow it down. To mitigate the hazard that the pacemaker
may increase the heart rate above physiological need, an Upper Rate Interval (URI)
is specified such that the pacemaker can increase the ventricular rate up to this limit.
We require that a ventricle pace (VP) can only occur at least TURI after a
ventricle event (VS, VP). The monitor PURI test is shown in Fig. 4.11(b). For the
property
ϕURI =A[] (PURI test.secV imply PURI test.t≥TURI)
we have:
H0‖P‖PURI test |= ϕURI
secVwait_2ndwait_1st
t=0
VP?
Vget?
VP?
t=0
Vget?
t=0
(a) Monitor PLRI test
secVwait_vpwait_v
Vget? t=0
t=0
VP?
Vget?
t=0
VP?
t=0
(b) Monitor PURI test
Figure 4.11: (a) Monitor for LRL: Interval between two ventricular events should be less
than TLRI, (b) Monitor for URL: Interval between a ventricular event and a VP should be
longer than TURI
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Figure 4.12: UPPAAL monitor for Property 1
As we saw in the above examples, the efficacy requirements are satisfied with the
most abstract heart model. Therefore no heart model refinements are necessary and
the requirements are satisfied under all possible heart conditions.
4.5 Safety Validation for Implantable Pacemaker
A dual chamber pacemaker is designed to increase the heart rate during bradycardia,
but it should also not increase the heart rate inappropriately. Inappropriate increase
of heart rate by the pacemaker is referred to as Pacemaker Mediated Tachycardia
(PMT). Previous work Jiang et al. [2014] used model checking to identify two known
PMT conditions. However, in order to avoid ambiguities in the counter-examples,
the properties for the two PMTs were specified very specifically, which abandoned
the advantage of model checking to find unknown safety violations.
With the abstraction tree approach, the ambiguities can potentially be resolved
since the abstraction tree considers all known heart conditions. Therefore the property
for PMTs can be specified more generally. Here we specify a property such that
ϕPMT : The interval between ventricular events (Vget, VP) should not be shorter than
TURI for 30 consecutive beats
which means that the ventricular rate should not be faster than the upper rate interval
(TURI) for too long, either intrinsically or because of pacemaker interaction. Counter-
example because of intrinsic fast ventricular rates can be removed from results after
analysis from the abstraction tree.
A UPPAAL monitor Mcon for the property is shown in Fig. 4.12, and the TCTL
property is specified as:
A[] not Mcon.err
The model checker UPPAAL was used to check Property ϕPMT on the pacemaker
model using the abstraction tree of heart models. The property is violated inH0||PM ,
thus thus the abstraction tree is followed to select pair H1 with the pacemaker model
and Property 1 is verified again. The process continues till either the leaves of the
tree are reached of the property is satisfied. The result is shown in Fig. 4.13, which
demonstrates 5 different scenarios that can happen when using the abstraction tree.
The shaded area marks the heart models with counter-examples.
55
H0
[20,2000]
[20,2000]
H1
[200,2000]
[200,2000]
[200,300]
[1000,2000]
[1000,2000]
[1000,2000]
[1000,2000]
[200,2000]
[200,300]
[1000,2000]
[1000,2000]
[1000,2000]
[1000,2000]
[200,2000]
[1000,2000]
[200,2000]
AVI AVI AVI
VP VP VP
<500
𝐂𝐄𝐚𝐟
Heart
Pacemaker
PVC AV
I
AVI AVI AVI
<500
VP VP VP
cond cond cond
𝐂𝐄𝑷𝑽𝑪
Heart
Pacemaker
VS𝐂𝐄𝒗𝒕
Heart
Pacemaker
VS VS VS VS VS
H2_1
H2_2
H2_3
H2_4
H3_1
H3_2
H3_3
H3_4H4_4
R7
R4
R4
R4
R4
R3
R3
R3
R5R3
AV
I
AVI AVI AVI
<500
VP VP VP𝐂𝐄𝒔𝒕
Heart
Pacemaker
[400,2000] [400,2000]
H2_5H3_5
R3
R4
Figure 4.13: Four different physiological conditions in which Property 1 is violated. In CEaf
the pacemaker extends a fast atrial rate to a dangerously fast ventricular rate; in CEvt the
ventricular rate is intrinsically fast; in CEst the pacemaker appropriately maintained A-V
conduction delay; in CEpvc the pacemaker inappropriately increased the ventricular rate,
causing Endless Loop Tachycardia
Case 1: Property 1 is violated in H2 1||PM but is satisfied in its children
H3 1||PM . Careful examination of the counterexample finds it to be spurious and
so it is successfully eliminated by model refinement.
Case 2: CEaf is returned by H3 2||PM and corresponds to intrinsic atrial tachy-
cardia with fast atrial rate, which is a sub-optimal but non-lethal condition. The AV
node of the heart will block a subset of the electrical events and maintain a normal
ventricular rate. However, despite the filters in the pacemaker, the pacemaker still
paces the ventricle for every 3 atrial activations, which extends fast atrial rate to
more dangerous fast ventricular rate. The condition is referred to as Atrial Tachycar-
dia Response in which the ventricular rate is increased inappropriately, thus requires
revision of the pacemaker design.
Case 3: CEvt is returned by H3 3||PM and corresponds to intrinsic ventric-
ular tachycardia with fast ventricular rate. The counter-example is physiologically
valid but the fast ventricular rate is due to the heart itself and is beyond pacemaker
functionality. Therefore this scenario demands no revision of the pacemaker design.
Case 4: CEst is returned by H3 5||PM and corresponds to sinus tachycardia,
for instance, when the patient is exercising. The pacemaker improved the open-loop
heart condition by pacing the ventricles AV I after each atrial event, which is a correct
operation of the pacemaker despite the requirement violation.
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Figure 4.14: (1) The component PVAS sends VP AS! event when a VP-AS pattern with
delay between [150,200] is detected; (2) Component ELTct. After 8 VP-AS pattern, the
algorithm increase TPVARP to 500ms. (3) Modified PVARP’ component. TPVARP can
only be set to 500 for one timing cycle.
Case 5: CEpvc is returned by H4 4||PM and has a very similar input-output
relationship to CEn. However, the activations of the atrial node are triggered by
retrograde conduction from ventricular paces (marker cond). The atrial activations
trigger another ventricular pace after AV I, which will trigger another retrograde
conduction. In this case the heart rate is inappropriately high, which corresponds to
a dangerous closed-loop behavior referred to as Endless Loop Tachycardia.
From the above result, it can be seen that abstraction tree is able to 1) refine a
heart model to eliminate spurious counter-examples as in Case 1; 2) provide (multi-
ple) physiological explanations to a counter-example as in Case 2-5; and 3) resolve
ambiguities caused by abstraction as in Case 4 and 5.
Device manufacturers have developed algorithms aiming to eliminate behaviors
showed in Case 2 and Case 5. In the following section we demonstrate the use of
abstraction tree to evaluate the effectiveness of these algorithms.
4.5.1 Terminating Endless Loop Tachycardia
Due to the limited information the pacemaker has about the heart, the pacemaker
cannot distinguish a retrograde atrial event from an intrinsic atrial event which is
triggered by the SA node. From the pacemaker’s point of view, the pacemaker paces
the ventricles as specified for every AS. That is why open-loop testing is unable to
detect this closed-loop behavior.
Modern pacemakers are equipped with anti-ELT algorithms to identify and ter-
minate potential ELT. One common algorithm identifies ELT by the ELT pattern
and terminates ELT by increasing TPVARP time once to block the AS caused by
the V-A conduction. By increasing the blocking interval after a ventricular event, the
pacemaker effectively ignores the early atrial signal detected due to the PVC.
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ELT termination algorithm
The ELT persists without intervention and the patient’s heart is forced to beat at
a fast rate approaching the Upper Rate Limit. Thus, device manufacturers require
a way to identify ELT and terminate it despite the limited information the pace-
maker can get. The ELT detection algorithm by Boston Scientific Boston Scientific
Corporation [2007a] utilizes these three features:
• Ventricular rate at Upper Rate Limit
• VP-AS pattern
• Fixed V-A conduction delay
The pacemaker first monitors VP-AS pattern with ventricular rate at upper rate limit.
Then it compares the VP-AS interval with previous intervals. ELT is confirmed if
the difference between the current VP-AS interval and the first VP-AS interval is
within ±32ms for 8 consecutive times. Then the pacemaker increases the PVARP
period to 500ms once so that the next AS will be blocked and will not trigger a VP,
terminating ELT. As the V-A conduction delays are patient-specific, the algorithm
compares the VP-AS interval to a previously sensed value instead of an absolute
value. Since we can not store past clock values in UPPAAL, we can not explicitly
model this ELT detection algorithm. However, since the conduction delay in our
heart model is within a known range, we can compare the VP-AS interval with this
range. The VP-AS pattern detection module V PAS for our anti-ELT algorithm is
shown in Fig. 4.14 (1). It detects the VP-AS pattern with ventricular rate at the
Upper Rate Limit and sends out a VP AS event if the interval qualifies.
A counter ELTct counts the number of qualified VP-AS patterns. It increases the
PVARP period to 500ms if eight consecutive VP-AS patterns are detected. (Fig. 4.14
(2)) The PVARP component is also modified so that the PVARP period can only be
changed once by the anti-ELT algorithm. (Fig. 4.14 (3))
Verification of the algorithm
With the new pacemaker model
P1 = LRI‖AV I‖URI‖PV ARP ′‖V RP‖ELTct‖V PAS
we first check whether the two efficacy properties still hold when the anti-ELT algo-
rithm is introduced. We have
H0‖P1‖PLRI test |= ϕLRI
H0‖P1‖PURI test |= ϕURI
Indicating the efficacy properties still hold after introducing the anti-ELT algorithm.
Then property ϕPMT is checked, we have
H2 4‖P1‖PELT det‖Pvv 6|= ϕPMT
which indicates the algorithm successfully eliminated all ELT executions.
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Figure 4.15: (a) After switching to VDI mode, the new LRI component LRI’ maintains a
minimum V-V interval; (b) After switching to VDI mode, the new AVI component AVI’
keeps track of the time after each atrial events.
4.5.2 Mode Switch Operation: Atrial Tachycardia Response
Pacemaker manufacturers have designed algorithms to detect and terminate behaviors
as in CEaf . Intuitively, the mode-switch algorithm first detects SVT. After confirmed
detection, it switches the pacemaker from a dual-chamber mode to a single-chamber
mode. During the single-chamber mode, the A-V synchrony function of the pacemaker
is deactivated thus the ventricular rate is decoupled from the fast atrial rate. After
the algorithm determines the end of SVT, it will switch the pacemaker back to the
dual chamber mode. The mode-switch algorithm (also known as atrial tachycardia
response) specification we use is similar to the one described in the Boston Scientific
pacemakers’ manual (Boston Scientific Corporation [2007b]). The algorithm first
measures the interval between atrial events outside the blanking period (AS, AR).
The interval is considered as fast if it is above a threshold (Trigger Rate) and slow
otherwise. In our UPPAAL model we model it as INT (see Fig. 4.16 (1)). A counter
CNT increments for fast events and decrements for slow events (see Fig. 4.16 (2)).
After the counter value reaches the Entry Count, the algorithm will start a Duration
(DUR) ,which is a time interval used to confirm the detection of SVT (see Fig. 4.16
(3)). In the Duration, the counter keeps counting. If the counter value is still positive
after the Duration, the pacemaker will switch to the VDI mode (Fallback mode). In
the VDI mode, the pacemaker only senses and paces the ventricle. At any time if the
counter reaches zero, the Duration will terminate and the pacemaker is switched back
to DDD mode. In our UPPAAL model of the mode-switch algorithm, we use nominal
parameter values from the clinical setting. We define trigger rate at 170bpm (350ms),
entry count at 8, duration for 8 ventricular events and fallback mode as VDI.
In order to model both DDD and VDI modes and the switching between them, we
made modifications to the AVI and LRI components. In each component two copies
for both modes are modeled, and switch between each other when switching events
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Figure 4.16: (1) Component INT: An atrial event (AS,AR) arrives before thresh after the
previous atrial event is regarded as a fast event. Atrial event arrives after thresh and AP are
regarded as slow event; (2) Component CNT: After 8 fast event the algorithm will start a
duration by sending du beg and will switch to VDI mode when the duration ends (du end);
(3) Component DUR :The duration length is 8 ventricular events (VS,VP)
(DDD, VDI) are received. During VDI mode, VP is delivered by the LRI component
instead of the AVI component. The clock values are shared between both copies in
order to preserve essential intervals even after switching. The modified AVI (AV I ′)
and LRI (LRI ′)components are shown in Fig. 4.15.
Verification of the Mode-Switch Algorithm
With the new pacemaker model
P2 = LRI
′‖AV I ′‖URI‖PV ARP ′‖V RP‖INT‖CNT‖DUR
we first check whether the two efficacy properties still hold when the anti-ELT algo-
rithm is introduced. We have
H0‖P2‖PLRI test 6|= ϕLRI
H0‖P2‖PURI test |= ϕURI
By analyzing the counter-example we found that when the pacemaker is switching
from VDI mode to DDD mode, the responsibility to deliver VP switched from LRI
component to AVI component. Since the clock reference is different (Ventricular
events in LRI component and Atrial events in AVI component), the clock value for
delivering the next VP is not preserved. As a result, if an atrial event which triggered
the mode-switch from VDI to DDD happens within [TLRI-TAVI, TLRI) after the
last ventricular event, the next ventricular pacing will be delayed by at most TAVI
time, which violates the Lower Rate Limit property (Fig. 4.17(a)). Then property
ϕPMT is checked, we have
H3 2‖P1‖PELT det‖Pvv 6|= ϕPMT
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Figure 4.17: (a) Safety Violation: VP is delayed due to the reset of timer during mode-
switch, (b) Efficacy Violation: The blocking period may block some atrial events, turning
two Fast events to one Slow event (Jiang et al. [2012b])
Indicating the mode-switch algorithm failed to eliminate the PMT scenario. The
counter-example trace returned by UPPAAL shows that a subset of atrial events fall
into the blanking period after a ventricular event (see Fig. 4.17(b)). As a result,
two fast events are reduced to one slow event and mode switch may never happen.
Therefore the mode-switch algorithm in our pacemaker model can not terminate all
PMT behaviors as specified as certain mild PMT events are admissible.
4.6 Discussion
Model checking is not widely use in industry, in part, due to scalability issues and
also because domain expertise must be a skill possessed by the verification engineer.
However, with rigorous abstraction of the system and its environment, model checking
can be used to identify known and even unknown mechanisms to induce hazards. In
this chapter, we demonstrated the use of closed-loop model checking to identify un-
known safety hazards in an implantable pacemaker. During the process we identified
the need to refine the heart models to eliminate false-positives introduced during the
abstraction, and demonstrated the difficulty to do so manually. The abstraction tree
approach is then proposed to reduce the effort needed for both the developers and the
domain experts, which makes model checking a viable approach for providing safety
and effectiveness evidence. With the abstraction tree of heart models, safety and effi-
cacy violations are identified within the pacemaker specification, which demonstrates
the capability of model checking to identify issues during the early development of
autonomous medical devices.
The abstraction tree approach can potentially be used in other application do-
mains (i.e. autonomous vehicles). However, note that in our application, the most
refined heart models can still be used for model checking, as the heart model struc-
ture is simple. Depending on the application, there may not exist environment models
that are simple enough for model checking. And there may not exist abstraction rules
that can guarantee behavior coverage.
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Chapter 5
Theme 3: Verified Model to
Verified Code
Model checking is performed on abstract models of the device, which is at an early
stage in the development process. However, there is no guarantee that the safety and
efficacy properties verified during model checking still hold in the device implemen-
tation. In this chapter, a model translation tool is developed to automatically and
rigorously translate the UPPAAL device model validated during model checking into
a Stateflow model, which is a step towards simulation-based testing and subsequently
to code generation. This work was done in collaboration with Dr. Miroslav Pajic.
5.1 Related Work
There are only few tools that can be used for automatic implementation of timed-
automata models designed in UPPAAL (e.g., Amnell et al. [2004], Hendriks [2001]).
A commonly used tool is Times ( Amnell et al. [2004]) that supports code generation
for general platforms, extended with task support for Lego MindstormTMplatform.
The code synthesized using Times has a very simple structure, where all transitions
are stored in an array. Each transition is represented with four fields: an activity
flag, source and destination location ids, and a synchronization id. The transitions
are evaluated in automatically generated check trans function, and for the code to
operate correctly the values for all clocks should be updated in a separate procedure,
triggered by the system timers. Since check trans performs a single evaluation
for each transition (in the order specified by the array structure), to ensure that
no transitions are missed the check trans function has to be continuously invoked
within an infinite loop, unless the code is executed on a LEGO Mindstorm RCX
brick running brickOS. Thus, in the general case, the code generated with Times
completely utilizes the CPU, disallowing instantiation of any other tasks. As we will
show later in the paper, this is not the case for the code that is synthesized using our
development framework.
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Due to this array-based structure, with the code obtained using Times it is not
straightforward to decouple the controller (in our case the pacemaker) and the envi-
ronment (e.g., the heart). For example, to facilitate the decoupling Kim et al. [2011]
propose a modification of the initial UPPAAL model by specifying the interaction be-
tween the controller and the environment using boolean shared variables. Although
the solution preserves behaviors of the initial model, as pointed out by the authors,
this type of manual modifications is effectively one of the most error prone aspects of
the model-based development. Hence, to avoid this type of errors, it is necessary to
provide modular code synthesis from verified UPPAAL models. We will later show
that UPP2SF resolves this issue, since the obtained code has a modular structure
(instead of maintaining an array of transitions).
Finally, the code generated from Times models does not guarantee that some
aspects of the UPPAAL timed-automata semantics will be preserved ( Ayoub et al.
[2010]). For example, it does not ensure that the requirement for committed states is
satisfied.
5.2 A Brief Overview of UPPAAL
In this section, we present an overview of the UPPAAL tool, including some of the
UPPAAL extensions ( Larsen et al. [1997], Behrmann et al. [2004], Bengtsson and Yi
[2004]) of the timed-automata formalism from Alur [1999].
5.2.1 UPPAAL Modeling of Real-time Systems
UPPAAL supports networks of timed automata. Each automaton is a state ma-
chine, equipped with special real-valued variables called clocks. Clocks spontaneously
increase their values with time, at the same fixed rate. Locations (i.e., states) in
automata have invariants that are predicates over clocks. A location in an automa-
ton can be active as long as its invariant is satisfied. Transitions in automata have
guards that are predicates over clocks and variables. A transition can be taken only
if its guard is true. Because clock values increase, an initially false guard can even-
tually become true, allowing us to model time-dependent behaviors, such as delays
and timeouts. When a transition is taken, an associated action is executed, which
can update variable values and reset clocks to integer values (possibly non-zero).
Automata in the network execute concurrently. They can communicate via shared
variables, as well as via events over synchronous channels. If c is a channel, c?
represents receiving an event from c, while c! stands for sending an event on c. In
the general case, an edge from location l1 to location l2 can be described in a form
l1
g,τ,r−−→ l2, if there is no synchronization over channels (τ denotes an ’empty’ action),
or l1
g,c∗,r−−−→ l2. Here, c∗ denotes a synchronization label over channel c (i.e., ∗ ∈ {!, ?}),
g represents a guard for the edge and r denotes the reset operations performed when
the transition occurs.
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Timed-Automata Semantics in UPPAAL
We denote with C the set of all clocks and with V the set of all data (i.e., boolean
and integer) variables. A clock valuation is a function u : C → R+, and we use RC to
denote the set of all clock valuations. A simple valuation is the function u0(x) = 0,
for all x ∈ C. Similarly, a data valuation is a function v : V → Z, while ZV denotes
the set of all data valuations. A valuation w, denoted by w = (u, v), is a function
w : C × V → R+ × Z such that w(x, i) = (u(x), v(i)), for clock valuation u and data
valuation v. Also, for a valuation w = (u, v), w + d denotes the valuation where
(w+ d)(x) = (u+ d)(x) = u(x) + d for x ∈ C, and (w+ d)(i) = v(i) for i ∈ Z. In the
rest of the paper, a clock valuation u that satisfies that for all x ∈ C, u(x) ∈ N0 will
be referred to as integer clock valuation, while a valuation w = (u, v), where u is an
integer clock valuation will be referred to as an integer valuation.
Furthermore, let B(C, V ) denote the set of conjunctions over simple clock and
variable conditions of the form x ./ n, x− y ./ n or i− j ./ k, where n ∈ N, x, y ∈ C,
i, j ∈ V , k ∈ Z and ./∈ {≤,≥,=, <,>}.1 Similarly, B(C) denotes the set of all
conjunctions over the clock variable conditions. Thus, a guard can be defined as
an element of B(C, V ).2 Reset operations are used to manipulate clocks and data
variables. They have the form x = n or i = c1∗j+c2, where x ∈ C, i, j ∈ V , c1, c2 ∈ Z
and n ∈ N0. We use R to denote the set of all possible reset operations, and for a
reset operation r ∈ R and valuation w, r(w) is the valuation obtained from w where
all clocks and data variables specified in r are assigned to the values obtained from
the appropriate expressions. Finally, we use K to denote the set of all channels, and
A = {α?|α ∈ K}∪ {α!|α ∈ K}∪ {τ} to denote the set of all actions. Here, τ denotes
an ’empty’ action – without synchronization.
Definition 5.1. An automaton A is a tuple (L, l0, A, C, V, E, I) where L denotes
the set of locations in the timed automaton, l0 is the initial location, A is a set of of
actions, C a set of clocks, V is a set of data variables, and E ⊆ L×A×B(C, V )×R×L
denotes the set of edges, while I assigns invariants to locations (i.e., I : L→ B(C) is
a mapping of each location to a constraint over some clocks).
If a clock valuation u satisfies the invariants at location l, we abuse the notation
and write u ∈ I(l). Similarly, we denote with w ∈ I(l), if w = (u, v) and u ∈ I(l).
Also, if a valuation w satisfies a condition g ∈ B(C, V ) we write w ∈ g.
A network of n timed automata is obtained by composingAi = (Li, l0i , C, A, V,Ei, Ii),
i ∈ {1, ..., n}. In this case, a location vector is defined as l¯ = (l1, l2, ..., ln). In addition,
the invariant for location vector l¯ is defined as I(l¯) = ∧iIi(li). To denote the vector
where ith element of vector l¯ (i.e., li) is substituted with l
′
i we use the notation l¯[l
′
i/li].
1In the latest UPPAAL versions n can also denote an expression over integer variables. Since
all results from this section are valid in the latter case, we use the simplified notation where n is a
constant integer.
2The default guard is true.
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(a) P0 automaton (b) P1 automaton (c) A run of the model
Figure 5.1: An UPPAAL model example.
Definition 5.2. Let A = {A1,A2...,An} be a network of n timed automata, and
let l¯0 = (l01, l
0
2, ..., l
0
n) be the initial location vector. The semantics of the network is
defined as a transition system 〈S, s0,→〉, where S = (L1×L2× ...×Ln)× (RC ×ZV )
is the set of states, s0 = (l¯0, w0) is the initial state, where w0 = (u0, v0) and v0 is any
initial data valuation, and →⊆ S × S is the transition relation defined by:
1. (l¯, w)→ (l¯, w+ d) if for all d′ such that 0 ≤ d′ ≤ d, it follows that w+ d′ ∈ I(l¯);
2. (l¯, w) → (l¯[l′i/li], w′) if exists li g,τ,r−−→ l′i such that w ∈ g, w′ = r(w) and w′ ∈
I(l¯[l′i/li]);
3. (l¯, w)→ (l¯[l′j/lj, l′i/li], w′) if there exist li gi,c?,ri−−−−→ l′i and lj
gj ,c!,rj−−−−→ l′j such that
w ∈ (gi ∧ gj), w′ = (ri ∪ rj)(w) and w′ ∈ I(l¯[l′j/lj, l′i/li]).
Since the first type of transitions is the result of time-passing, unless otherwise
stated, in the rest of the paper when we use the term UPPAAL transition we will
refer to either case (2) or (3) of the above definition.
To illustrate the above definition, consider the model from Fig. 5.1, where both
automata have separate local clocks t. Location P0.l0 has invariant t ≤ 10, while
the edge P0.l0 → P0.l1 has the guard condition t ≥ 10, reset action t = 0, and
transmission over channel e1. Hence, synchronization over the channel e1 ensures
that the transitions P0.l0→ P0.l1 and P1.l0→ P1.l1 occur simultaneously. Finally,
note that clocks do not have to be reset to zero (e.g., as on the edge P0.l1→ P0.l0).
For semantics 〈S, s0,→〉, a sequenceR := (l¯0, w0)→ (l¯1, w1)→ ...→ (l¯i, wi)→ ...,
is called a run, and we use notation wRk = wk, l¯
R
k = l¯k, for all k ≥ 0. An example
run for the model from Fig. 5.1 is shown in Fig. 5.1(c). To simplify the notation, we
assume that in each run R no two consecutive transitions are result of time-elapsing
(case (1) of Def. 5.2), since these transitions can be merged into a single transition of
that type.
Additional UPPAAL Extensions of the Timed-Automata Formalism
Beside integer variables and synchronization channels, UPPAAL extends timed-automata
with committed and urgent locations where time is not allowed to pass (i.e., no delay
is allowed). Committed locations are more restrictive and they are usually used to
model atomic sequences of actions. In a network of timed automata, if some automata
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are in committed locations then only transitions outgoing from the committed loca-
tions are allowed. UPPAAL also introduces broadcast channels, where one sender can
synchronize with multiple receivers (e.g., zero, one, or more than one). Furthermore,
urgent channels can be used for synchronization, to specify that if a transition with
synchronization over an urgent channel is enabled, then the transition should occur
without any delay.
5.3 Extracting Runs from UPPAAL Models
To develop the UPP2SF model translation tool, we consider the problem of extracting
runs for UPPAAL models. We focus on a large class of UPPAAL models without
clock conditions of the form x > E, where x is a clock and E an expression. The
restriction, while not limiting in modeling of real control system, guarantees that all
invariants and guards are expressed as intersections of left semi-closed (LSC) intervals.
Thus, we refer to this class as Class LSC, and in this work we consider only this type
of models.
To obtain a run of an UPPAAL model it is sufficient to simulate the model only
at integer time points ( Pajic et al. [2012a]), which allows for the use of discrete-time
based tools for model simulation. Since the execution of UPPAAL models is non-
deterministic, a transition in UPPAAL can occur at any point at which it is enabled.
However, at each time instance it may not be straightforward to determine whether
a currently enabled transition will still be enabled at the next integer-time point.
Therefore, to simplify the translation procedure we consider runs of UPPAAL models
that are obtained using the maximal progress assumption (MPA).
Definition 5.3. For semantics 〈S, s0,→〉, a run R := (l¯0, w0)→ ...→ (l¯i, wi)→ ... ,
satisfies the maximal progress assumption (MPA) if for all k ≥ 0 such that
1. l¯k+1 = l¯k and wk+1 = wk + d for some d > 0, and
2. (l¯k+1, wk+1)→ (l¯k+2, wk+2) satisfies either case (2) or (3) of Def. 5.2,
there does not exist a d′, 0 ≤ d′ < d, for which there exist a transition (l¯k, wk + d′)→
(l¯k[l
′
j/lj], w
′) or a transition (l¯k, wk +d′)→ (l¯k[l′p/lp, l′q/lq], w′) for the given semantics.
A run that satisfies the MPA will be referred to as an MPA run. Note that from
the definition, if some transitions in an MPA run are enabled, one of them should
occur.
Theorem 5.1. Consider an UPPAAL model from the Class LSC. For every MPA
run R of the model and for all k ≥ 0, the clock valuation uRk satisfies that for each
clock x, uRk (x) ∈ N0 (i.e., all transitions of R occur at integer time points).
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Proof. Lets assume that the theorem does not holds – i.e., there exists an MPA
run R for which there exists k ≥ 0 and a clock x such that uRk (x) /∈ N0. By k0 we
denote the first (i.e., lowest) such k. Since all clocks are initialized to zero, k0 > 0 and
wk0−1 = (uk0−1, vk0−1) is an integer valuation. Thus, consider the part (l¯k0−1, wk0−1)→
(l¯k0 , wk0) → (l¯k0+1, wk0+1) of the run R. From Def. 5.2 one of the following cases is
valid:
1. (l¯k0−1, wk0−1)→ (l¯k0 , wk0) satisfies case (1) of Def. 5.2 (i.e., time passing). Then
from the definition of a run, the transition (l¯k0 , wk0)→ (l¯k0+1, wk0+1) is described
by either case (2) or (3) from Def. 5.2. In the former case l¯k0+1 = l¯k0 [l
′
i/li],
meaning that there exists li
g,τ,r−−→ l′i such that wk0 = (uk0 , vk0) ∈ g, wk0+1 =
r(wk0), and wk0+1 ∈ I(l¯k0+1). Consider the valuation w′k0 = bwk0c = (buk0c, vk0).
Since wk0 ∈ g then w′k0 also satisfies all variable conditions from g. For each
clock x, if uk0(x) satisfies the clock guard conditions of the form x ./ n, where
n ∈ N0 and ./∈ {≤,≥,=, <}, then uk0(x) belongs to an intersection of left-
closed intervals with integer boundaries. Thus, buk0(x)c belongs to the same
intersection of the intervals, meaning that u′k0 = buk0c satisfies this type of
clock constraints from g. Furthermore, if for some clocks x and y, valuation uk0
satisfies constraints of the form x− y ./ n, it follows that uk0(x)− uk0(y) ./ n.
From uk0 = uk0−1 + d (where d is the elapsed time), we have: u
′
k0
(x)− u′k0(y) =buk0(x)c−buk0(y)c = uk0−1(x) + bdc− (uk0−1(y) + bdc) = uk0−1(x)−uk0−1(y) =
uk0−1(x) + d − uk0−1(y) − d = uk0(x) − uk0(y). Thus, u′k0(x) − u′k0(y) ./ n is
true, and all clock constraints of this form are also satisfied, implying that
w′k0 ∈ g. Similarly, for w′k0+1 = r(w′k0) = (u′k0+1, v′k0+1), from w′k0 = bwk0c and
wk0+1 = r(wk0) it follows that v
′
k0+1
= vk0+1 and u
′
k0+1
= buk0+1c (all reset
clocks are equal, since clocks are reset to integer values). Therefore, as for the
guard, it can be shown that wk0+1 ∈ I(l¯k0+1) implies that w′k0+1 ∈ I(l¯k0+1),
which proves that the transition (l¯k0 , w
′
k0
) → (l¯k0+1, w′k0+1) was also enabled.
Since w′k0(x) < wk0(x) it follows that in this case R is not an MPA run, which
violates our initial assumption.
A similar proof can be used in the latter case when (l¯k0 , wk0) → (l¯k0+1, wk0)
satisfies case (3) of Def. 5.2, by showing the existence of a transition enabled for
buk0c. Since buk(x)c < uk(x), the transition (l¯k0 , wk0) → (l¯k0+1, wk0+1) cannot
be in an MPA run.
2. (l¯k0−1, wk0−1)→ (l¯k0 , wk0) satisfies either case (2) or (3) of Def. 5.2. Then, there
exists a transition with reset r such that wk0 = r(wk0−1), or a synchronized
transition with resets ri, rj such that wk0 = (ri ∪ rj)(wk0−1). However, since
wk0−1 is an integer valuation, in both cases uk0(x) ∈ N because no clock can
be reset to a non-integer value. This conflicts our initial assumption, and thus
concludes the proof.
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The theorem presents the basis for the translation procedure. It allows us to obtain
an MPA run by evaluating transitions from active locations in each automaton only
at integer time points. Note that each automaton may be evaluated more than once,
as more than one transition could occur within a single automaton at any integer
time.
Theorem 5.1 can be easily extended for UPPAAL models with committed and
urgent locations, and urgent and broadcast channels. For example, urgent locations
can be modeled by adding an extra clock xu that is reset to zero on all incoming edges
to urgent locations, and adding condition xu ≤ 0 to invariants in all urgent locations.
Yet, this does not affect the proof of Theorem 5.1, and thus the theorem is still valid.
In addition, semantics for UPPAAL models that employ urgent channels is similar to
the semantics from Def. 5.2, with an additional condition in case (1) of the definition.
In this case (l¯, w)→ (l¯, w+ d), if for all d′, 0 ≤ d′ < d it holds that w+ d′ ∈ I(l¯), and
for any urgent channel c there does not exist li
gi,c?,ri−−−−→ l′i and lj
gj ,c!,rj−−−−→ l′j such that
w+ d′ ∈ (gi∧ gj) and (ri∪ rj)(w+ d′) ∈ I(l¯[l′j/lj, l′i/li]). Similarly, broadcast channels
semantics does not require that exactly one transition with receiving channel occurs
simultaneously with a transition that contains a transmission over the channel – with
broadcast channels none, one or more than one ’receiving’ transitions could occur.
Thus, Theorem 5.1 is also satisfied even if urgent and broadcast channels are used.
5.4 Brief Overview of Stateflow
A Stateflow chart (i.e., model) employs a concept of finite state machines extended
with additional features, including support for different data types and events that
trigger actions in a part or the whole chart. Here, we present a small subset of the
Stateflow features used in the translation procedure. Detailed descriptions of other
features can be found in Inc. [2016], Scaife et al. [2004], Hamon and Rushby [2007],
Hamon [2005].
A state in a Stateflow chart can be active or inactive, and the activity dynamically
changes based on events and conditions. States can be defined hierarchically – i.e., a
state can contain other states (referred to as substates). A decomposition of a chart
(or a state) determines if its states (substates) are exclusive or parallel states. Within
a chart (or a state), no two exclusive states can be active at the same time, while any
number of parallel states can be simultaneously activate (but executed sequentially).
Unlike in UPPAAL, transitions between states in Stateflow are taken as soon
as enabled. They are described in the form (where each part of the description is
optional)
Event[condition]{condition actions}/{transition actions} (5.1)
Event identifies the event that enables the transition (which is enabled by default if
Event is not stated), if the condition (if specified, by default it is true) is valid. The
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condition is described using basic logical operations on conditions over chart variables
and Stateflow operators. Actions in condition actions and transition actions include
event broadcasting and operations on data variables. The Stateflow semantics speci-
fies that when a transition from a state si to state sj occurs, then condition action are
executed first, before the state si becomes inactive. This is followed by the execution
of transition actions, and finally activation of the state sj (i.e., during the execution
of transition actions none of the states is active).
A Stateflow chart runs on a single thread and it is executed only when an event
occurs. All actions that occur during an execution triggered by an event are atomic
to that event. After all activities that take place based on the event are finished,
the execution returns to its prior activity (i.e., activity before receiving the event).
All parallel states within a chart (and similarly, all parallel substates in a state) are
assigned with a unique execution order. Furthermore, all outgoing transitions from
a state have different execution indices. Thus, the execution of a Stateflow chart is
fully deterministic – Stateflow semantics specifies that active states are scheduled,
and state transitions are evaluated in the execution order (starting from the lowest
execution index).3
Notion of Time in Stateflow
Stateflow temporal logic can be used to control execution of a discrete-time chart in
terms of time. It defines time periods using absolute-time operators based on the
simulation time, or event-based operators that use the number of event occurrences.
Absolute-time logic defines operators after, before as
after(n, sec) =
{
0, if t < n
1, if t ≥ n , before(n, sec) = not(after(n, sec)) (5.2)
where t denotes the time that has elapsed since the activation of the associated state
(i.e., from the last transition to the state - including self-transitions). The value for
time t can be obtained using the operator temporalCount(sec). Similarly, event-based
temporal logic operators are used for event counting – e.g., after(n, clk) returns 1 if
the event clk has occurred more than (n−1) times after the state has been activated.
5.5 UPP2SF: Model Translation Procedure
In this section, we present an overview of the UPP2SF translation procedure. We
also describe the translation rules for UPPAAL models with urgent and broadcast
channels, urgent and committed locations, and local clocks, as these functionalities
are used for the pacemaker modeling. For the full UPP2SF description refer to Pajic
et al. [2012c].
3The user can specify the execution index for each transition and state – default values are
assigned by the order of instantiation. Parallel states (or transitions from a state) must have different
execution indices.
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5.5.1 Overview of UPP2SF
Consider an UPPAAL model with automata P1, ..., Pn. The UPP2SF translation pro-
cedure would produce a two-level Stateflow chart as in Fig. 5.2, with parallel states
P1, ..., Pn (referred to as the parent states) derived from the automata, parallel states
Gc x1, ..., Gc xm (referred to as clock states) that model all global clocks x1, ..., xm
from the UPPAAL model,4 and the state Eng that is used as the chart’s control
execution engine. In addition, the chart has predefined global data variables (and
constants) with appropriate variable ranges and initial values obtained from the UP-
PAAL model. Since all automata in UPPAAL are simultaneously active, the obtained
Stateflow chart is a collection of parallel states with unique execution orders. Also,
in every UPPAAL automaton exactly one location is active at a time. Thus, each of
the parent states is a collection of exclusive states, extracted from locations in the
UPPAAL automaton.
To ensure that the extracted chart is simulated at integer time points, input
trigger event clk is added to the chart and a signal generator block is added to the
parent Simulink model. We call a clk execution the execution of the chart from the
moment the chart is triggered by a clk event, until processing of the event has been
finished. Since our goal is to derive a Stateflow chart whose execution is one of the
MPA runs of the initial UPPAAL model, it is possible that more than one transition
within the model (and even within a single automaton) occur at any time point.
Therefore, the chart can (re)activate itself by transmitting local (within the scope of
the chart) events from the additional parallel state Eng, which is executed last of all
chart’s parallel states. Processing of the events triggered during a clk execution is
considered a part of the clk execution. Since event processing is atomic in Stateflow,
no time elapses (in Simulink) during a clk execution regardless how many additional
event broadcasts have occurred. With this approach, a single activation of the chart
triggers all transitions enabled at that integer time point, effectively extracting an
MPA execution trace of the model.
Finally, any UPPAAL edge from location lki to lkj in any automaton Pk, which
does not use global clocks and synchronization over binary channels, is mapped into a
Stateflow transition Pk.lki → Pk.lkj between the corresponding substates in the parent
state Pk. In the rest of the section we provide a description of the edge translation
procedure.
Remark: In the general case, the edge lki
g,α,r−−→ lkj (where α ∈ {τ, c!, c?} and c is a
binary or broadcast channel) is mapped into a more complex structure in Stateflow
between the substates Pk.lki and Pk.lkj . If the edge uses global clocks then a junction
Jij and transition Pk.lki → Pk.Jij are introduced to update global clock values used
in the edge’s guard and invariants. Also, if α does not use a binary channel, a single
transition is introduced from Jij to Pk.lkj . However, if α uses a binary channel, to
preserve the semantics three edges and a junction are added between Jij and Pk.lkj .
4Note that if no global clocks are used in the UPPAAL model, the obtained Stateflow chart would
not contain parallel global clocks states Gc xj .
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Figure 5.2: Structure of Stateflow charts derived by UPP2SF. Parent states P1, ..., Pn are
derived from automata, while the clock states Gc x1, ..., Gc xm model all global clocks
x1, ..., xm from the UPPAAL model. The state Eng is used to control execution of the
chart.
5.5.2 Mapping UPPAAL Edges Without Synchronization
Consider an UPPAAL edge lki
g,τ,r−−→ lkj in automaton Pk. The guard g can be split into
a conjunction of data and clock conditions, and thus during the translation UPP2SF
introduces a Stateflow transition Pk.lki → Pk.lkj of the form:
[GC(I(lki) ∧ g) ∧GV (g) ∧GC(r, I(lkj))︸ ︷︷ ︸
GC,V (lki ,lkj ,g,r)
]/{RV (r);RC(r);︸ ︷︷ ︸
RC,V (r)
RS(r); } (5.3)
where:
1. GC(h) (GV (h)) translates the clock (data) conditions from UPPAAL condition
h into an equivalent Stateflow condition,
2. RC(r) (RV (r)) maps clock (data) resets in r to an equivalent Stateflow assign-
ment,
3. GC(r, I(lkj)) maps the condition that the clock valuation after the reset r sat-
isfies the invariant at the ‘new’ location lkj ,
4. RS(r) controls execution of the chart.
Data resets (RV (r)) and guard conditions (GV (g)) are directly mapped into the
identical Stateflow expressions. Mapping local clocks’ resets and guards is described
below.
Mapping Clock Conditions and Resets
In UPPAAL, each clock condition h ∈ B(C) is specified as h = h1∧h2∧...∧hM , where
hi’s are basic clock conditions. Therefore, GC(h) = GC(h1) ∧GC(h2) ∧ ... ∧GC(hM),
and it is only necessary to provide a set of rules for the translation of basic clock
conditions of the form x ./ n or x − y ./ n, where x, y ∈ C and n ∈ Z (or an
expression over integer variables and constants).
To specify conditions over clocks, UPP2SF employs event based Stateflow tempo-
ral logic operators that (only) count the number of clk event occurrences. When the
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UPPAAL condition (x ∈ C, n ∈ N0) Stateflow condition – x replaced by uS(x)
x ≤ n (temporalCount(clk) ≤ n− nx)
x < n before(n− nx, clk)
x = n (temporalCount(clk) == n− nx)
x ≥ n after(n− nx, clk)
x− y ./ n nx − ny ./ n
Table 5.1: Mapping UPPAAL conditions over clocks into Stateflow
temporal logic operators are used in a chart with the two-level hierarchy shown in
Fig. 5.2, Stateflow associates a unique counter with each parallel (i.e., parent) state.
It is important to highlight here that Stateflow semantics specifies that when the ap-
propriate event activates the chart (i.e., when clk triggers the chart) all these counters
are incremented at the beginning of the chart’s execution - i.e., even before the first
parallel state begins its execution. Consequently, when each of the parallel states is
executed, the counter value is equal to the number of the event’s appearances from
the activation of its currently active substate. For each parent state Pk this values is
temporalCount(clk), and thus we denote this value by tCPk . In addition, we define
tCx = tCPk if x is a local clock defined in the automaton Pk.
Unlike in UPPAAL where clocks might not be reset to zero during a transition,
for a parallel state in the Stateflow chart the aforementioned counter is always reset
when a transition occurs (when the associated substate is activated). Thus, while
mapping edges from the automaton Pk, we explicitly model each local (from Pk)
clock x by introducing the accounting variable nx that maintains the clock value
from the moment of the last state activation. This is done using RC(r) from (5.3),
which is specified as
[RC(r)](x) =
{
nx = nx + temporalCount(clk), if x /∈ r
nx = r(x), if x ∈ r (5.4)
Our goal is that at integer time points UPPAAL valuation u of the clock x (i.e., u(x))
is equal to the value uS(x) defined as uS(x) = nx + tCx (we will show this in the next
section). Note that a single counter value is used for all local clocks defined within
the same automaton (i.e., tCx = tCy if x, y are local clocks defined in automaton Pk).
The transformation of the basic clock conditions presented in Table 5.1 employs
event-based temporal logic operators while taking into account the values of the
accounting variables for all used clocks. In the mapping each clock x is replaced with
the value uS(x). In addition, we used a relationship between Stateflow temporal logic
operators from (5.2) to simplify the notation. For example, the condition x < n for
a local clock x is mapped into nx + temporalCount(clk) < n, which is equivalent to
before(n− nx, clk) (since before(n− nx, clk) = 1⇔ temporalCount(clk) < n− nx).
Finally, as specified in Def. 5.2, the requirement that the new clock valuation
satisfies the invariant at the (new) location lkj is equivalent to the condition that
both the non-reset and the reset clock values satisfy the clock invariants at location
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lkj . Hence, if I(lkj) = h1 ∧ ... ∧ hk, then GC(r, I(lkj)) = GC(r, h1)) ∧ ... ∧ GC(r, hk))
where
GC(r, x ./ n) =
{
r(x) ./ n, if x ∈ r
uS(x) ./ n if x /∈ r ,GC(r, x−y ./ n) =

r(x)− r(y) ./ n, if x, y ∈ r
r(x)− uS(y) ./ n, if x ∈ r, y /∈ r
uS(x)− r(y) ./ n, if x /∈ r, y ∈ r
uS(x)− uS(y) ./ n if x, y /∈ r
(5.5)
The expression for GC(r, I(lkj)) can be significantly simplified. If r(x) resets the clock
x to a constant (which is the prevailing case in UPPAAL), conditions from (5.5) can be
evaluated during the translation and can be replaced with fixed terms (false or true).
5.5.3 Obtaining an MPA Execution of the Chart
The execution semantics of Stateflow ensures that in each of the parent states tran-
sitions from the active state will be evaluated at least once during a clk execution.
However, to obtain an MPA run of the model, after a transition occurs it is nec-
essary that in each parent state transitions from the active state are reevaluated.
We guarantee this by reactivating the chart if at least one transition has occurred.
Thus, in the chart, UPP2SF introduces the parallel state Eng (Fig. 5.2), which is
executed last among the parent (and clock) states. Furthermore, additional chart
event tt and flag act are defined, and as a part of each transition, by adding act = 1;
to RS(r) from (5.3), act is set to 1. Finally, Eng contains a single substate and it
broadcasts the event tt to the chart if act has been set to 1, using the lowest priority
self-transition of the form
[act == 1]{act = 0; send(tt)} (5.6)
5.5.4 Translating Broadcast Channels
Events in Stateflow are a good semantic match for broadcast channels in UPPAAL.
Therefore, for each broadcast channel c, UPP2SF defines a Stateflow event c assigned
with a unique positive integer ID(c). To translate edge li
g,c!,r−−−→ lj from automaton
Pk, UPP2SF uses a centralized approach where the Eng state broadcasts events and
controls execution of the chart by using additional variable sent that can have the
following values (here, ExO(Pk) > 0 is the execution order of the parent state Pk)
sent =

ID(c), event c is scheduled for broadcast
0, no event scheduled for broadcast
−ExO(Pk), an event is broadcast, only receiving edges are enabled
(5.7)
Note that ID(c) > 0, and ExO(Pi) 6= ExO(Pj) if Pi 6= Pj.
Table 5.2 shows the mapping of UPPAAL edges into Stateflow. Action c! is
mapped into sent = ID(C) assignment, thus disabling all ‘non-receiving’ transitions
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UPPAAL edge Stateflow transition
li
g,τ,r−−→ lj [(sent == 0) ∧GC,V (li, g, r, lj)]/{RC,V (r);RS(r); }
li
gj ,c!,rj−−−−→ lj [(sent == 0) ∧GC,V (li, g, r, lj)]/{RC,V (r); sent = ID(c); }
li
gi,c?,ri−−−−→ lj c[(sent ∼= −ExO(Pk)) ∧GC,V (li, g, r, lj)]/{RC,V (r); }
Table 5.2: Mapping UPPAAL edges from automaton Pk into Stateflow transitions
due to their condition (sent == 0). Similarly, condition (sent ∼= −ExO(Pk))
disables all ‘receiving’ transitions in the parent state Pk, ensuring that the parent
state does not synchronize with itself. Finally, the Eng state is used to broadcast
events by adding for each event c the following self-transition in the state:
[(sent == ID(c))]{sent = −ExO(Pk); send(c); } (5.8)
In addition, to reset sent and to ensure that all previously disabled transitions are
reevaluated by reactivating the chart after the event is processed (i.e., after all parent
states are re-executed), UPP2SF adds the following self-transition in the state Eng
[(sent < 0)]{sent = 0; send(tt); } (5.9)
Transitions (5.8), (5.9) have precedence (i.e., lower execution order) over the transi-
tion (5.6).
Remark: In general, more than one UPPAAL automaton could transmit over
a shared broadcast channel. In this case, Eng state would not always be able to
determine the parent state Pk that has initiated the event broadcast. Thus, variable
ExOP would have to be defined along with additional reset action ExOP = ExO(Pk)
in transitions with sent = ID(c); (from Table 5.2). Also, transition (5.8) would take
the form [(sent == ID(c))]{sent = −ExOP ; send(c); }. However, since this case
does not occur in most UPPAAL models, due to the space limitation we present the
simpler formulation.
5.5.5 Translating Urgent and Committed States
UPP2SF also preserves semantics of urgent and committed states, and urgent chan-
nels. By extracting MPA runs of the UPPAAL model we ensure that no time passes
in the states from which there exists an enabled transitions. Thus, as a byproduct,
semantics of urgent channels and locations are preserved. On the other hand, if some
automata in UPPAAL are in committed locations, then only transitions outgoing
from one of the committed locations are allowed. Thus, to deal with committed lo-
cations we introduce a new ‘control’ variable comm that always contains the number
of active committed states. For all transitions incoming to a committed state expres-
sion comm = comm + 1; is added to the reset operations (i.e., RS(r) from (5.3)).
Similarly, for all outgoing transitions from a committed state comm = comm − 1;
is added to the reset. To disable transitions from non-committed states when there
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exists an active committed state, guard condition (comm == 0) is added to all ‘non-
receiving’ transitions outgoing from a non-committed state. Note that setting act to
1 (as specified in (5.6), for all transitions in parent states) reactivates the chart to
ensure that all transitions are reevaluated, including the ones that have been disabled
due to (comm == 0) condition.
5.5.6 Stateflow Chart Optimization
Stateflow charts obtained using the described set of rules can usually be significantly
simplified. For example, clock guards and invariants specify fixed left-closed intervals
if in conditions from Table 5.1 n denotes a constant. These intervals can be expressed
in Stateflow with maximum two terms from Table 5.1 (e.g., invariant t ≤ n and guard
t ≥ n can be combined into a single Stateflow condition temporalCount(clk) ==
n − nt). In addition, it is possible to remove updates to an accounting variable nx
from transitions incoming to a state, if on all paths from the state there exist resets of
the clock x before the clock is used in a transition guard or invariant. Similarly, due
to (5.9) there is no need to reactivate the chart with the act = 1 reset on transitions
to a committed/urgent state that are conditioned with event receiving. The same
holds if outgoing transitions from a new state are disabled (which is a common case)
at the time of activation, and no shared variable has been updated on the incoming
transition.
5.6 Correctness of the Translation Procedure
In this section, we show that the set of rules specified in the previous section preserves
the UPPAAL semantics. Specifically, we show that the execution of the obtained
Stateflow chart presents one of MPA runs of the initial UPPAAL model. However,
since the Stateflow semantics is informally defined, formally proving correctness of the
translation procedure is not possible. For a subset of Simulink features, there exist
some attempts to derive formal semantics (e.g., Hamon and Rushby [2007], Hamon
[2005]), which have been validated by testing on many examples. We follow a similar
approach in this work. We start by formulating basic assumptions on the semantics of
the Stateflow charts obtained by UPP2SF – i.e., with the structure shown in Fig. 5.2
and which utilize only a small subset of Stateflow functionalities.
Consider a deadlock-free UPPAAL model with automata P1, ..., Pn, where each
automaton has at least one location, and the extracted two-level Stateflow chart as
in Fig. 5.2, with parent states P1, ..., Pn and the parallel state Eng. Since none of the
chart’s parallel states has transitions5 the following proposition holds.
Proposition 5.2. All parallel states in the chart will always be active.
5Parallel states in Stateflow do not typically use transitions ( Inc. [2016], Hamon and Rushby
[2007]).
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The translation rules specify that all transitions in parent states do not have
condition action (from (5.1)), and no event broadcasting is specified in transition actions.
Thus, when a transition Pk.l → Pk.l′ occurs in a parent state Pk, substate l′ will be
directly activated (i.e., activity will be directly passed from l to l′).6 In addition,
transitions in the Eng state do not have transition actions and they broadcasts
events as part of condition actions.7 That means that the state Eng.l0 will never be
deactivated.
Proposition 5.3. Each parallel state in the chart always has an active substate.
In the general case, event broadcasting to the whole chart introduces recursive
behavior (we will also see this later, in Section 5.9.1, during the analysis of the
pacemaker code – Listing 5, Fig. 5.3). These recursions are in general very difficult
to control and analyze, and Hamon and Rushby [2007] restricted the use of events
to the definition of sequencing behaviors. In UPP2SF-derived charts, only Eng can
broadcast events, on self-transitions from the (only) substate Eng.l0. Since Eng
state is executed last within each chart activation, and within its execution only a
single transition may occur, local event broadcasts can only occur at the end of
chart activations. Therefore, although event broadcasts from the self-transitions in
Eng state introduce recursive behavior to the chart, we can consider these recursive
runs as series of sequential chart activations with different active events – i.e., we can
disregard the recursive behavior.
Consequently, we can describe the state of the chart as a θS = (l¯S , wS , fS), where
l¯S is the vector of size n containing active substates for each of the n parent states.8
In addition, wS = (uS , vS) where uS is defined in (5.5.2) and vS denotes the Stateflow
variables mapped from UPPAAL variables – i.e., vS(i) is the value of the Stateflow
variable i. Finally, fS = (act, sent, comm,AE, k) denotes the values of all control
flags introduced by UPP2SF. AE (AE ∈ {clk, tt, φ, SCE} ∪ {c|c ∈ K}) is the cur-
rently active event being processed by the chart,9 while k, k ∈ {0, 1, ..., n, n+1}, is the
state index of the currently executed parallel state.10 We denote by l¯S [lkj/lki ] a vector
6Broadcasting events in transition actions would result in deactivation of the substate l and event
broadcasting before the substate l′ is activated. Thus, during the event’s processing (including
processing events sent during the event’s processing) the parent state Pk would not have active
substates and would be effectively removed from the execution. On the other hand, broadcasting
events in condition actions would usually result in an infinite behavior (since in most cases the
condition would still be satisfied ( Inc. [2016]).)
7Note that in this case infinite cycle behavior does not occur, since the data values enabling a
transition guard are changed before broadcasts – this disables the transition in the next activation.
8Note that since Eng state has a single substate that is always active, we do not specify it in the
vector l¯S .
9Here, φ denotes the case when no event is active - when the chart is sleeping, between consecutive
clk executions, while SCE is the Simulink Call Event, an intrinsic way for Simulink to activate a
Stateflow chart.
10In general, f should also contain a transition index denoting the transition (from the active
substate of the parallel state k) which is being evaluated. However, to simplify our notation we have
omitted this term.
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where the active substate of the parent state Pk in vector l¯
S has changed from lki to
lkj , and use a similar notation for w
S and fS updates – e.g., fS [k = k + 1] denotes
fS where only k is increased by 1. For UPPAAL models we use the notation from
Sec. 5.2, and for w = (u, v) we write w = wS (and u = uS , v = vS) if ∀x ∈ C, i ∈ V ,
u(x) = uS(x) and v(i) = vS(i).
We can now formalize the behavior (i.e., semantics) of extracted Stateflow charts.
From translation rules, the initial vector of active substates l¯S0 is equal to the initial
location vector in UPPAAL (i.e., l¯S0 = l¯0), and w
S
0 = w0 (w0 is the initial UPPAAL
valuation), fS0 = (0, 0, 0, SCE, 1) (AE = SCE, as charts are executed during initial-
ization).
Definition 5.4. A transition relation for a UPP2SF-derived chart is defined as:
1. (l¯S , wS , fS)→ (l¯S , wS [uS = uS + 1], fS [k = k + 1]) if k = 0 and AE = clk,
2. (l¯S , wS , fS)→ (l¯S , wS , fS [AE = clk]) if k = 0 and AE = φ,
3. (l¯S , wS , fS)→ (l¯S , wS , fS [k = k + 1]) if k = 0 and AE /∈ {clk, φ},
4. (l¯S , wS , fS)→ (l¯S1 , wS1 , fS1 ) if k ∈ {1, ..., n}, where
(l¯S1 , w
S
1 , f
S
1 ) =

(l¯S [lki0/lk], R
i0
C,V [w
S ], Ri0S [f
S ][k = k + 1]),
∃i, (Gis ∧GiC,V ) = True, and
(ei not specified or AE = ei)
i0 = min i
(l¯S , wS , fS [k = k + 1]), otherwise
and all transitions outgoing from the active substate lk (in Pk) are represented as
ei[Gis∧GiC,V ]/{RiC,V ;RiS; } (i is the transition index, and for example, Ri0C,V [wS ]
denotes the value of wS after reset operations specified in Ri0C,V are performed
on wS);
5. (l¯S , wS , fS)→ (l¯S , wS , fS1 ) if k = n+ 1, where
fS1 =
{
Ri0S [f
S ][k = 0, AE = ei], ∃i, Gis = True, where i0 = min i
fS [k = 0, AE = φ]), otherwise
and all self-transitions in Eng state are described as [Gis]{RiS; send(ei); }.
We define the chart’s execution trace RS as a sequence of consecutive chart states
θS0 → θS1 . . .→ θSt → . . . . We also denote by θSt0
∗−→ θSti (referred to as an SF-transition)
a sequence θSt0 → θSt1 . . .→ θSti of the execution such that one of the following holds:
• the sequence does not contain any transitions mapped from UPPAAL edges, and
k = 1, AE = clk in θSti ; in this case we denote the sequence by θ
S
t0
∗(+d)−−−→ θSti , since
(as none of the transitions in parent states has occurred during the sequence) for
some d ∈ N (when i > 0), for all x, y ∈ C, uSti(x)− uSt0(x) = uSti(y)− uSt0(y) = d.
77
• k 6= 0 or AE 6= clk in all θStj , j ≤ i− 1; also, θSti−1 → θSti is a transition mapped
from some UPPAAL edge lf
g,τ,r−−→ lj, and it is the only transition in the sequence
mapped from any UPPAAL edge; in this case we also use the notation θSt0
∗τ−→ θSti ,
• k 6= 0 or AE 6= clk in all θStj , j ≤ i − 1, and the sequence contains exactly
one transition mapped from some UPPAAL edge lf
g,b!,r−−−→ lj, which is the first
transition in the sequence that is mapped from any UPPAAL edge; followed by
a number of transitions (i.e., 0, 1 or more) mapped from UPPAAL edges of the
form lp
g,b?,r−−−→ lq (i.e., receiving over channel b), where θSti−1 → θSti is the last of
them; in addition, the next transition in the execution trace which is mapped
from an UPPAAL edge is not mapped from an edge ln
g,b?,r−−−→ lm; here, we also
use the notation θSt0
∗b!?−−→ θSti .
From the above definition, the following lemma follows directly.
Lemma 5.4. If θSt0
∗τ−→ θSti then for all n ∈ {t0, ..., ti − 1}, l¯Sn = l¯St0 and wSn = wSt0.
Proposition 5.5. Assume that θSt0
∗τ−→ θSti, and l¯St0 = l¯ and wSt0 = w. If θSti−1 → θSti is
a transition mapped from UPPAAL edge lkf
g,τ,r−−→ lkj in automaton Pk (k is the state
index from f), then (l¯, w)→ (l¯[lkj/lkf ], r(w)) in UPPAAL, and r(w) = wSti , l¯[lkj/lkf ] =
l¯Sti.
Proof. From Lemma 5.4, l¯Sti−1 = l¯
S
t0
= l¯ and wSti−1 = w
S
t0
= w. Since θSti−1 → θSti is
a transition mapped from lkf
g,τ,r−−→ lkj , it follows that l¯[lkj/lkf ] = l¯Sti , and from (5.3)
GC(I(lkf )∧ g)∧GV (g)∧GC(r, I(lkj)) is satisfied. GV (g) presents the identical condi-
tions over data variables as in the UPPAAL guard g, and since vSti−1 satisfies GV (g),
then v satisfies data conditions in g. Similarly, since uSti−1 satisfies GC(I(lkf ) ∧ g)
from Table 5.1, then from uSti−1 = u we have that u satisfies the guard and invariant
at lkf – i.e., u ∈ g and u ∈ I(lkf ). Finally, uSti−1 satisfies GC(r, I(lkj)) defined in (5.5),
and using the same reasoning we have that r(u) ∈ I(I(lkj)), implying w ∈ g and
r(w) ∈ I(I(lkj)).
In addition, wSti = (u
S
ti
, vSti), where v
S
ti
= RV (r)[v
S
ti−1] and u
S
ti
= RC(r)[u
S
ti−1].
Since RV (r) specifies the identical data expressions as r, v
S
ti
= r(vSti−1) = r(v). On
the other hand, when a transition occurs temporalCount(clk) is reset. Thus, for all
x ∈ C, uSti(x) = nx, and if x ∈ r from (5.4) uSti(x) = r(x); otherwise nx = uSti−1(x),
meaning that uSti(x) = u
S
ti−1(x). Consequently, u
S
ti
= r(u), and wSti = r(w), which
concludes the proof.
The following results can be proven using similar approaches as in the above proof.
Proposition 5.6. Assume that θSt0
∗b!?−−→ θSti, for a broadcast channel b, and l¯St0 = l¯
and wSt0 = w. If the sequence contains transitions mapped from UPPAAL edges
lj
gj ,b!,rj−−−−→ l′j in automaton Pj, and lji
gji ,b?,rji−−−−−→ l′ji in automata Pji (i = 0, ...,m), then
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(l¯, w)→ (l¯[l′j/lj, l′j0/lj0 , ..., l′jm/ljm ], (rj ∪mi=0 rji)(w)) in UPPAAL. Furthermore,
(rj ∪mi=0 rji)(w) = wSti and l¯[l′j/lj, l′j0/lj0 , ..., l′jm/ljm ] = l¯Sti.
sketch. We first show that after the transition mapped from the edge lj
gj ,b!,rj−−−−→ l′j
occurs it is not possible in the obtained chart to have a ’non-receiving’ transition, or a
’receiving’ transition conditioned with an event c, where c 6= b. We prove then that j 6=
ji for i = 0, ...,m, and jp 6= jq for p, q = 0, ...,m and p 6= q (i.e., an automaton cannot
synchronize with itself, or synchronize twice with another automaton for a single
broadcast). After showing these properties, using a similar approach as for Prop. 5.5
we show that the UPPAAL semantics for broadcast channels is preserved.
Proposition 5.7. Consider a sequence θSt0
∗(+d)−−−→ θSti, for some d ∈ N, and lets assume
l¯St0 = l¯ and w
S
t0
= w. Then wSti = w + d, and (l¯, w)→ (l¯, w + d) is the only transition
relation in the semantics of the UPPAAL model from (l¯, w) – i.e., there does not exist
a transition (l¯, w)→ (l¯1, w1) specified by either case (2) or (3) of Def. 5.2.
Note that the chart’s execution trace RS can be decomposed into a sequence of
SF-transitions. Therefore, since the initial UPPAAL location vector l¯0 and valuation
w0 are equal to the initial Stateflow vector of active states and valuation w
S , from the
above three propositions and Theorem 5.1 we have that the sequence of SF-transitions
for the UPP2SF-derived chart corresponds to an MPA run of the initial UPPAAL
model. Furthermore, it is worth noting that these proofs can be easily extended to
show that the semantics of committed locations is also preserved by the translation
rules (semantics of urgent channels and locations are guaranteed by the MPA-runs
requirement).
In the rest of the chapter, we will demonstrate the use of the UPP2SF-based MDD
framework on the pacemaker case study.
5.7 Pacemaker Stateflow Design
From the model shown in Fig. 4.1, using the UPP2SF tool we obtained the pacemaker
Stateflow chart presented in Fig. 5.3. For closed-loop verification in UPPAAL we
modeled both the heart and pacemaker, and therefore the obtained chart contains
both models of the controller (i.e., pacemaker) and environment (i.e., the heart). To
be able to use the obtained Stateflow chart for both simulation and code generation
it was necessary to decouple the pacemaker from the heart model.
Note that the verified UPPAAL model also contains several monitors used to spec-
ify verification queries. Since none of these monitors uses shared variables, and they
only interact with the rest of the model by receiving synchronization over broadcast
channels, they do not affect behavior of the basic automata from Fig. 4.1. Thus, to
simplify Fig. 5.3, we did not show the parallel states that were obtained from them.
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Figure 5.3: Pacemaker Stateflow chart extracted using UPP2SF from the UPPAAL model
in Fig. 4.1; the heart and buffer models are highlighted.
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5.7.1 Decoupling the Controller and Environment
Here we present the approach used to decouple the pacemaker and heart. The same
approach can be used to decouple models of the environment and controllers in most
commonly used scenarios where they only interact by broadcasting events.
Since the interaction between the heart and the pacemaker model is modeled
using synchronization over broadcast channels, the pacemaker model can be easily
extracted from the chart shown in Fig. 5.3. This is done by removing the parent
states that model the heart and buffers (RH a, RH b, ASbuf, VSbuf), and by defining
AinB and V inB as input events. Also, the Eng state has to be modified to remove
the transitions used to broadcast these input events. In our case we removed the
transitions that broadcast AinB or BinB (highlighted in red in Fig. 5.3).
Stateflow does not allow the use of output events to condition internal transi-
tions. Hence, it is necessary to define additional output events from the chart, and in
our case for local events a p and v p two output events (AP and VP) were defined.
These events are broadcast on the same transitions used to broadcast a p and v p,
respectively. In addition, to deal with some implementation issues (details are pro-
vided in Section 5.9), for each output Event an empty C function sendHW Event is
added using Simulink features for integrating custom C code. The function does not
affect Simulink chart simulations, but allows for the correct output generation from
the synthesized code. For example, the Eng transition highlighted with dotted green
rectangle was modified to
[(sent == 3)]{sent = −1; send(V P ); sendHW V P (); send(v p); }
Note that if the user specifies all components that are part of the controller, UPP2SF
can automatically perform the above actions to decouple it from the environment.
It is interesting to compare the chart from Fig. 5.3 with the manually designed
Stateflow model of the DDD pacemaker ( Jiang et al. [2010b]), which is slightly
simpler as it does not use event broadcasting. Thus, each clk execution has a single
chart activation, causing a violation of several of the pacemaker requirements. For
example, the URI requirement is not satisfied because URI state is always scheduled
after AV I state; since the chart is not reactivated within a clk execution, after URI
period expires, AP will be generated late – in the next clk activation.
Since the UPP2SF mapping has been validated, we ensure that the chart’s ex-
ecution will be equivalent to one of the MPA runs of the initial UPPAAL model.
However, the chart also contains the model the environment and has no inputs and
outputs, and thus we performed validation of the pacemaker Stateflow chart after the
decoupling, by extending the approach for testing real-time constraints by Clarke and
Lee [1995].
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Figure 5.4: Test points for behavioral real-time constraints.
5.8 Stateflow Model Validation
We performed validation of the pacemaker Stateflow chart after the decoupling by
extending the approach for testing real-time constraints described in Clarke and Lee
[1995]. The same approach was also used for the testing of the final physical imple-
mentation (Section 5.10).
In Clarke and Lee [1995], the authors proposed a testing procedure for behavioral
and performance constraints if the following assumptions are satisfied:
1. All output sequences of a system under test must be eventually distinguishable.
2. All time bounds must be constant.
3. There is no sharing of resources between concurrent threads.
4. Specification intervals are implemented in software as continuous, linear do-
mains.
In our case, all of the assumptions are inherently satisfied, and thus we adapted
the method for the pacemaker testing. From the formal specifications we derived an
appropriate set of tests to validate correctness of the obtained pacemaker design. For
each performance constraint we used a test that validates whether the appropriate
output has been generated within the required interval. On the other hand, testing
behavioral constraints was more complex. For each interval boundary we generated
two tests. For closed boundaries we applied inputs that were exactly at the boundary
point and tests that were outside the interval, at the distance  from the boundary
point (see Fig. 5.4). For open boundaries we generated inputs that were inside and
outside the interval, at the distance  from the boundary point.
To perform validation of the Stateflow chart and the physical implementation, we
used the model parameters from Table 5.3. For testing in Simulink we considered only
tests for the ideal system specifications. Since the chart was activated every 1ms, and
transitions in Stateflow are instantaneous (all transition actions are atomic) we used
 = 0.5ms and  = 1ms for simulations. All the ‘ideal’ real-time constraints (and
thus, the constraints with tolerances) were satisfied in Simulink. This was expected
since all actions within a clk execution are atomic to the event and no simulation
time elapses during them.
In addition, the chart exhibited the same behaviors as the initial UPPAAL model.
For example, for the aforementioned model parameters, when no inputs were applied
the chart generated AP and VP pulses at the same time points as the UPPAAL
model (i.e., AP were generated at tapi = (850 + 1000(i − 1))ms, i = 1, 2, ..., and VP
at tvpi = (1000i)ms, i = 1, 2, ...). Similarly, no time was spent in committed states
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st3C CC in AVI, and inter CC states in PVARP and VRP parallel states, and
outgoing transitions from the states would occur immediately after the states were
activated. To illustrate a more complex behavior we also showed that, as in UPPAAL,
if st3 state in AVI parent state was active when the transition URIst1 → URIst2
occurred (causing broadcast of uri s event), then no time had elapsed in the URIst2
state, before the transition URIst2→ URIst1 conditioned with v p took place.
5.9 Pacemaker Implementation
We generated C code from the pacemaker Stateflow chart using the Simulink Real-
Time Workshop Embedded Coder (RTWEC).11,12 The code was generated for the
general embedded real-time target and as a result we obtained the main procedure,
rt OneStep, which processes the three input events, V inB, AinB and clk. To ensure
that the model semantics is preserved (modulo the execution time), clk input events
should be created every 1ms, followed by the procedure’s activation.13 This makes it
suitable for implementation on top of a real-time operating system (RTOS).
Code Structure
The structure of the code is straightforward. The current state of the procedure and
all variables defined in the chart are maintained in the structure rtDWork, along with
counter values used for temporal logic operators (i.e., a counter per parallel state). In
addition, rtDWork contains a structure (List. 1, Fig. 5.5) that for each parent state
specifies if it is active, along with which of its substates is active. For example, for the
state AVI variable is active AVI describes whether the state is active, while is AVI
specifies which of its exclusive substates is active.14
11Since Matlab R2011b, RTWEC toolbox is referred to as Simulink Embedded Coder.
12Although we focus on a specific implementation, code with the same structure would be gener-
ated from all Stateflow charts obtained from UPPAAL models using UPP2SF (due to the derived
charts’ structure).
13In this case, the procedure’s execution corresponds to the clk execution.
14Note that since all parent states are decomposed into exclusive states, activity status for all of
the substates within a parent state can be specified with a single variable. However, in the general
case, if a state consists of a group of parallel states, RTWEC would define a new variable for each
of the parallel states.
Parameter Range Value Tolerance
LRId 343-1200 ms 1000ms ±4ms
AV Id 70-300 ms 150ms ±4ms
URId 1000 ms 400ms ±4ms
V RPd 150-500 ms 150ms ±4ms
ARPd 150-500 ms 200ms ±4ms
Table 5.3: Pacemakers parameters.
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Figure 5.5: Structure of the pacemaker code obtained from the Stateflow chart shown in
Fig. 5.3.
The structure of rt OneStep is shown in List. 2, Fig. 5.5. After detecting active
input events, an execution of the chart procedure c1 ChartName is invoked for each
active input event. The variable sfEvent is used to denote the event that is pro-
cessed during the chart execution. As in Stateflow, starting from input events with
lower indices, the events are processed in a prespecified order (using c1 ChartName
function). After all events are processed the procedure updates the outputs and event
states in the prespecified order. This means that although we broadcast output events
and the local events corresponding to them (e.g., VP and v p) as a part of same tran-
sitions, the outputs will be actually updated at the end of rt OneStep procedure.
This can cause a couple of problems. First, ordering of the generated output events
can differ from the order of the corresponding local events. Note that this does not
affect simulations in Simulink, since all actions within a clk execution are atomic from
perspective of the rest of the Simulink model. The second problem is that with this
approach, for each output event only a single output trigger can be generated at the
end of a clk execution. Thus, if an output event is broadcast more than once within a
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single clk execution, the corresponding output events will be actually generated one
by one, at the end of the consecutive clk executions (i.e., separated by the duration
of clk period).
These issues are resolved using the aforementioned SendHW EventName functions.15
Using Simulink features for integrating custom C code with Stateflow charts in
Simulink, we define empty C functions for each output event (e.g., for VP we de-
fine SendWH VP). When the code is implemented on a particular hardware platform,
the user needs to define these functions. For example, the simplest implementation
would include toggling a particular CPU pin every time the function is invoked.
At the beginning of the chart execution procedure (List. 3, Fig. 5.5) all counters
associated with the event (stored in sfEvent ) are increased. Since the pacemaker
code uses only clk event in temporal logic operators, the five counters will be incre-
mented only when clk is processed. After this, the functions associated with each of
the parallel states are called in the order specified by the execution order.
List. 4 from Fig. 5.5 presents a pseudo-code for processing each of the parallel
states. If the state is active, all transitions outgoing from its active substate are
evaluated in the prespecified execution order. The first enabled transition is taken
and associated transition actions are executed. In the generated code only Eng state,
which is executed last, is used to broadcast events as part of its transition actions. As
shown in List. 5, Fig. 5.5, broadcasting an event associates the (current event) variable
sfEvent with the event, before it reactivates the chart (by calling c1 ChartName()).
5.9.1 Platform Implementation
The pacemaker code generated by the Simulink RTWEC was executed on nanoRK
( Nano-RK [2007]), a fixed-priority preemptive RTOS that runs on a variety of
resource constrained platforms. We tested the implementation on the TI MSP-
EXP430F5438 Experimenter Board interfaced with a signal generator that provides
inputs for the pacemaker code (Fig. 5.6). The compiled (without optimization) pace-
maker procedure uses 2536 B for code and additional 180 B for data. To interface the
code with the environment, each of the inputs (AinB, V inB) triggers an interrupt
routine used to set the appropriate event for rt OneStep function.
The pacemaker code was run as a task with period 1ms. Table 5.4 shows mea-
sured execution times for the pacemaker tasks, for two different CPU frequencies. As
expected, an increase in CPU frequency scales into a reduction in the task’s execution
time. Note that the measurements from Table 5.4 can be mapped to CPU utilization
for the pacemaker task. With the average utilization of 9.2% for an 8MHz CPU, we
can run multiple tasks on the RTOS.
15These issues do not present a problem for the pacemaker design from Fig. 5.3, since only a single
AP or a single VP can be broadcast within one clk execution. However, in this chapter we describe
the general approach that allows utilization of the UPP2SF translation tool for all UPPAAL models.
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Figure 5.6: Hardware setup with MSP430F5438 experimenters board.
5.9.2 Decoupling the Controller and the Environment
In Sec. 5.7 and 5.9.1 we have described the method we used to decouple models
of the pacemaker and the heart. The solution guarantees that the implemented
code generates output events as soon as the corresponding local events are generated.
However, our implementation introduces some problems regarding processing of input
signals. By introducing an interrupt routine that sets a flag if the input occurs, we
effectively synchronize asynchronous input signals. This has a twofold effect on the
implemented code. First, each input signal will be processed at most once even if
it appears more than one time between consecutive task’s activations. This is not a
problem for the pacemaker, since in the initial UPPAAL model, due to the buffers,
all inputs after the first input in a cycle are disregarded until at least dL a (or dL v)
time. Second, it introduces a latency up to the task’s period (i.e., clk interval, in our
case 1ms) before the input signals are processed. To solve this issue, the extracted
procedure could be activated as soon as an input appears. Beside problems with tasks
scheduling, if the input signal could affect clock valuations in the initial UPPAAL
model this would introduce a time measurement error in the code. For example, if
Ain occurs 0.5ms before the next clk activation and the procedure is instantaneously
activated as a result of the input, the clock in ASbuf would be reset to zero. Thus,
CPU Average Minimal Maximal Standard
frequency ex. time ex. time ex. time deviation
4MHz, OL 176.1µs 167.6µs 462.9µs 14.2µs
4MHz 180.9µs 167.6µs 738.2µs 17.3µs
8MHz, OL 89.5µs 84.7µs 234.6µs 7.2µs
8MHz 92.0µs 84.9µs 370.4µs 13.7µs
Table 5.4: Execution times for the pacemaker procedure; OL denotes open-loop, without
inputs from the signal generator.
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the next clk activation of the procedure would set t to 1, although only 0.5 ms have
passed since the input.
This problem occurs even if the code has been generated using Times, or any
other tool, since the number of clocks used in models is usually greater than the
number of timers that CPU provides. To avoid this type of errors, we opted to use
the aforementioned approach where input events only set a flag to indicate the need to
process input events in the following procedure activation. To take this into account
in the initial UPPAAL model, we reverified the safety properties for the model where
input buffers increase the upper bound on the introduced delay (i.e., dH a, dH v).
The bounds are increased to incorporate the maximal input latency introduced by
synchronous processing of the input events (in our case 1ms).
5.9.3 Worst Case Execution Time Estimation in UPPAAL
Correctness of the generated code relies on the assumption that execution of the code
completes before the next external activation. To make sure that it does, we need to
estimate the WCET of the code execution, taking into account that the c1 ChartName
procedure (i.e., the chart) may be internally activated multiple times. We propose
an approach that does not require translation from UPPAAL to Stateflow. Rather it
uses the initial UPPAAL model to calculate an upper bound on the maximal number
of internal activations Ni within an external activation (i.e., per clk execution). This
enables a WCET estimation at an early stage, during system modeling in UPPAAL.
Since the chart is reactivated with event broadcasts and some transitions, to de-
termine the bound for Ni we extend the model with the following accounting features:
• Global variable tr cnt and the automaton TrMonitor (Fig. 5.7) that resets the
variable at integer time points,
• In the controller part of the UPPAAL model, reset operation tr cnt = tr cnt+1
should be added to all edges with transmissions over a broadcast channel, or
edges that would be translated into Stateflow transitions with act = 1 reset
(i.e., the transition for which Eng state would reactivate the chart),
• Reset tr cnt = tr cnt+1 to the edges with transmissions over broadcast channels
that present inputs to the controller,
• Introduce UPPAAL temporal formula A tr cnt ≤ N˜i.
With the above changes the variable tr cnt bounds the number of internal acti-
vations of the chart. Therefore, if the above proposition is satisfied, the value N˜i + 1
provides an upper bound for the number of chart executions within a single clk ex-
ecution (1 is due to external activation). For the pacemaker UPPAAL model from
Fig. 4.1 we added the reset operation to 8 transitions. We proved that the formula
87
(a) Basic monitor (b) Transition automaton with input ordering
Figure 5.7: Transition monitors (TrMonitor) used for the worst-case execution time esti-
mation.
holds for N˜i = 5. Note that since the UPPAAL model contains a model of the en-
vironment (i.e., the heart), N˜i takes into account chart activations caused by inputs.
On the other hand, when we considered open-loop execution of the pacemaker (with-
out input events from the heart), using the pacemaker model Fig. 4.1 without the
model of the environment (i.e., RH automata) we proved that the formula holds for
N˜ oli = 1. Thus, in this case at most two chart executions can occur within a single
clk execution (i.e., task activation).
If these results are compared with the execution time measurements from Ta-
ble 5.4, we can notice that for the open-loop experiments, the ratio between the
maximal and minimal execution time is less than 3. Similarly, for the experiments
with the test generator, the ratio is less than 5. Since in our case the minimal execu-
tion time corresponds to a single chart execution during the task’s activation (which
in general might not be the case), we can infer that N oli = 1 and Ni = 3. There-
fore, our WCET analysis provided the exact bound for the open-loop scenario and a
conservative bound for the closed-loop case.
The reason for this is that the transition monitor from Fig. 5.7(a) does not take
into consideration the order of the input events processing, and if both AinB! and
V inB! occur at the same time instance, the UPPAAL model might synchronize over
the channel AinB first. On the other hand, the pacemaker model in Stateflow,
and thus the obtained code, have a fixed input ordering, meaning that the inputs
are always processed in the predefined order; in the pacemaker code V inB is al-
ways processed before AinB (and the clk event is processed last). To take this
into account we used the monitor from Fig. 5.7(b) and specified the proposition as
A ((tr cnt ≤ N˜i) || (TrMonitor.l2)). This effectively disregards scenarios in which
AinB is processed before V inB within a task execution. We proved that this formula
holds for N˜i = 4, thus improving the bound. Note that if the obtained code has more
than two inputs (beside clk) it is necessary to specify all possible invalid combinations
of the inputs’ ordering, which might significantly increase the verification time.
5.10 Testing of the Physical Implementation
We validated the physical implementation using the procedure from Section 5.8. Un-
like validation of the Stateflow chart, for physical testing we considered two types
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Figure 5.8: A test screen shot for property B4.2; clk pulses are highlighted.
of tests. For the ideal system specifications we used  ≤ 80µs, since 84.9µs was the
chart’s minimal execution time (Table 5.4). Similarly, since the values for all the pre-
defined tolerances are ±4ms, for the second set of tests we used 4ms <  ≤ 4.08ms.
Table 5.5 presents testing results for the pacemaker implementation executed on
the MSP430 Experimenter Board. When the tolerances are not taken into account
some of the properties that were verified in UPPAAL and validated in Simulink were
violated during the tests. The reason is that the UPPAAL semantics uses an unreal-
istic assumption that the machine executing the code is infinitely fast (i.e., no time
elapses during transitions) and the system’s reaction to synchronization is instanta-
neous. In the general case, the execution delays can cause violation of the UPPAAL
semantics in the obtained physical implementation, which is the main reason for vi-
olation of some of the verified safety properties. However, when interval tolerances
are taken into account, all properties were satisfied, as shown in Table 5.5.
For example, consider the property B4.2. Fig. 5.8 presents one of the oscilloscope
screenshots obtained during the testing. The signals shown are Ain (top), AS (mid-
dle) and clk (bottom). As shown, Ain appeared right after the first clk occurrence.
It sets the appropriate flag in the interrupt routine, but the processing of the corre-
sponding event occurred with the next clk. The event processing takes approximately
232µs before AS is generated. This, along with the time (up to 1ms) between Ain
and the following clk, results in delay of up to 1.232ms. Thus, ideal requirement B4.2
is violated. However, since the delay is within the tolerance bound, the requirement
is satisfied when the tolerances are taken into account.
Requirement P1.1 B1.1 B1.2 P2.1 P2.2 B2.1 B2.2
Ideal Pass Fail Pass Pass Pass Fail Fail
With tolerance Pass Pass Pass Pass Pass Pass Pass
Requirement P3.1 B3.1 B3.2 P4.1 B4.1 B4.2
Ideal Pass Fail Fail Pass Fail Fail
With tolerance Pass Pass Pass Pass Pass Pass
Table 5.5: Results of the tests performed on the setup from Fig. 5.6.
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5.11 Discussion
We have described the design of the UPP2SF tool for automatic translation of UP-
PAAL models in Stateflow. We have shown that for a large class of UPPAAL models,
UPP2SF preserves behavior of the initial UPPAAL model. Furthermore, we have pre-
sented an UPP2SF-enabled Model-Driven Development framework for safety-critical
system design. By applying the UPP2SF model translation tool on the dual-chamber
implantable cardiac pacemaker case study, we have demonstrated the process starting
from the formalization of the device specifications, followed by system modeling and
verification in UPPAAL, to closed-loop system simulation in Simulink/Stateflow and
testing of the physical implementation. We have also shown how the translation tool
provides a way to estimate WCET during modeling and verification stage in UP-
PAAL, and facilitates development of modular code from UPPAAL timed-automata
based models.
However, UPPAAL as a design tool cannot be used to design more complex sys-
tems. For instance, in UPPAAL the value of the clocks cannot be saved. Systems
that require timing information as history cannot be explicitly modeled in UPPAAL,
which also limits the application of UPP2SF.
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Chapter 6
Theme 4: in-silico Pre-clinical
Trials for Implantable Cardiac
Devices
10,000 people in the U.S. receive an Implantable Cardioverter Defibrillator (a heart
rhythm adjustment device) every month (ICD [2015]). Clinical trials have presented
evidence that patients implanted with ICDs have a mortality rate reduced by up to
31% (Moss et al. [2012]). Unfortunately, ICDs suffer from a high rate of inappropriate
therapy, which takes the form of unnecessary electric shocks or pulse sequences deliv-
ered to the heart. Inappropriate therapy increases patient stress, reduces their quality
of life, and is linked to increased morbidity (Rosenqvist et al. [1998]). Depending on
the particular ICD and its settings, the rates of inappropriate therapy range from
46% to 62% of all delivered therapy episodes (Gold et al. [2012]).
After the verification and testing effort is completed, regulatory agencies like the
F.D.A. require that the safety and efficacy of new devices be demonstrated in a CT
(Fig. 6.1). In a trial, a group of patients that are treated with the new device (this
is the ‘intervention group’) are compared to a group of patients who are treated with
the current standard of care (e.g., a different device currently on the market; this
is the ‘control group’). The objective is to see whether the different devices result
in significantly different effects on the patients. Clinical trials are major endeavors,
involving physicians, patients, statisticians, clinical centers, companies and regulators,
sometimes in several countries. Late-phase trials can run for several years, and cost
millions of dollars. For example, a 2002 trial for stents lasted 2 years, enrolled 800
patients and cost $10 to $12 million and lasted 24 months (Kaplan et al. [2004]). Trials
also pose an inherent risk to the patients in the intervention group by exposing them
to an unproven device. Thus it is crucial that they be well planned, and rigorously
executed.
In reality, any trial runs the risk of errors during its planning and execution stages,
which can invalidate the results of the trial. In this paper, we pose and propose an
answer to the following question: how can modeling of CPS assist in the planning
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Figure 6.1: Bringing a device to market. Clinical trials are the last step before a new
device’s market approval. Model-based clinical trials will provide insight during planning
and execution of clinical trials, leading to reduction in costs and increasing the chance of a
successful trial.
and execution of a clinical trial, so as to increase the chances of a successful trial?
Most medical models today are aimed at either better understanding the phe-
nomenon under study (Ten Tusscher et al. [2007]) or at device debugging and verifi-
cation (Jiang et al. [2012a]). There is only one case in which a computer model has
been used to intervene in the regulatory process of medical devices, namely the T1
Diabetes Model (T1DM) of UVA/PADOVA (C. Toffanin, M. Messori, F. Di Palma,
G. De Nicolao, C. Cobelli, L. Magni [2014]). T1DM models glucose kinetics in hypo-
glycemia, and has been accepted by the FDA as a substitute for animal trials. The
T1DM has a fixed virtual cohort with 300 patients. Its objective is to test the efficacy
of new glucose control algorithms by simulating them on the virtual cohort. While
our models can be used in this way, our objective here is to target specific clinical
trials steps and improve how they are conducted. This dictates the experimental
setup and the cohort generation considerations.
The Avicenna consortium (Avicenna Consortium [2015]) lays out a vision for In-
Silico Clinical Trials’ similar to our approach. However, the emphasis in Avicenna
is on individualized patient models, as they propose to customize the model to each
patient enrolled in a trial. In the present work, we propose a usage of in-silico pre-
clinical trial prior to recruitment. Thus our models need not be fitted to a given
patient’s data, which might be impossible, invasive, or burdensome for the conduct
of the trial.
In this chapter, we demonstrate how computer models can be used for early,
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affordable and reproducible testing of a clinical trial’s premises and assumptions.
Model-based empirical validation of the premises reduces the risk of conducting a
trial that fails to demonstrate the desired effect (typically, an improvement of new
intervention over the control). We used the Rhythm ID Going Head to Head Trial
(RIGHT) (Gold et al. [2012]), which lasted five years and sought to compare the
diagnostic algorithms used by two ICDs for correctly diagnosing potentially fatal
tachycardias (abnormally fast heart rhythms).
6.1 Clinical trials and RIGHT
At the clinical trial stage (Fig. 6.1), the objective is no longer to find bugs in the
device: it is, rather, to evaluate the safety and efficacy of the validated device on
humans. RCT are the gold standard for evaluating the safety and efficacy of a new
medical device (L. M. Friedman and C. D. Furberg and D. L. DeMets [2010]). They
constitute the only time prior to market use where the effects of the device on humans
are actually observed, and are legally mandated for new high-risk medical devices like
ICD. The planning and execution of an RCT requires carefully navigating a number
of technical, logistical and ethical issues to obtain reliable and statistically significant
results.
Because of the very high cost of RCT in terms of money, time, and the risk of
harm they present to enrolled patients, our focus in this paper is on the use of CPS
models, formalized in an in-silico pre-clinical trial, to validate the assumptions made
by the investigators and thus increase the chances of success of an RCT. We illustrate
our approach by applying it to the Rhythm ID Going Head-to-Head Trial (RIGHT)
(Gold et al. [2012]), which we present next.
6.1.1 The RIGHT trial
We first provide a brief background to better understand RIGHT. Tachycardias (ab-
normally elevated heart rates) can be divided into VT, which originate in the heart’s
ventricles, and SVT, which originate above the ventricles. A sustained VT can be
fatal, while an SVT is typically non-fatal. The therapy applied by the ICD often takes
the form of a high-energy electric shock. The shock can be pro-arrhythmic, and was
even linked to increased morbidity (Rosenqvist et al. [1998]). Therefore, one of the
biggest challenges for ICDs is to guarantee shock delivery for VT, and simultaneously
reduce inappropriate shocks during SVT (Ellenbogen et al. [2011]).
RIGHT is a trial that sought to compare the VT/SVT discrimination abilities
of two algorithms (Gold et al. [2012]): the Rhythm ID detection algorithm found in
Boston Scientific’s Vitality II ICDs ( Boston Scientific Corporation [2007b]), and the
PR Logic + Wavelet (PRL+W) detection algorithm found in a number of Medtronic’s
ICDs (Medtronic Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD). Inappro-
priate therapy was defined as therapy applied to an arrhythmia other than VT or VF
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Rate of Inappropriate Therapy
PRL+W: 54.1%
Rhythm ID: 62.2%
Figure 6.2: ICD connected to the heart. The atrial, ventricular, and shock electrogram
signals are measured by the device, which uses them to diagnose the current state of the
heart and determine whether therapy is required.
(VF is a type of VT). RIGHT enrolled 1962 patients and ran for approximately five
years. It was fully sponsored by Boston Scientific.
One of the trial’s assumptions was that Rhythm ID would reduce the risk of in-
appropriate therapy by 25% over PRL+W ( Berger et al. [2006]). The outcome of
the trial ( Gold et al. [2012]), however, was that patients implanted with ICDs run-
ning Rhythm ID had a 34% risk increase of inappropriate therapy as compared
to patients implanted with ICD running PRL+W. This result is the opposite of the
effect hypothesized by the trial investigators. In this paper, we design an in-silico
pre-clinical trial to test early and quickly whether the hypothesized effect holds by
comparing the two ICDs on a large synthetic cohort.
Organization: In the following sections we describe the building blocks of in-silico
pre-clinical trials: modeling the heart, processing 100’s of real patients’ data, mapping
the timing and morphology components of the signal to a heart model we developed,
generating a population of 10,000+ synthetic heart models, implementing the device
algorithms and conducting multiple trials for the comparative rate of inappropriate
therapy, condition-level rates and evaluating the effect of device parameters on dis-
crimination rates.
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6.2 Virtual Cohort Generation
Implantable Cardioverter Defibrillators (ICDs) can diagnose VT and VF by observing
the electrical activity through three channels, as shown in Fig. 6.2. The measured
signals are known as electrograms, or EGMs. VT and SVT can share similar heart
rates and might even occur simultaneously, so an SVT can be mis-diagnosed as a
VT. This is problematic because VT therapy consists of low and high energy electric
shocks of 30-40 Joules (∼800V) delivered directly to the heart, which is very painful
to the patient, and has been shown to increase morbidity (Rosenqvist et al. [1998])1.
Therefore, one of the biggest challenges for ICDs is to discriminate between VT that
typically requires a shock, and SVT that typically should not be shocked (Ellenbogen
et al. [2011]).
An EGM signal can be characterized by the timing of events that produced it,
and the morphology of the signal itself. An ‘event’ is roughly characterized as the
source of the largest peak in the EGM (e.g. a ventricular depolarization), and event
timing is a crucial element of an arrhythmia’s definition in clinical Electrophysiology.
The ‘morphology’ refers to the shape of the EGM (see Fig. 6.5 for examples). Both
aspects are used by the ICD to make its decision. Correspondingly, our model has
two components: a timing model, and a morphology model.
6.2.1 Timing Model
The node and path topology used in the in-silico pre-clinical trials is shown in Fig.
6.3. The hollow nodes are passive nodes representing key locations within the heart
where electrical events may be blocked. These include the Atrioventricular node
(AV), Right Bundle Branch (RBB) and Left Ventricle Apex (LVA). The filled nodes
in red, Sinoatrial (SA) node and Right Ventricle Apex (RVA) node, represent the
heart locations where ICD electrodes are placed to measure the EGMs. The timing
of the activation events at these nodes determines the timing of corresponding EGMs.
Different sources for tachyarrhythmias are represented by arrhythmia nodes (dashed
filled nodes) which are capable of self-activating at prescribed rates. These include
Premature Atrial Complexes (PACs) and Premature Ventricular Complexes (PVCs)
which are sources of rhythm disturbances.
Every node and path automaton has timing parameters that determine, for ex-
ample, the delay between events, and how long it takes to conduct an electrical event
between two nodes. These timing parameters can be directly derived from clinical
data (Josephson [2008]), and the model structure is compatible with clinical Electro-
physiology concepts. Thus we know the ranges for these parameters. In Jiang et al.
[2012a], the timing model’s capability to simulate various normal and abnormal heart
conditions was validated quantitatively and by cardiac electrophysiologists.
In this work we use the same heart model structure to ensure the correct timing
1Physicians compare a shock to a “horse kicking you in the chest”
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Figure 6.3: Timing model of the heart
of the EGM signals into the ICD. In order to account for inherent timing variability,
during simulation the heart model randomly selects timing parameters within a pre-
specified range, instead of choosing specific values. By choosing the range, we control
the variability of the signals produced by a given model instance.
6.2.2 Morphology Model
The ICD uses the EGM morphology in two ways: first, the atrial and ventricular
EGMs are used to sense when events occur via peak detection (Section 6.3.1). Second,
the Shock channel EGM is used in the morphology comparison discriminators (Section
6.3.2, Gold et al. [2002], C. D. Swerdlow et al [2002]). It is known that sensing (the
detection of events) can be responsible for up to 20% of inappropriate therapies
(Daubert et al. [2008]). Therefore, it is important that our model generate realistic
and varied EGM waveforms for a proper evaluation of the detection algorithms.
The timing model provides the time stamps for electrical events to happen at the
interfacing nodes (SA,RVA). From path conduction we also know the source of the
signals. In the heart model structure shown in Fig. 6.3 there are 5 different sources
for SA node activation and 5 different sources for RVA node activation. Based on the
clinical observations that electrical events from the same source produce very similar
EGM morphologies, we can generate EGM signals by overlaying EGM templates
corresponding to different sources onto the timing event diagram. The procedure
is shown in Fig. 6.4. We also introduce small variations on EGM templates. The
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Figure 6.4: EGM waveform generation. From a given model instance and set of tachycardias,
an EGM waveform is generated for the duration of an episode. The timing model determines
event timings. When an event occurs, the EGM morphology for the event is output from
the morphology model.
variations are obtained by a wavelet decomposition of the signatures followed by a
random scaling of the 25% smallest coefficients. We guarantee that this does not
change the signature of the EGM, by running one of the morphology comparison
discriminators described in Section 6.3.2. This variation is parametrized, e.g. the
percentage of modified coefficients, the range of the random scaling.
6.2.3 Patient Data Adjudication and EGM Template Extrac-
tion
In order to obtain realistic morphologies for our simulations we utilize the Ann Ar-
bor Electrogram Libraries (AAEL), a database of over 500 EGM recordings made
during clinical electrophysiology studies ( Jenkins and Jenkins [2003]). The AAEL
is used by all major ICD manufacturers and is licensed by the US FDA. The AAEL
provides descriptive annotations of records at a high level. We performed additional
detailed examination to precisely segment each record according to rhythm type.
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Figure 6.5: (Left) The EGM record is segmented into episodes with distinct rhythms in
each. (Right) From each episode, individual EGM morphologies are extracted and stored.
123 records from 47 patients were manually examined and adjudicated into segments
called episodes containing one specific rhythm, e.g. NSR or VF. The adjudication
was performed by a cardiologist. Fig. 6.5 (left) shows an example record (Record
A185660) which has undergone this adjudication. From each episode, we developed
an automated process which extracted EGMs from a given episode. The EGM are
collected and organized by both patient record and by the type of rhythm which was
annotated during the adjudication process. These extracted rhythm signatures pro-
vide the basis for the morphology information in the signal generated by our model.
Fig. 6.5 (right) depicts an example of 10 signatures extracted from the record.
6.2.4 Cohort generation
Let p = (p1, . . . , pn) ∈ <n be the vector of timing and morphological parameters of
the heart model. Let Pi ⊂ < be the range of parameter pi. We generate a synthetic
cohort of N probabilistic model instances. To produce one of these instances, for each
scalar parameter pi, we randomly select a sub-interval Ii of its range: Ii ⊂ Pi. The
sub-interval Ii is chosen so that it fits with the tachycardia that this model instance
is meant to simulate. E.g., for modeling VT, the rest period of the VT node might be
assigned the sub-interval Ii = [260, 280]ms, reflecting the firing rate in the ventricles.
When a model instance is simulated, each parameter pi’s value changes beat to beat
by sampling it uniformly within its sub-interval Ii. Thus each generated model is
probabilistic to reflect inherent rhythm variability.
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6.3 Implementing Device Algorithms
Due to the limited sensing capability of ICDs, device manufacturers have developed
different algorithms to identify the electrical events and correctly diagnose the car-
diac arrhythmia as being VT or SVT. In this chapter we implemented the detection
algorithm Rhythm ID of Boston Scientific (Boston Scientific Corporation [2007b], El-
lenbogen et al. [2011]),and PRLogic+Wavelet (PRL+W) of Medtronic (Singer [2001],
C. D. Swerdlow et al [2002]). We also set up a testing platform to validate our im-
plementations against real ICDs using conformance testing.
6.3.1 Cardiac Signal Sensing
Sensing is the process by which cardiac signals measured through the leads of the
ICD is converted to cardiac timing events. Appropriate sensing is essential for proper
ICD detection algorithm operation which relies heavily on accurate event timing and
morphology information provided by sensing. An event corresponds to a depolariza-
tion in the heart and manifests as a displacement from the baseline amplitude of the
signal. In its simplest form, the sensing algorithm declares an event whenever the
amplitude of the signal exceeds a given threshold. Once an event has been declared,
the peak of the amplitude is measured and a refractory period begins, during which
a consecutive event is ignored for a short period of time. This is to ensure that the
same event is not counted repeatedly.
ICDs require a balance in sensitivity in order to operate in noisy, complex, envi-
ronments where cardiac events can vary greatly in signal amplitude and frequency,
such as during VF. Setting the threshold low achieves higher sensitivity to events of
small amplitude, but increases the chances for incorrectly sensing other cardiac elec-
trical artifacts such as T-waves and noise artifacts (oversensing). Conversely, setting
the threshold too high allows sensing to be more robust to noise and other cardiac
electrical events, but creates the potential for undersensing events of interest, such as
during VF when the peak amplitude can be low.
In order to achieve adequate balance, ICD sensing algorithms are enhanced by
applying dynamic adjustment of the sensitivity threshold. Initially, the threshold
is raised during the refractory period after an event and once the refractory period
concludes, the threshold is decayed to a minimum pre-set threshold. In our device
models, we implemented the AGC algorithm of Boston Scientific and the AAS of
Medtronic ICDs to incorporate dynamic threshold adjustment.
The complexity of these enhancements adds to the difficulty of properly program-
ming device settings of ICDs and requires calibration process at the time of ICD
implantation and during patient follow-up visits.
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Figure 6.6: SVT/VT detection algorithm by Boston Scientific (Boston Scientific Corpora-
tion [2007b]). The two cases on the right illustrate two different decisions by the algorithm.
(a) illustrates a sustained VT case where at the end of the Duration, the ventricular rate is
faster than the atrial rate. The algorithm correctly identified the rhythm as VT and deliv-
ered therapy. (b) illustrates a SVT case where at the end of the Duration, the ventricular
rate is slower than the atrial rate. Then by comparing the EGM morphology in the Shock
channel (Marker 1) with the stored NSR template (Marker 2) for the last 10 EGM events,
the algorithm decided that the morphology is correlated, therefore therapy is inhibited.
6.3.2 VT Detection Algorithm
Device companies have developed different algorithmic components to distinguish
SVT from VT, referred to as discriminators. Each discriminator utilizes the history
of timing and/or morphology of the EGM signals to determine whether the current
rhythm is a VT or SVT (or neither). No single discriminator is sufficient on its own to
discriminate between SVT and VT, because these classes of arrhythmias can appear
similar in a number of criteria. Therefore discriminators are organized in a decision
tree.We have implemented the detection algorithms Rhythm ID from Boston Scientific
and PRL+W from Medtronic. This section gives an overview of both algorithms.
Rhythm ID
Rhythm ID’s decision tree is shown in Fig. 6.6. Rhythm ID detects an episode by
continuously examining the last 10 ventricular intervals and comparing them with VT
and VF thresholds. If 8/10 intervals are shorter than the VF threshold for a certain
pre-set VF Duration (e.g., 2.5 seconds) then the algorithm declares VF. Otherwise,
if 8/10 intervals are shorter than the VT threshold for a certain VT Duration, then
further discriminators are used. First, if the ventricular rate is greater than the
atrial rate for the last 10 ventricular beats, Rhythm ID will determine the condition
is VT. Otherwise, the Vector Timing and Correlation (VTC) discriminator ( Gold
et al. [2002]) compares EGM morphology of the last 10 ventricular events with an
EGM template saved during NSR. VTC is based on the assumption that the EGM
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morphology of the shock channel during VT is different from its morphology during
SVT and NSR. If the correlation between the current EGM’s morphology and the
stored NSR morphology is above a pre-set threshold, the current rhythm is more
likely to be SVT than VT, and therapy is withheld. Otherwise, if the atrial rate is
equal to a pre-set fibrillation rate and the variance of the ventricular interval length
exceeds a certain limit, the algorithm decides it’s an SVT. Otherwise, it decides this
is a VT.
PR Logic+Wavelet
PRL+W also utilizes rate-based and morphology-based discriminators similar (but
not identical) to Rhythm ID. The morphology discriminator used in PRL+W is sim-
ilar to VTC in Rhythm ID, but operates in the wavelet domain ( C. D. Swerdlow et
al [2002]). PRL+W also continuously compares the pattern of atrial and ventricular
activation to 19 pre-defined patterns ( Singer [2001]). Each pattern is associated to a
heart condition, like Sinus Tachycardia or VT. A match between the current activity
and one of the pre-defined patterns is used as an indication that the current rhythm
is explained by the associated condition.
6.3.3 Validation
Conformance testing was used to validate the software implementations of the Vi-
tality II device by Boston Scientific. The validation hardware setup is illustrated in
Fig. 6.7. 14 different scenarios were specified and programmed into an EGM Wave-
form generator (CRM3 Simulator, Guidant, USA) such that it would output a signal
to the connected Vitality II device. The various scenarios traverse 7 out of 9 branches
of the detection algorithm for Boston Scientific described in Sec. 6.3.2 and shown in
Fig. 6.6. The response of the ICD interrogated using an ICD programmer (ZOOM
Latitiude, Boston Scientific). As the waveform was applied to the ICD, the waveform
was simultaneously acquired using a National Instruments DAQ board. The recorded
waveform was then applied to the device model and response was compared. Fig. 1.7
shows an example of one such scenario, specificallly VF. In this case, the software
model matched to the decision of the actual ICD which also determined that therapy
should be applied.
In all scenarios, the decision of model conformed to that of the ICD. The re-
maining two branches were not reachable due to the limited output capability of
the programmer. The Medtronic software implementation can be validated using a
similar process.
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Figure 6.7: Example of validation output screenshots (Ventricular fibrillation) showing
matching therapy decision for the ICD and our implementation.
6.4 Results
6.4.1 The rate of inappropriate therapy
The first objective of the in-silico pre-clinical trials is to estimate the rate of inappro-
priate detection t¯ for each of the two algorithms for all arrhythmias combined, i.e.,
for the entire synthetic cohort. The rate of inappropriate therapy is defined as
t¯ =
Number of inappropriately applied therapies
Number of applied therapies
From this we can confirm or invalidate the assumption that Rhythm ID outperforms
PRL+W. We generated a synthetic cohort of 11,400 heart instances, equally dis-
tributed among the 19 arrhythmias. The number of instances was obtained from a
Monte Carlo calculation.
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Conclusion 1: PRL+W delivers less inappropriate therapy. The ob-
tained rates of inappropriate detection were 6.65% for Boston Scientific and 2.91%
for Medtronic (P ¡ 0.0001), assuming an equal number of patients from each arrhyth-
mia in the synthetic cohort. The corresponding relative improvement of Medtronic
over Boston Scientific is 56%. In other words, the in-silico pre-clinical trial reveals
that the PRL+W algorithm from Medtronic actually differentiates between VT and
SVT better than Rhythm ID from Boston Scientific. Our findings are consistent with
the observations of the RIGHT trial itself ( Gold et al. [2012]).
Conclusion 2: result holds across population characteristics. The above
rates were obtained under the assumption that each arrhythmia is equally represented
in the cohort. A significant feature of in-silico pre-clinical trial is that it allows us to
study the endpoint of interest (here, rate of inappropriate detection) on a variety of
populations, which have the various arrhythmias in different proportions. This may
not be feasible in a real clinical trial, which has to contend with the population present
at the clinical centers where the trial is conducted. We may then ask: does PRL+W
maintain a lower rate of inappropriate detection across different populations? To
answer this question, we varied the distribution of the arrhythmias in the synthetic
cohort, and re-computed the cohort-wide rates of inappropriate therapy. Fig. 6.8
shows the results for 10 random variations of the arrhythmia distribution. It can be
seen that indeed, PRL+W maintains a better rate of arrhythmia discrimination (and
by inference, less inappropriate therapy) across the board.
This illustrates very well the benefit that an in-silico pre-clinical trial can bring to
the planning of an RCT: the fact that Rhythm ID could not be shown to be better
than PRL+W can cause the investigators to re-consider their assumptions and the
feasibility of the trial. In this case, the in-silico pre-clinical trial casts doubt on the
assumed direction of the effect, i.e. whether intervention is better than control, or the
other way around. This early check can mean the difference between an expensive
trial that fails at showing the desired effect, and a trial that is appropriately sized to
demonstrate the desired effect size.
Thus, while an in-silico pre-clinical trial does not replace or mimic the RCT since
we can not capture patient-level outcomes of the therapy, it can provide but early
insight at a small fraction of the RCT cost and duration and without the ethical
issues.
6.4.2 Condition-level rates
Having a heart model allows us to better estimate the sensitivity and specificity of
the diagnostic algorithms’ performance, something which is not possible in a clinical
trial because the device only records a limited number of episodes. These are defined
as
Sensitivity =
Number of correctly classified VTs
Number of true VTs
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Figure 6.8: Rate of inappropriate detection (2nd and 4th columns) for different arrhyth-
mia distributions (1st and 3d columns). The arrhythmias are (left to right on the x axis):
Atrial fibrillation, Atrial flutter, Premature Ventricular Complexes, Nonsustained Ventricu-
lar Fibrillation, Supraventricular Tachycardia, Sinus Brady-Tachy, Ventricular Fibrillation,
Ventricular Tachycardia (Josephson [2008]). The top left distribution is uniform, and the
bottom right distribution is that of the baseline characterization in RIGHT (Gold et al.
[2012]).
Specificity =
Number of correctly classified SVTs
Number of true SVTs
In words, the sensitivity measures how well the device recognizes VTs. Specificity
measures how well the device discriminates between VT and SVT. An ideal device
would have 100% sensitivity and specificity. Unfortunately, these are typically com-
peting goals: the more sensitive the device, the more likely it will mis-diagnose some
SVTs as VTs, so its specificity will drop.
We calculated sensitivity and specificity in our in-silico pre-clinical trials, and
report them in Table 6.1 on a per-arrhythmia basis. The conditions are drawn from
RIGHT’s baseline characterization (Gold et al. [2012]). Specificity is reported for
SVTs and sensitivity is reported for VTs. It can be seen from these results that in
our synthetic cohort, Atrial flutter and other Supraventricular tachycardias are the
main source of inappropriate detection for Rhythm ID compared to PRL+W. In the
case of Atrial flutter, Rhythm ID categorizes it inappropriately as VT for 41.7% of
the cases.
Condition-level analysis pinpoints the specific pathways of the discrimination al-
gorithm which must be addressed to reduce the device’s rate of inappropriate therapy.
It is difficult to get such insight through an RCT as the patient population is fixed
and the conditions are determined retroactively. Such analysis can be further used
to investigate condition distributions across different patient population types (e.g.
abnormal heart rhythms in children vs geographic region-specific or race-specific con-
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Arrhythmia Rhythm
ID
PR
Logic +
Wavelet
P value
Specificity (%)
Atrial Fibrilla-
tion
99.8 99.6 0.3167
Atrial flutter 58.3 79.33 < 0.0001
Premature
ventricular
complexes
100 100 1
Nonsustained
ventricular
tachycardia
100 99.8 0.3171
Other
Supraventricu-
lar tachycardia
96.3 99.7 < 0.0001
Brady-Tachy 100 98.83 0.0079
Sensitivity (%) P value
Ventricular fib-
rillation
100 100 1
Ventricular
tachycardia
100 100 1
Table 6.1: Specificity and sensitivity under different heart conditions.
dition distributions).
6.4.3 Effect of Device Parameters on Discriminating Capa-
bility
ICDs have a number of parameters which can be tuned to accommodate specific pa-
tient conditions by the physicians. Currently there are very few clinical results on the
effect of tuning parameters and their effect on sensitivity and specificity ( Moss et al.
[2012]). One of the main causes of VT/SVT mis-classifications is inappropriate pa-
rameter settings ( Daubert et al. [2008]). In order for the physicians to set appropriate
parameters, it is very important to understand how the change of one parameter can
affect the discriminating capability of the device. It is costly to experiment this on
real patients. With in-silico pre-clinical trial, one can use the same population across
multiple devices with different parameter settings at virtually no cost.
In this section, we use in-silico pre-clinical trial to demonstrate the effects of
changing two common parameters on SVT/VT discrimination specificity. The first
parameter is the duration of arrhythmia before the ICD makes a therapy decision.
For Boston Scientific ICD the value can be set to 1 to 30 seconds. In this experiment
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Figure 6.9: Effects of Duration and VF threshold parameters on Specificity
we explore the values {1,2,3,4,5,8,10}. The equivalent parameter for Medtronic ICD
is the number of consecutive fast ventricular intervals which can be set from 8 to 20
beats. In this experiment we explore the values {8,10,12,16,18,24,30} which roughly
correspond to the parameters of Boston Scientific ICD. Intuitively, with a longer du-
ration the device can examine a longer history of the arrhythmia episode, and also
allows a greater chance for the arrhythmia to self-terminate. This can prevent inap-
propriate therapy. Setting the duration too long can also delay and in some cases
withhold appropriate therapy. These results are in agreement with the recently con-
ducted ADVANCE-III RCT which showed that longer arrhythmia detection windows
reduce shocks for Medtronic ICDs ( Gasparini et al. [2013]).
The second parameter we varied is the VF threshold. For both devices, if the
ventricular rate is faster than the VF threshold for a period of time the devices
will deliver therapy without going into the SVT/VT discrimination algorithm. So a
higher VF threshold means that more signals are passing through the discrimination
algorithm. In this experiment we explored the values {170,184,200} for both algo-
rithms. Intuitively the higher the threshold, the more episodes will be examined by
the SVT/VT discrimination algorithm, which may increase specificity.
Conducting the Model-based Clinical Trial. For each of the 21 parameter com-
binations described above, we ran an in-silico pre-clinical trial with 11,400 EGM
episodes on both device models. From the results we observe that for both algo-
rithms the specificity increases monotonically with the length of the duration. When
the duration is longer than 5, sensitivities dropped below 100%, which is in line
with the intuition. However, Rhythm ID and PRL+W displayed opposite trends
for the VF threshold. For PRL+W, the specificity increased when the VF thresh-
old was increased from 170BPM to 184BPM - i.e. a higher threshold admits more
signals through the discrimination algorithm which performs better across all rates.
For Rhythm ID the specificity dropped when the VF threshold was increased from
170BPM to 184BPM - i.e. the discrimination algorithm is less effective at higher
rates. One possible interpretation of the result is that the Boston Scientific algorithm
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is more prone to inappropriate therapies for SVTs with ventricular rate between
170BPM to 184BPM, which may be a useful for the physicians to consider during
parameter settings.
6.5 Discussion
The above experiment has illustrated a practical application of computer modeling
for the support of clinical trial planning and execution. We now present the medically
relevant limitations of this particular experiment, then discuss the in-silico pre-clinical
trial approach in general. First, we did not account for post-shock detection (a phase
of detection that follows the delivery of therapy), which was part of the RIGHT
results. The Onset discriminator was not implemented so the results exclude its
effects. RIGHT included both dual-chamber and single-chamber devices, whereas
we only implemented the algorithms for dual-chamber devices. For the VTC and
Wavelet algorithms, the literature did not specify which samples are taken from the
electrogram. We chose to sample the electrogram uniformly in time, and validated
that this gives correct results.
Clinical trials study the effect of an intervention in the patient, and report patient-
level results (e.g., “The event of interest was observed in X% of patients in Group 1”).
Our results are at the condition level: they take the form “the event of interest was
observed in X% of generated conditions”. To produce patient-level estimates requires
an estimate of how conditions are distributed among patients. This low-level data is
not readily available.
It is important to stress that in general, one should not expect absolute numbers
from an in-silico pre-clinical trial to match those from a clinical trial, nor should this
be the goal. For example, in this work, it is unlikely that our in-silico pre-clinical
trials will yield rates of inappropriate therapy that are equal to the rates obtained by
RIGHT itself. The reasons for this are many:
• Many factors that affect the outcomes of the trial (such as changes in patient
lifestyle) are not modeled.
• The adjudication of episodes in RIGHT (and other trials) is limited by the
fact that only therapy episodes were recorded by the devices. The adjudication
process is further limited by the lack of surface EKGs, which makes it hard to
reliably distinguish certain atrial arrhythmia. Neither of these is a limitation in
in-silico pre-clinical trial since we have the ground truth: we know exactly what
arrhythmia is being simulated by the model. Furthermore, the AAEL signals
have both device electrograms (EGMs) and the corresponding surface EKGs
which allow for precise adjudication.
• Experts may disagree on how to adjudicate the more complex episodes, so our
classification of episodes from the AAEL database and the classification of the
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RIGHT investigators have an irreducible discrepancy. Again, this will affect the
statistics that they and we compute.
That said, we can expect that a good heart model will reveal the trend of the
results, such as improvement of intervention over control or not, as shown in this
paper.
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Chapter 7
Conclusion
Closed-loop medical devices like implantable cardiac devices have both diagnostic
and therapeutic capabilities and interact with the patient autonomously in closed-
loop. Their autonomy makes them among the highest risk devices which require
the most stringent regulation. Currently, clinical trials are the primary means to
identify risks associated with the closed-loop interaction between the devices and the
patients. While such clinical trials are necessary, they are expensive and ineffective
for validation of the safety and efficacy of medical device software.
Model-based approaches enable closed-loop evaluation throughout the device life-
cycle, which require validated physiological models that represent the closed-loop
behaviors of different physiological conditions from the device’s perspective. In this
effort, implantable cardiac devices are used as example to demonstrate the application
of model-based approaches in providing safety and effectiveness towards “regulatory
grade evidence” of the device and describe how these activities align into the regu-
latory process. A heart model structure that captures the electrical behaviors of the
heart was developed. The model structure was based on clinical electrophysiology,
which can be easily interpreted by physicians and its parameters can be identified
from patient data. The model structure was applied in two model-based closed-loop
validation applications for implantable cardiac devices.
During device development, the safety and efficacy of a device design can be
evaluated using closed-loop model checking. In closed-loop model checking, the vari-
ability of patient conditions is captured by applying over-approximating behaviors
of the heart models. An abstraction tree framework was developed to capture all
possible observable behaviors of a human heart from the device perspective, and pro-
vide physiological contexts to the counter-examples returned by the model checker.
We demonstrated that closed-loop model checking can effectively identify safety and
efficacy violations of device design.
An automated translation tool was developed to translate UPPAAL model to
Stateflow chart. The rigorous translation together with automated code generation
guarantee that properties validated during model checking also hold in the final device
implementation. The complete verified model to verified code toolchain encourages
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the application of model-based design for other autonomous medical devices.
Before a device is finally evaluated on real patients in clinical trials, in-silico pre-
clinical trials can be performed to further increase the confidence of device safety
and efficacy. In in-silico pre-clinical trial, the variability of patient conditions is
captured by generating a large number of individual physiological models across a
number of physiological conditions. This allows us to explore a wider range of heart
behaviors and expose more corner cases to isolate software safety issues prior to an
actual clinical trial. in-silico pre-clinical trials for medical device software have the
potential to complement the current regulatory approach by reducing the cost, scope
and probability of failure of a traditional clinical trials.
The area of Medical Cyber-Physical Systems is in its early days with several excit-
ing and urgent fundamental challenges in modeling, control, verification and testing
for higher confidence life-critical systems. Similar approaches used in this disser-
tation can potentially be applied in developing other autonomous medical devices.
The major challenge is the amount of physiological domain expertise required to de-
velop appropriate physiological models. The model developer needs to identify the
minimum amount of details required in the model to interact with the device and
interpret different physiological conditions. The physiological models are then re-
quired to be optimized for appropriate formalism in order to do closed-loop model
checking. Variations of the physiological models are also required for different model
applications and different physiological requirements. Most importantly, the validity
of the physiological models have to be justified to provide confidence to the evaluation
results.
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